

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:12:24 ON 17 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1  
DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can l7

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 9001-84-7 REGISTRY

CN **Phospholipase A2 (9CI)** (CA INDEX NAME)

OTHER NAMES:

CN Acanthoxin A1

CN Agelotoxin

CN Ammodytoxin C

CN **Calcium-dependent phospholipase A2**

CN Conodipine-M

CN E.C. 3.1.1.4

CN Lecitase

CN Lecitase 10L

CN Lecithinase A

CN Nigroxin C1

CN Nigroxin C2

CN Nigroxin C3

CN Phosphatidase

CN Phosphatide acyl-hydrolase

CN Phosphatidolipase

CN **Phospholipase A**

CN **Phospholipase III**

CN Phospholipin

CN PLA2

CN Superbin

CN Superbin a

CN Superbin b

CN Superbin c

CN Superbin d

CN Superbin I

CN Superbin II

DR 195159-59-2, 195159-60-5

MF Unspecified

CI COM, MAN

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
EMBASE, IFICDB, IFIPAT, IFIUIDB, IPA, MSDS-OHS, NAPRALERT, PROMT, RTECS\*,  
TOXCENTER, USPAT2, USPATFULL

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-308-4498  
[jan.delaval@uspto.gov](mailto:jan.delaval@uspto.gov)

(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

11790 REFERENCES IN FILE CA (1962 TO DATE)  
108 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
11808 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:230679  
REFERENCE 2: 137:230482  
REFERENCE 3: 137:230417  
REFERENCE 4: 137:229772  
REFERENCE 5: 137:228256  
REFERENCE 6: 137:226804  
REFERENCE 7: 137:217139  
REFERENCE 8: 137:215484  
REFERENCE 9: 137:214098  
REFERENCE 10: 137:212737

=> d ide can l13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN 172732-68-2 REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN LY 315920  
FS 3D CONCORD  
MF C21 H20 N2 O5  
CI COM  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, PHAR, PROMT, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

34 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
35 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
 REFERENCE 2: 136:64164  
 REFERENCE 3: 136:64151  
 REFERENCE 4: 136:64112  
 REFERENCE 5: 135:331344  
 REFERENCE 6: 135:236446  
 REFERENCE 7: 135:236432  
 REFERENCE 8: 135:170901  
 REFERENCE 9: 135:152715  
 REFERENCE 10: 135:87174

=> d ide can l14

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 172733-42-5 REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, monosodium salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN LY 315920 sodium

CN LY 315920Na



CN Varespladib sodium

MF C21 H20 N2 O5 . Na

SR CA

LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, DRUGUPDATES, PHAR,  
 TOXCENTER, USPATFULL

CRN (172732-68-2)



19 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
 REFERENCE 2: 135:331344  
 REFERENCE 3: 135:236446

REFERENCE 4: 135:236432  
REFERENCE 5: 135:152715  
REFERENCE 6: 135:46087  
REFERENCE 7: 135:46086  
REFERENCE 8: 135:46085  
REFERENCE 9: 133:53700  
REFERENCE 10: 131:332096

=> d his

(FILE 'HOME' ENTERED AT 13:54:16 ON 17 OCT 2002)  
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:54:27 ON 17 OCT 2002

E TODO S/AU  
L1 165 S E3,E5-E8,E10  
E WO99-JP5528/AP, PRN  
L2 1 S E3,E4  
E JP98-292423/AP, PRN  
L3 1 S E4  
E SHIONOGI/PA,CS  
L4 8797 S SHIONOG?/PA,CS  
L5 1 S L1,L4 AND L2,L3  
SEL RN

FILE 'REGISTRY' ENTERED AT 13:56:45 ON 17 OCT 2002

L6 28 S E1-E28  
L7 1 S L6 AND PHOSPHOLIPASE  
L8 27 S L6 NOT L7  
L9 23 S L8 AND 46.150.18/RID  
L10 16 S L9 AND NC4-C6/ES  
L11 9 S L10 AND 3/NR  
L12 2 S L11 AND C21H20N2O5  
L13 1 S L12 NOT 172732-61-5  
L14 1 S 172732-68-2/CRN

FILE 'HCAPLUS' ENTERED AT 14:04:51 ON 17 OCT 2002

L15 36 S L13 OR L14  
L16 6 S LY315920 OR LY() (315920 OR 315 920 OR 315920NA OR 315 920NA)  
L17 38 S L15,L16  
L18 2 S 3 2 AMINO 1 2 DIOXOETHYL 2 METHYL 1 PHENYLMETHYL 1H INDOL 4 Y  
L19 39 S L17,L18  
L20 25 S L19 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L21 6 S L20 AND L1-L5  
L22 11809 S L7  
L23 14337 S PHOSPHOLIPASE A2  
L24 497 S SPLA2  
L25 2964 S PHOSPHOLIPASE A  
L26 1431 S L22 AND L25  
L27 4209 S PLA2 OR LECITHINASE A OR (EC OR "E") ()3 1 1 4  
L28 18 S L20 AND L22-L27  
L29 25 S L20,L21,L28  
L30 2 S L20 AND ?ISCHEM?  
L31 1 S L20 AND ?PERFUS?  
L32 25 S L29,L30,L31



L33 1 S 3 AMINOOXOACETYL 2 ETHYL 1 PHENYLMETHYL 1H INDOL 4 YL OXY ACE  
L34 25 S L32,L33

FILE 'REGISTRY' ENTERED AT 14:12:24 ON 17 OCT 2002

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:12:59 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16  
FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d 134 bib abs hitrn retable tot

L34 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:453013 HCAPLUS

DN 135:46087

TI Preparation of indoles as drug intermediates

IN Sawyer, Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044185	A1	20010621	WO 2000-US32447	20001211 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-171218P	P	19991216 <--		
OS	CASREACT 135:46087; MARPAT 135:46087				
AB	HZR2 [R2 = H, OH, NH2, alkyl, aryl, etc.; Z = (un)substituted 1,2-indolediyl] were prepd. by cyclization of R2CH:CR3Z1NO2 [R3 = H, halo, alkyl, alkoxy, etc.; Z1 = (un)substituted 1,2-phenylene] in the presence				

of CO and a catalyst.

IT 172732-68-2P 172733-42-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of indoles as drug intermediates)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach, N	1997			US 5654326 A	HCAPLUS
Denney, M	1999			WO 9956752 A	HCAPLUS
Draheim, S	1996	39	5159	Journal of Medicinal	HCAPLUS
Kawase, M	1987	24	1499	Journal of Heterocyc	HCAPLUS
Lilly Co Eli	1998			WO 9842343 A	HCAPLUS
Lilly Co Eli	1999			WO 9925339 A	HCAPLUS
Littell, R	1973	38	1504	Journal of Organic C	HCAPLUS
Nissan Chem Ind LTD	1982	006		JP 57-028046 A	HCAPLUS
Nissan Chem Ind Ltd	1982	006		JP 57-028045 A	HCAPLUS
Nissan Chem Ind Ltd	1982	006		JP 57-099568	HCAPLUS
Rajeswari, S	1989	29	415	Heterocycles	HCAPLUS
Soderberg, B	1997	62	5838	Journal of Organic C	HCAPLUS
Somei, M	1981	29	726	Chemical and Pharmac	HCAPLUS
Squibb Bristol Myers Co	1994			EP 0598383 A	HCAPLUS
Tollari, S	1994	87	203	Journal of Molecular	HCAPLUS
Tollari, S	1998	135	241	Journal of Molecular	HCAPLUS

L34 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:453012 HCAPLUS

DN 135:46086

TI Preparation of indoles as drug intermediates

IN Martinelli, Michael John; Sawyer, Jason Scott

PA Eli Lilly and Co., USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044184	A1	20010621	WO 2000-US32444	20001211 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-171230P P 19991216 <--

OS MARPAT 135:46086

AB R1ZR2 [R1 = H, alkyl, aryl, alkanoyl, aroyl, etc.; R2 = H, OH, NH2, alkyl, alkoxy, aryl, alkanoyl, aroyl, etc.; Z = (un)substituted indole-1,2-diyl] were prepd. by cyclization of R2CONR1Z1CHRR3 [R3 = trisubstituted P; Z1 = (un)substituted 1,2-phenylene].

IT 172732-68-2P 172733-42-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of indoles as drug intermediates)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
----------------------------	---------------	--------------	-------------	--------------------------	--------------------

Ashton, M	1985		US 4493843 A	HCAPLUS
Bach, N	1997		US 5654326 A	HCAPLUS
Blechert, S	1985  68	1835	HELVETICA CHIMICA AC	HCAPLUS
Cirrinzione, G	1995  50	849	IL FARMACO	HCAPLUS
Ferrer, P	1995  10	1895	LIEBIGS ANNALEN: ORG	
Le Corre, M	1985  41	5313	TETRAHEDRON	HCAPLUS
Prasitpan, N	1992  29	335	JOURNAL OF HETEROCYC	HCAPLUS

L34 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:453010 HCAPLUS

DN 135:46085

TI Preparation of indoles as drug intermediates

IN Beight, Douglas Wade; Sawyer, Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044182	A2	20010621	WO 2000-US32446	20001211 <--
	WO 2001044182	A3	20020307		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-171236P P 19991216 &lt;--

OS MARPAT 135:46085

AB R1ZR2 [R1 = H, alkyl, aryl, alkanoyl, aroyl, etc.; R2 = H, OH, NH2, alkyl, alkoxy, aryl, alkanoyl, aroyl, etc.; Z = (un)substituted 1,2-indolediyl] were prep'd. by cyclization of R2COCHR3Z1NRR1 [R = amino-protective group; R3 = H, halo, alkyl, alkoxy, etc.; Z1 = (un)substituted 1,2-phenylene].

IT 172732-68-2P 172733-42-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of indoles as drug intermediates)

L34 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:283786 HCAPLUS

DN 134:290409

TI Preparation of V type and/or X type sPLA2 inhibitors

IN Ono, Takashi; Ueno, Masahiko; Hanasaki, Kohji

PA Shionogi &amp; Co., Ltd., Japan

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent



LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001026653	A1	20010419	WO 2000-JP7024	20001010 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 1999-293273 A 19991015 <--  
 OS MARPAT 134:290409  
 GI



AB V type and/or X type **sPLA2** inhibitors which contain as the active ingredient compds. represented by general formulas [I; X = CHR2, N; X1 = C, N; X2 = C, N; Y = R6; Z = R7; YZ = C(CONH2):CHCH:CH; R1 = OH, NHSO2C6H5; R2, R3, R4 independently = H, CH3, C6H5, F; ; R5 = 4-C6H5C6H4CH2, C6H5CH2, cyclohexylmethyl, 2-cyclopentylphenyl; R6 = H, C1-3 alkyl; R7 = COCONH2, CH2CONH2; dotted bond = single, double], prodrugs thereof, and pharmaceutically acceptable salts of the same or solvates of the same are prepd. as V type and/or X type **sPLA2** inhibitors. Thus, the title compd. II was prepd. and tested for X type **sPLA2** inhibition with an IC50 of 3 nM.

IT 172732-68-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of V type and/or X type **sPLA2** inhibitors)

IT 9001-84-7, Phospholipase A2

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of V type and/or X type **sPLA2** inhibitors)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eli Lilly And Company				JP 07285933 A	HCAPLUS
Eli Lilly And Company				EP 1043991 A1	HCAPLUS
Eli Lilly And Company				JP 10503208 A	
Eli Lilly And Company				JP 10505336 A	
Eli Lilly And Company				JP 10505584 A	

Eli Lilly And Company				CN 1098714 A	HCAPLUS
Eli Lilly And Company				CN 1098715 A	HCAPLUS
Eli Lilly And Company				CN 1114310 A	HCAPLUS
Eli Lilly And Company				CN 1158121 A	HCAPLUS
Eli Lilly And Company				CA 2121321 A	HCAPLUS
Eli Lilly And Company				CA 2121323 A	HCAPLUS
Eli Lilly And Company				CA 2146097 A	HCAPLUS
Eli Lilly And Company				CA 2195432 A	HCAPLUS
Eli Lilly And Company				CA 2195569 A	HCAPLUS
Eli Lilly And Company				CA 2195570 A	HCAPLUS
Eli Lilly And Company				US 5578634 A	HCAPLUS
Eli Lilly And Company				US 5641800 A	HCAPLUS
Eli Lilly And Company				US 5654326 A	HCAPLUS
Eli Lilly And Company				US 5684034 A	HCAPLUS
Eli Lilly And Company				US 5733923 A	HCAPLUS
Eli Lilly And Company				US 5919810 A	HCAPLUS
Eli Lilly And Company				US 5919943 A	HCAPLUS
Eli Lilly And Company				HU 70205 A	HCAPLUS
Eli Lilly And Company				HU 70836 A	HCAPLUS
Eli Lilly And Company				JP 710838 A	
Eli Lilly And Company				HU 72048 A	HCAPLUS
Eli Lilly And Company				JP 725850 A	
Eli Lilly And Company				EP 769940 A1	HCAPLUS
Eli Lilly And Company				EP 772592 A1	HCAPLUS
Eli Lilly And Company				EP 772596 A1	HCAPLUS
Eli Lilly And Company				HU 77867 A	HCAPLUS
Eli Lilly And Company				NO 9401360 A	HCAPLUS
Eli Lilly And Company				NO 9401361 A	HCAPLUS
Eli Lilly And Company				BR 9401482 A	HCAPLUS
Eli Lilly And Company				BR 9401484 A	HCAPLUS
Eli Lilly And Company				FI 9401766 A	HCAPLUS
Eli Lilly And Company				FI 9401767 A	HCAPLUS
Eli Lilly And Company				ZA 9402614 A	HCAPLUS
Eli Lilly And Company				ZA 9402615 A	HCAPLUS
Eli Lilly And Company				AU 9459486 A	HCAPLUS
Eli Lilly And Company				AU 9459492 A	HCAPLUS
Eli Lilly And Company				NO 9501252 A	HCAPLUS
Eli Lilly And Company				BR 9501404 A	HCAPLUS
Eli Lilly And Company				FI 9501553 A	HCAPLUS
Eli Lilly And Company				ZA 9502693 A	HCAPLUS
Eli Lilly And Company				BR 9508298 A	HCAPLUS
Eli Lilly And Company				AU 9516217 A	HCAPLUS
Eli Lilly And Company				AU 9531406 A	HCAPLUS
Eli Lilly And Company				AU 9531459 A	HCAPLUS
Eli Lilly And Company				AU 9531980 A	HCAPLUS
Eli Lilly And Company				AU 9914073 A	
Eli Lilly And Company	1994			EP 620214 A1	HCAPLUS
Eli Lilly And Company	1994			EP 620215 A1	HCAPLUS
Eli Lilly And Company	1995			EP 675110 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603120 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603376 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603383 A1	HCAPLUS
Eli Lilly And Company	1999			WO 9925340 A1	HCAPLUS
Sawada, H	1999	26	826	Eur J Biochem	
Shionogi & Co Ltd				AU 9862292 A	HCAPLUS
Shionogi & Co Ltd				EP 987250 A1	HCAPLUS
Shionogi & Co Ltd				AU 9930543 A	HCAPLUS
Shionogi & Co Ltd	1998			WO 9837069 A1	HCAPLUS
Shionogi & Co Ltd	1999			WO 9951605 A1	HCAPLUS

TI Preparation of morpholinoethyl ester derivative of an indole **sPLA2**  
inhibitor  
IN Sawyer, Jason Scott; Morin, John Michael, Jr.; Beight, Douglas Wade; Sall,  
Daniel Jon; Buben, John Andrew  
PA Eli Lilly and Company, USA  
SO U.S., 6 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6140327	A	20001031	US 1999-310563	19990512 <--
	WO 2000069818	A1	20001123	WO 2000-US6704	20000508 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				
	ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000010448	A	20020213	BR 2000-10448	20000508 <--
	EP 1181276	A1	20020227	EP 2000-930084	20000508 <--
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				

PRAI US 1999-310563 A 19990512 <--  
WO 2000-US6704 W 20000508

AB ((3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholinoethyl ester was prepd. Its use as a highly bioavailable indole compd. for inhibiting **sPLA2** mediated release of fatty acids for treatment of conditions such as septic shock was reported.

IT 172732-68-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

IT 9001-84-7, Phospholipase A2

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

RETABLE

Referenced Author (RAU)	Year     (RPY)	VOL     (RVL)	PG     (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998			WO 9842343	HCAPLUS
Anon	1999			WO 9921559	HCAPLUS
Anon	1999			WO 9925339	HCAPLUS
Bach	1997			US 5654326	HCAPLUS
Lipsky	1996	348	1357	The Lancet	HCAPLUS

L34 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:441578 HCAPLUS

DN 133:53700

TI Combination therapy for the treatment of sepsis with activated protein C and a secretory **phospholipase A2 (sPLA2)** inhibitor

IN Maciak, Ronald Steven

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000037022	A2	20000629	WO 1999-US30433	19991220 <--
	WO 2000037022	A3	20020613		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000019408	A1	20000712	AU 2000-19408	19991220 <--
	EP 1214041	A2	20020619	EP 1999-963109	19991220 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
PRAI	US 1998-113124P	P	19981221 <--		
	WO 1999-US30433	W	19991220 <--		
OS	MARPAT 133:53700				
AB	The invention provides a method of prevention and treatment for sepsis for mammals. The treatment is a combination therapy of activated protein C and an <b>sPLA2</b> inhibitor.				
IT	<b>172732-68-2DP</b> , prodrug derivs. <b>172732-68-2P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (activated protein C-secretory <b>phospholipase A2</b> inhibitor combination for sepsis treatment)				
IT	<b>172733-42-5 172733-42-5D</b> , prodrug derivs. RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (activated protein C-secretory <b>phospholipase A2</b> inhibitor combination for sepsis treatment)				
IT	<b>9001-84-7, Phospholipase A2</b> RL: BSU (Biological study, unclassified); BIOL (Biological study) (secretory; activated protein C-secretory <b>phospholipase A2</b> inhibitor combination for sepsis treatment)				

L34 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:260237 HCAPLUS

DN 132:279109

TI Process for preparing 4-substituted-1H-indole-3-glyoxamides

IN Anderson, Benjamin Alan; Harn, Nancy Kay; Miller, Richard Duane; Plocharczyk, Edward Francis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021929	A1	20000420	WO 1999-US8325	19990415 <--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,			

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9935644 A1 20000501 AU 1999-35644 19990415 <--  
 EP 1119549 A1 20010801 EP 1999-917552 19990415 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2002527421 T2 20020827 JP 2000-575838 19990415 <--  
 US 6380397 B1 20020430 US 2001-787587 20010319 <--

PRAI US 1998-103604P P 19981009 <--  
 WO 1999-US8325 W 19990415 <--

OS CASREACT 132:279109; MARPAT 132:279109  
 GI



AB The title compds. [I; R1 = alkyl, (un)substituted CH<sub>2</sub>Ph, (CH<sub>2</sub>)<sub>2</sub>Ph, etc.; R2 = H, halo, alkyl, etc.; R4 = CO<sub>2</sub>H, SO<sub>3</sub>H, PO(OH)<sub>2</sub>, etc.; R5 = H, alkyl, alkoxy, etc.], useful for inhibiting **sPLA2** (no data), were prepd. E.g., a multi-step synthesis of I [R1 = CH<sub>2</sub>Ph; R2 = Et; R4 = COOMe; R5 = H], was given.

IT **172732-68-2P**

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)

# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Draheim	1996	39		Journal of Medicinal	HCAPLUS
Eli Lilly And Company	1995		37	EP 0675110 A1	HCAPLUS
Shionogi & Co Ltd	1998		6	WO 9837069 A1	HCAPLUS

L34 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:260062 HCAPLUS

DN 132:284251

TI Remedies or preventives containing **sPLA2** inhibitors for  
**ischemic** reflow failure

IN **Todo, Satoru**

PA **Shionogi & Co., Ltd., Japan**

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021563	A1	20000420	WO 1999-JP5528	19991007 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				



IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,  
 MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
 TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9960047 A1 20000501 AU 1999-60047 19991007 <--  
 EP 1157704 A1 20011128 EP 1999-970328 19991007 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 PRAI JP 1998-292423 A 19981014 <--  
 WO 1999-JP5528 W 19991007 <--  
 OS MARPAT 132:284251  
 AB The invention relates to remedies or preventives for **ischemic**  
 reflow failure which contain an **sPLA2** inhibitor, e.g. [[  
 3-[2-Amino-1,2-  
 dioxoethyl]-2-methyl-1-[  
 phenylmethyl]-1H-indol-4-yl  
 ]oxy]acetic acid, as active ingredient.  
 Capsules were formulated contg. **sPLA2** inhibitor 250, starch 200  
 and magnesium stearate 10 mg/capsule.  
 IT 172732-68-2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (remedies or preventives contg. **sPLA2** inhibitors for  
**ischemic** reflow failure)  
 IT 9001-84-7, **Phospholipase A2**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (secretory, inhibitor of; remedies or preventives contg. **sPLA2**  
 inhibitors for **ischemic** reflow failure)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon				JP 07285933 A	HCAPLUS
Anon				CN 1098714 A	HCAPLUS
Anon				CN 1114310 A	HCAPLUS
Anon				CA 2121321 A	HCAPLUS
Anon				CA 2146097 A	HCAPLUS
Anon				NZ 260299 A	
Anon				NZ 270848 A	
Anon				TW 306914 A	
Anon				US 5578634 A	HCAPLUS
Anon				US 5654326 A	HCAPLUS
Anon				US 5733923 A	HCAPLUS
Anon				US 5919774 A	HCAPLUS
Anon				US 5919810 A	HCAPLUS
Anon				US 5919943 A	HCAPLUS
Anon				JP 710838 A	
Anon				EP 779211 A1	
Anon				EP 779273 A1	HCAPLUS
Anon				CZ 9400894 A3	
Anon				NO 9401360 A	HCAPLUS
Anon				BR 9401484 A	HCAPLUS
Anon				FI 9401766 A	HCAPLUS
Anon				ZA 9402614 A	HCAPLUS
Anon				AU 9459486 A	HCAPLUS
Anon				EP 946495 A1	HCAPLUS
Anon				CZ 9500822 A3	

Anon			NO 9501252 A	HCAPLUS
Anon			BR 9501404 A	HCAPLUS
Anon			FI 9501553 A	HCAPLUS
Anon			MX 9501608 A	
Anon			ZA 9502693 A	HCAPLUS
Anon			AU 9516217 A	HCAPLUS
Anon			BR 9612347 A	HCAPLUS
Anon			AU 9711497 A	HCAPLUS
Anon			AU 9712897 A	HCAPLUS
Anon			AU 985592 A	
Anon			AU 9855983	HCAPLUS
Anon			HU 9901984 A2	
Eisai Co Ltd			JP 07285866 A	HCAPLUS
Eisai Co Ltd			CN 1112920 A	HCAPLUS
Eisai Co Ltd			CA 2141987 A	HCAPLUS
Eisai Co Ltd			ZA 9501467 A	HCAPLUS
Eisai Co Ltd			AU 9512374 A	HCAPLUS
Eisai Co Ltd	1995		EP 672415 A1	HCAPLUS
Eli Lilly And Company			JP 10503208 A	
Eli Lilly And Company			JP 10505336 A	
Eli Lilly And Company			JP 10505584 A	
Eli Lilly And Company			CN 1098715 A	HCAPLUS
Eli Lilly And Company			CA 2121323 A	HCAPLUS
Eli Lilly And Company			NZ 260298 A	
Eli Lilly And Company			TW 268942 A	
Eli Lilly And Company			US 5641800 A	HCAPLUS
Eli Lilly And Company			US 5684034 A	HCAPLUS
Eli Lilly And Company			US 5916922 A	HCAPLUS
Eli Lilly And Company			US 5972972 A	HCAPLUS
Eli Lilly And Company			JP 725850 A	
Eli Lilly And Company			EP 769940 A1	HCAPLUS
Eli Lilly And Company			EP 772592 A1	HCAPLUS
Eli Lilly And Company			EP 772596 A1	HCAPLUS
Eli Lilly And Company			EP 839806 A1	HCAPLUS
Eli Lilly And Company			EP 846687 A1	HCAPLUS
Eli Lilly And Company			CZ 9400893 A3	
Eli Lilly And Company			NO 9401361 A	HCAPLUS
Eli Lilly And Company			BR 9401482 A	HCAPLUS
Eli Lilly And Company			FI 9401767 A	HCAPLUS
Eli Lilly And Company			ZA 9402615 A	HCAPLUS
Eli Lilly And Company			EP 944636 A1	HCAPLUS
Eli Lilly And Company			AU 9459492 A	HCAPLUS
Eli Lilly And Company			BR 9508298 A	HCAPLUS
Eli Lilly And Company			AU 9531406 A	HCAPLUS
Eli Lilly And Company			AU 9531459	HCAPLUS
Eli Lilly And Company			AU 9531980 A	HCAPLUS
Eli Lilly And Company			MX 9700511 A1	
Eli Lilly And Company			ZA 9710878 A	HCAPLUS
Eli Lilly And Company			KR 97704695 A	
Eli Lilly And Company			AU 9851494 A	HCAPLUS
Eli Lilly And Company			AU 9853655 A	HCAPLUS
Eli Lilly And Company			AU 9854544 A	HCAPLUS
Eli Lilly And Company			NO 9901831 A	HCAPLUS
Eli Lilly And Company	1994		EP 620214 A1	HCAPLUS
Eli Lilly And Company	1994		EP 620215 A1	HCAPLUS
Eli Lilly And Company	1995		EP 675110 A1	HCAPLUS
Eli Lilly And Company	1996		WO 9603120 A1	HCAPLUS
Eli Lilly And Company	1996		WO 9603383 A1	HCAPLUS
Eli Lilly And Company	1996		WO 963376 A1	
Eli Lilly And Company	1997		WO 9721664 A1	HCAPLUS
Eli Lilly And Company	1997		WO 9721716 A1	HCAPLUS
Eli Lilly And Company	1998		WO 9818464 A1	HCAPLUS
Eli Lilly And Company	1998		WO 9824437 A1	HCAPLUS

Eli Lilly And Company	1998			WO 9824794 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9824856 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9825609 A1	HCAPLUS
Jun, T	1998	440	377	FEBS Letters	
Sargent, C	1992	262	1161	J Pharm Ther	HCAPLUS
Shionogi & Co Ltd	1999			WO 9951605 A1	HCAPLUS
Shionogi & Co Ltd	1999			WO 9959999 A1	HCAPLUS
Sonnino, R	1997	42	972	Dig Dis Sci	HCAPLUS
Windt, L	1998	180	65	Mol Cell Biochem	
Yoshihiro, S	1998	107		J Kyoto Pref Univ Me	

L34 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:116896 HCAPLUS

DN 132:151679

TI Preparation of indole **sPLA2** inhibitors

IN Mihelich, Edward David; Phillips, Michael Leroy; Warshawsky, Alan M.

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 70 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000007591	A1	20000217	WO 1999-US17460	19990802	<--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9953314	A1	20000228	AU 1999-53314	19990802	<--
	EP 1100493	A1	20010523	EP 1999-938937	19990802	<--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002522386	T2	20020723	JP 2000-563276	19990802	<--
PRAI	US 1998-95109P	P	19980803			<--
	WO 1999-US17460	W	19990802			<--
OS	MARPAT 132:151679					
GI						



AB The title compds. [I; R1 = alkyl, haloalkyl, alkenyl, etc.; R2 = H, a group contg. 1-4 non-hydrogen atoms; R3 = L3-Z (wherein L3 = CH2, O, S, NH, CO; Z = acetamide, thioacetamide, glyoxylamide, etc.); R4, R5 = H, non-interfering substituent, La-acylsulfonamide (La = a divalent linker

having a linker length of 1-8; provided that at least one of R4 and R5 must be La-acylsulfonamide); R6, R7 = H, cycloalkyl, heterocyclyl, etc.], useful for inhibiting **sPLA2** mediated release of fatty acids for treatment of inflammatory diseases such as septic shock, were prepd. and formulated. Thus, reacting 1-benzyl-2-ethyl-4-carboxymethyloxy-indole-3-glyoxylamide (prepn. given) with methanesulfonamide in the presence of 4-dimethylaminopyridine and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH<sub>2</sub>Cl<sub>2</sub> afforded 19% II which showed IC<sub>50</sub> of 12 nM against human secreted **PLA2**.

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(prepn. of indole **sPLA2** inhibitors)

IT **172732-68-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of indole **sPLA2** inhibitors)

RETABLE

Referenced Author (RAU)	Year   (RPY)	VOL   (RVL)	PG   (RPG)	Referenced Work (RWK)	Referenced File
Bach	1997			US 5641800 A	HCAPLUS
Bach	1997			US 5654326 A	HCAPLUS

L34 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:760327 HCAPLUS

DN 132:87548

TI Structure-based design of a new class of anti-inflammatory drugs: secretory **phospholipase A2** inhibitors, SPI

AU Mihelich, E. D.; Schevitz, R. W.

CS Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Co., Indianapolis, IN, USA

SO Biochimica et Biophysica Acta (1999), 1441(2-3), 223-228

CODEN: BBACAQ; ISSN: 0006-3002

PB Elsevier Science B.V.

DT Journal; General Review

LA English

AB A review with 14 refs. Human non-pancreatic secretory

**phospholipase A2** (hnps-**PLA2**) is a group IIA

enzyme that is massively over-expressed in a variety of severe inflammatory diseases. The enzyme degrades membrane phospholipids and it has been hypothesized that this activity can lead to a loss of tissue and organ integrity and function. This report overviews efforts directed toward the identification and clin. evaluation of a new class of anti-inflammatory drugs that specifically targets and inhibits the catalytic site of this hydrolytic enzyme. To achieve this goal, structure-based drug design was applied to a lead mol. identified by random high vol. screening. Through an iterative process consisting of X-ray structure detn. followed by inhibitor modification and testing, the lead compd. was improved more than 6000-fold. Detailed information learned from earlier X-ray studies of stable substrate mimics aided this inhibitor improvement process. The optimized drug candidate, **LY315920/S-5920**, is currently undergoing phase II clin. evaluation. The outcome of studies such as these will define with greater clarity the pathol. role of hnps-**PLA2** in human inflammatory diseases.

IT **9001-84-7, Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(structure-based design of anti-inflammatory **phospholipase A2** inhibitors)

RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
-------------------	------	-----	----	-----------------	------------

(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Balsinde, J	1999	39	175	Annu Rev Pharmacol T	HCAPLUS
Draheim, S	1996	39	5159	J Med Chem	HCAPLUS
Fox, N	1996	308	195	Eur J Pharmacol	HCAPLUS
Green, J	1991	15	355	Inflammation	HCAPLUS
Kramer, R	1989	264	5768	J Biol Chem	HCAPLUS
Pruzanski, W	1992	16	451	Inflammation	HCAPLUS
Pruzanski, W	1993	8	161	J Lipid Med	HCAPLUS
Santos, A	1994	219	183	Ann Surg	MEDLINE
Schevitz, R	1995	2	458	Nat Struct Biol	HCAPLUS
Scott, D	1991	254	1007	Science	HCAPLUS
Snyder, D	1999	288	1117	J Pharmacol Exp Ther	HCAPLUS
Thunniissen, M	1990	347	689	Nature	
Wery, J	1991	352	79	Nature	HCAPLUS
Yu, L	1991	88	9325	Proc Natl Acad Sci U	HCAPLUS

L34 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:723018 HCAPLUS

DN 131:332096

TI Secretory phospholipase A2 (sPLA2)

inhibitors for treatment of inflammatory bowel disease

IN Macias, William Louis

PA Eli Lilly and Co., USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9957100	A1	19991111	WO 1999-US8654	19990420 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2330856	AA	19991111	CA 1999-2330856	19990420 <--
AU 9936562	A1	19991123	AU 1999-36562	19990420 <--
BR 9910095	A	20001226	BR 1999-10095	19990420 <--
EP 1084108	A1	20010321	EP 1999-918711	19990420 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
US 6340699	B1	20020122	US 1999-673675	19990420 <--
JP 2002513783	T2	20020514	JP 2000-547070	19990420 <--
NO 2000005479	A	20001220	NO 2000-5479	20001031 <--
PRAI US 1998-83874P	P	19980501	<--	
WO 1999-US8654	W	19990420	<--	

OS MARPAT 131:332096

AB A method is disclosed for the treatment of inflammatory bowel disease by administering to a human in need thereof a therapeutically effective amt. of an sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide sPLA2 inhibitor.

IT 172732-68-2 172732-68-2D, derivs. 172733-42-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

## IT 9001-84-7, Phospholipase A2

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Dillard, R		39	5137	J Med Chem	HCAPLUS
Dillard, R	1996	39	5119	J Med Chem	HCAPLUS
Draheim, S	1996	39	5159	Indole Inhibitors of	HCAPLUS
Eli Lilly And Company	1995			EP 675110 A1	HCAPLUS
Murthy, S	1992	16	259	Increased Phospholip	HCAPLUS
Peterson, J	1996	39	698	Gut	MEDLINE

L34 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:722903 HCAPLUS

DN 131:336938

TI Preparation of [(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid N-morpholino Et ester as sPLA2 inhibitor ester

IN Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer, Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9956752	A1	19991111	WO 1999-US8538	19990420 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331036	AA	19991111	CA 1999-2331036	19990420 <--
AU 9936525	A1	19991123	AU 1999-36525	19990420 <--
EP 1073440	A1	20010207	EP 1999-918666	19990420 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9910149	A	20011002	BR 1999-10149	19990420 <--
JP 2002513761	T2	20020514	JP 2000-546777	19990420 <--
US 6274578	B1	20010814	US 2000-673677	20001017 <--
NO 2000005477	A	20001031	NO 2000-5477	20001031 <--
PRAI US 1998-83873P	P	19980501	<--	
WO 1999-US8538	W	19990420	<--	

AB Prepn. of [(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid N-morpholino Et ester is disclosed, together with its use as a highly bioavailable indole sPLA2 inhibitor compd.

## IT 9001-84-7, Phospholipase A2

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL

(Biological study)

(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as **sPLA2** inhibitor)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Denny	1999			WO 99215545	

L34 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:691078 HCAPLUS

DN 131:299367

TI Process for preparing 1H-indole-3-glyoxamides

IN Anderson, Benjamin Alan; Harn, Nancy Kay

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 42 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954300	A1	19991028	WO 1999-US8332	19990415 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2326515	AA	19991028	CA 1999-2326515	19990415 <--
AU 9935648	A1	19991108	AU 1999-35648	19990415 <--
AU 750368	B2	20020718		
BR 9909697	A	20001219	BR 1999-9697	19990415 <--
EP 1071663	A1	20010131	EP 1999-917556	19990415 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002512225	T2	20020423	JP 2000-544641	19990415 <--
US 6265591	B1	20010724	US 2000-647471	20000927 <--
NO 2000005148	A	20001109	NO 2000-5148	20001013 <--
PRAI US 1998-82110P	P	19980417 <--		
WO 1999-US8332	W	19990415 <--		
OS CASREACT 131:299367; MARPAT 131:299367				
GI				



AB A multistep synthetic scheme for prepg. title compds. [I; R = COCONH<sub>2</sub>; R<sub>1</sub> = alkyl, (un)substituted CH<sub>2</sub>Ph, biphenylmethyl, etc.; R<sub>2</sub> = H, halo, alkyl, alkoxy, etc.; R<sub>4</sub> = CO<sub>2</sub>H, SO<sub>3</sub>H, P(O)(OH)<sub>2</sub>, etc.; R<sub>5</sub> = H, halo, (halo)alkyl, etc.] was disclosed. Thus, 2-(2-oxobutyl)-1,3-

cyclohexanedione was cyclocondensed with PhCH<sub>2</sub>NH<sub>2</sub> and the product aromatized to give, after etherification by BrCH<sub>2</sub>CO<sub>2</sub>Me, I (R = R<sub>5</sub> = H, R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = Et, R<sub>4</sub> = CO<sub>2</sub>Me).

IT 172732-68-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 1H-indole-3-glyoxamides)

RETABLE

Referenced Author (RAU)	Year    (RPY)	VOL   (RVL)	PG   (RPG)	Referenced Work (RWK)	Referenced   File
Draheim	1996  39	5161		Journal of Medicinal	
Eli Lilly and Company	1995			EP 0675110 A1	HCAPLUS

L34 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:576777 HCAPLUS

DN 131:204622

TI Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate

IN Confer, William Lester; Tai, Hideaki

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944604	A1	19990910	WO 1999-US4516	19990302 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2322796	AA	19990910	CA 1999-2322796	19990302 <--
AU 9927998	A1	19990920	AU 1999-27998	19990302 <--
BR 9908479	A	20001205	BR 1999-8479	19990302 <--
EP 1058547	A1	20001213	EP 1999-908612	19990302 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6166062	A	20001226	US 1999-260490	19990302 <--
JP 2002505282	T2	20020219	JP 2000-534206	19990302 <--
NO 2000004306	A	20001010	NO 2000-4306	20000829 <--
PRAI US 1998-76659P	A2	19980303 <--		
WO 1999-US4516	W	19990302 <--		

GI





I

AB A lyophilized pharmaceutical compn. is described which contains I, a solubilizer, and stabilizer. Such compns. are storage stable and readily dissolve in aq. medium to give injectable soln. for treatment of sepsis, etc. I was prepd. and addn. of tri-Na citrate solubilizer to I solns. improved stability of the soln.

IT 172733-42-5P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pharmaceuticals contg. the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate and stabilizers and solubilizers)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Fiedler	1989	1	309	Lexikon Der Hilfssto	
Fiedler	1989	2	751	Lexikon Der Hilfssto	
Lilly Co Eli	1995			EP 0675110 A	HCAPLUS

L34 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:350593 HCAPLUS

DN 131:5185

TI Preparation of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA2** inhibitors

IN Watanabe, August Masaru

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925339	A1	19990527	WO 1998-US24234	19981113 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2310249	AA	19990527	CA 1998-2310249	19981113 <--
AU 9914058	A1	19990607	AU 1999-14058	19981113 <--
EP 1039901	A1	20001004	EP 1998-957915	19981113 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			

JP 2001522883 T2 20011120 JP 2000-520773 19981113 <--  
 US 6436983 B1 20020820 US 2000-529247 20000410 <--  
 PRAI US 1997-66036P P 19971114 <--  
 WO 1998-US24234 W 19981113 <--  
 OS MARPAT 131:5185  
 GI



AB Title compds. (I; R = COCONH2) [II; R1 = (un)substituted CH2Ph, CH2C6H4Ph-4, CH2C6H4(CH2Ph)-4, etc.; R2 = halo, Me, Et, Pr, cyclopropyl; 1 of R4,R5 = ZR3 and the other = H or ZR3; R3 = CO2H, SO3H, P(O)(OH)2; R6,R7 = H, halo, alkyl, alkoxy, etc.; when R4 .noteq. H Z = CH2CH2, OCH2, OCHMe, etc.; when R5 .noteq. H Z = OZ1C6H4, NHZ1C6H4, C6H4C6H4Z1C6H4, etc.; Z1 = (un)substituted CH2] were prepd. as **sPLA2** inhibitors (no data). Thus, II (R1 = CH2Ph, R2 = Et, R4 = OCH2CO2H, R5-R7 = H) was prepd. starting from 2,3-Me(MeO)C6H3NHC02CMe3 and EtCON(OMe)Me.

IT **172732-68-2P 172733-42-5P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA2** inhibitors)

IT **9001-84-7, Phospholipase A2**  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (secretory; mediated disorders; treatment; prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA2** inhibitors)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach	1998			US 5733923 A	HCAPLUS

L34 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:325791 HCAPLUS

DN 130:338017

TI Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds

IN Yagami, Tatsuro; Takasu, Nobuo

PA **Shionogi & Co., Ltd., Japan**

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924033	A1	19990520	WO 1997-JP4104	19971112 <--
W: JP, US				
CA 2308269	AA	19990520	CA 1998-2308269	19981110 <--
WO 9924026	A2	19990520	WO 1998-JP5042	19981110 <--

WO 9924026 A3 19990715  
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9897630 A1 19990531 AU 1998-97630 19981110 <--  
 EP 1037630 A2 20000927 EP 1998-951749 19981110 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI  
 PRAI WO 1997-JP4104 A 19971112 <--  
 WO 1998-JP5042 W 19981110 <--  
 OS MARPAT 130:338017  
 GI



I



II

- AB A method is disclosed for the treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds. I [E, F = C, N; the dotted line indicates the presence or absence of a double bond; R11 = alkyl, etc.; R12 = H, halo, etc.; R14 = H, etc.; R15 = H, etc.; R16 = H, carboxyl or ester thereof; R17 = H, alkyl, etc.; X = O, S]. Indole deriv. II (prepn. given) in vitro suppressed neuronal death depending on its concn.
- IT **172732-68-2P 172733-42-5P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)
- IT **9001-84-7, Phospholipase A2**  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Dillard, R	1996	1		WO 9603383 A	HCAPLUS
Draheim	1996	39	5159	J Med Chem	HCAPLUS
Gonzalo, J	1993	23	2372	European Journal of	HCAPLUS
Lilly Co Eli	1995			EP 0675110 A	HCAPLUS
Lilly Co Eli	1995			WO 9517183 A	HCAPLUS
Russel, R	1996			WO 9640982 A	HCAPLUS

L34 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:233807 HCAPLUS

DN 130:267344

TI Compounds for treatment of cystic fibrosis

IN Macias, William Louis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 260 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916453	A1	19990408	WO 1998-US19906	19980923 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2304482	AA	19990408	CA 1998-2304482	19980923 <--
AU 9896641	A1	19990423	AU 1998-96641	19980923 <--
EP 1007056	A1	20000614	EP 1998-950654	19980923 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
JP 2001517707	T2	20011009	JP 2000-513587	19980923 <--
PRAI US 1997-60128P	P	19970926 <--		
WO 1998-US19906	W	19980923 <--		
OS MARPAT 130:267344				
AB	Title compds., <b>sPLA2</b> inhibitors (no data), were selected from indoleglyoxylamides, -acetamides, -acetic acid hydrazides, etc. Prepn. of [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl-1H-indol-4-yl]oxy]acetic acid was described.			
IT 172732-68-2P 172733-42-5P				
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (compds. for treatment of cystic fibrosis)			

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Blake	1995			US 5436258 A	HCAPLUS
Edwards	1996			US 5532366 A	HCAPLUS
Finke	1998			US 5719149 A	HCAPLUS
Gyorkos	1998			US 5807829 A	HCAPLUS
Perrier	1995			US 5453443 A	HCAPLUS
Talley	1996			US 5547975 A	HCAPLUS
Talley	1996			US 5565482 A	HCAPLUS
Veale	1995			US 5405852 A	HCAPLUS

L34 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:172589 HCAPLUS

DN 130:196575

TI Method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor.

IN Macias, William Louis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 273 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9909978	A1	19990304	WO 1998-US17778	19980827	<--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301586	AA	19990304	CA 1998-2301586	19980827	<--
	AU 9891231	A1	19990316	AU 1998-91231	19980827	<--
	EP 1011670	A1	20000628	EP 1998-943430	19980827	<--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	JP 2001513555	T2	20010904	JP 2000-507368	19980827	<--
	ZA 9807867	A	20000228	ZA 1998-7867	19980828	<--
PRAI	US 1997-57726P	P	19970828			<--
	WO 1998-US17778	W	19980827			<--
OS	MARPAT 130:196575					
GI						



AB A method for treatment of non-rheumatoid arthritis by administration of of an **sPLA2** inhibitor is claimed (no data). Thus, preferred compd. (I) was prepd. in 6 steps via 2-ethyl-4-methoxy-1H-indole.

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(inhibitors; method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

IT **172732-68-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

IT **172733-42-5**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=====	+	+	+	+	+

Chorvat	1979		US 4180666 A	HCAPLUS
Hinkley	1973		US 3732292 A	HCAPLUS
Kelley	1996	972	Preparation of indan	HCAPLUS
Shen	1976		US 3954852 A	HCAPLUS

L34 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:166097 HCAPLUS

DN 130:332298

TI Pharmacology of **LY315920/S-5920**, [[3-(**aminooxoacetyl**)-2-ethyl-1-(**phenylmethyl**)-1H-indol-4-yl]oxy]acetate, a potent and selective secretory **phospholipase A2** inhibitor: a new class of anti-inflammatory drugs, SPI

AU Snyder, David W.; Bach, Nicholas J.; Dillard, Robert D.; Draheim, Susan E.; Carlson, Donald G.; Fox, Niles; Roehm, Neal W.; Armstrong, Christopher T.; Chang, Chan H.; Hartley, Lawrence W.; Johnson, Lea M.; Roman, Carlos R.; Smith, Amy C.; Song, Min; Fleisch, Jerome H.

CS Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA

SO Journal of Pharmacology and Experimental Therapeutics (1999), 288(3), 1117-1124

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB **LY315920** is a potent, selective inhibitor of recombinant human, group IIA, nonpancreatic secretory **PLA2** (**sPLA2**). In a chromogenic isolated enzyme assay, **LY315920** inhibited **sPLA2** activity with an IC<sub>50</sub> of 9 .+- . 1 nM or 7.3 .times. 10<sup>-6</sup> mole fraction, which approached the stoichiometric limit of this assay. The true potency of **LY315920** was defined using a deoxycholate/phosphatidylcholine assay with a mole fraction of 1.5 .times. 10<sup>-6</sup>. **LY315920** was 40-fold less active against human, group IB, pancreatic **sPLA2** and was inactive against cytosolic **PLA2** and the constitutive and inducible forms of cyclooxygenase. Human **sPLA2**-induced release of thromboxane A<sub>2</sub> (TXA<sub>2</sub>) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by **LY315920** with an IC<sub>50</sub> of 0.79 .mu.M. The release of TXA<sub>2</sub> from these cells by N-formyl-methionyl-leucyl-phenylalanine or arachidonic acid was not inhibited. The i.v. administration of **LY315920**, 5 min before harvesting the bronchoalveolar lavage cells, resulted in the inhibition of **sPLA2**-induced prodn. of TXA<sub>2</sub> with an ED<sub>50</sub> of 16.1 mg/kg. Challenge of guineapig lung pleural strips with **sPLA2** produced contractile responses that were suppressed in a concn.-dependent manner by **LY315920** with an apparent KB of 83 .+- . 14 nM. Contractile responses induced by arachidonic acid were not altered. I.v. or oral administration of **LY315920** to transgenic mice expressing the human **sPLA2** protein inhibited serum **sPLA2** activity in a dose-related manner over a 4-h time course. **LY315920** is a potent and selective **sPLA2** inhibitor and represents a new class of anti-inflammatory agent designated SPI. This agent is currently undergoing clin. evaluation and should help to define the role of **sPLA2** in various inflammatory disease states.

IT 9001-84-7, **Phospholipase a2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(inhibitors; pharmacol. of **LY315920/S-5920**, a potent and selective secretory **phospholipase A2** inhibitor, in relation to SPI anti-inflammatory drugs)

IT 172732-68-2, **Ly315920**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(pharmacol. of LY315920/S-5920, a potent and selective  
secretory **phospholipase A2** inhibitor, in relation  
to SPI anti-inflammatory drugs)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arbibe, L	1998	102	1152	J Clin Invest	HCAPLUS
Beaton, H	1994	37	557	J Med Chem	HCAPLUS
Becker, G	1994	12	69	BioTechnology	HCAPLUS
Brideau, C	1996	45	68	Inflamm Res	HCAPLUS
Dillard, R	1996	39	5119	J Med Chem	HCAPLUS
Draheim, S	1996	39	5159	J Med Chem	HCAPLUS
Fleisch, J	1996	278	252	J Pharmacol Exp Ther	HCAPLUS
Fox, N	1996	308	195	Eur J Pharmacol	HCAPLUS
Glaser, K	1993	39	C30	Agents Actions	HCAPLUS
Jain, M	1989	28	4135	Biochemistry	HCAPLUS
Kennedy, B	1995	270	22378	J Biol Chem	HCAPLUS
Kortekangas, P	1994	23	68	Scand J Rheumatol	MEDLINE
Kramer, R	1993	266	26796	J Biol Chem	
Macphee, M	1995	81	957	Cell	HCAPLUS
Marshall, L	1995	274	1254	J Pharmacol Exp Ther	HCAPLUS
Masferrer, J	1994	91	3228	Proc Natl Acad Sci U	HCAPLUS
Mihelich, E	1997		140	Basic and Clinical A	HCAPLUS
Minami, T	1993	88	1076	Am J Gastroenterol	MEDLINE
Minami, T	1994	35	1593	Gut	MEDLINE
Nevalainen, T	1992	38	1824	Clin Chem	HCAPLUS
Nevalainen, T	1993	34	1133	Gut	MEDLINE
Prasit, P	1995	5	364	Med Chem Res	HCAPLUS
Pruzanski, W	1991	18	117	J Rheumatol	
Reynolds, L	1994	217	25	Anal Biochem	HCAPLUS
Reynolds, L	1992	204	190	Analyt Biochem	HCAPLUS
Rintala, E	1993	17	864	Clin Infect Dis	MEDLINE
Schadlich, H	1987	25	505	J Clin Chem Biochem	MEDLINE
Schevitz, R	1995	2	458	Nat Struct Biol	HCAPLUS
Snyder, D	1993	266	1147	J Pharmacol Exp Ther	HCAPLUS
Tibes, U	1997	6	279	Exp Opin Invest Drug	HCAPLUS
Tramposch, K	1992	189	272	Biochem Biophys Res	HCAPLUS
Vadas, P	1993	39	160	Circ Shock	HCAPLUS
Vadas, P	1986	55	391	Lab Invest	HCAPLUS
van Rossum, J	1963	143	299	Arch Int Pharmacodyn	HCAPLUS
Waud, D	1976		145	Advances in General	HCAPLUS
Weinrauch, Y	1996	97	250	J Clin Invest	HCAPLUS
Weiss, J	1994	269	26331	J Biol Chem	HCAPLUS
Wright, G	1990	265	6675	J Biol Chem	HCAPLUS

L34 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:31976 HCAPLUS

DN 130:81400

TI Process for preparing 4-substituted-1H-indole-3-glyoxamides

IN Khau, Vien Van; Martinelli, Michael John; Pawlak, Joseph Matthew

PA Eli Lilly and Company, USA

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 887342	A2	19981230	EP 1998-304994	19980625 <--
	EP 887342	A3	19990107		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO  
 TW 455581 B 20010921 TW 1998-87109902 19980619 <--  
 WO 9900360 A1 19990107 WO 1998-US12173 19980622 <--  
 W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH,  
 GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
 LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI,  
 SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG  
 AU 9879613 A1 19990119 AU 1998-79613 19980622 <--  
 AU 735516 B2 20010712  
 BR 9810481 A 20000912 BR 1998-10481 19980622 <--  
 JP 2002506460 T2 20020226 JP 1999-505568 19980622 <--  
 US 5986106 A 19991116 US 1998-105381 19980626 <--  
 NO 9906432 A 20000209 NO 1999-6432 19991223 <--  
 CN 1343662 A 20020410 CN 2001-132979 20010907 <--  
 PRAI US 1997-50877P P 19970626 <--  
 US 1997-50891P P 19970626 <--  
 WO 1998-US12173 W 19980622 <--  
 OS MARPAT 130:81400  
 GI



AB An 8-step process for prepg. 1H-indole-3-glyoxamides I [R1 = alkyl, aralkyl; R2 = H, halogen, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, aryl, aryloxy, heterocyclic; R3 = CO2H, SO3H, P(O)(OH)2; R4-R6 = H, alkyl, alkoxy, haloalkoxy, haloalkyl, Br, Cl, F, I, aryl], useful for inhibiting **sPLA2**, from R2COCH2CO2R7 [R7 = alkyl, aryl, heterocyclic] is claimed. Thus, EtCOCH2CO2Me was treated with 1,3-cyclohexanedione to give 2-(2-oxobutyl)-1,3-cyclohexanedione which was cyclized to tetrahydroindole with PhCH2NH2. The tetrahydroindole was dehydrogenated over Pd-C, treated with BrCH2CO2Me, treated with oxalyl chloride and NH3, and subjected to ester hydrolysis to give I [R1 = CH2Ph, R2 = Et, R3 = CO2H, R4-R6 = H].

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
 -inhibiting activity)

IT **172732-68-2P 172733-42-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
 -inhibiting activity)

L34 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:708940 HCAPLUS

DN 129:326101

TI Method for the treatment of stroke using N-heterocyclic glyoxylamide compounds

IN Genba, Takefumi; Hori, Yozo

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 66 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847507	A1	19981029	WO 1997-JP1421	19970424 <--
	W: JP				
	WO 9847508	A1	19981029	WO 1998-JP1880	19980423 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9870807	A1	19981113	AU 1998-70807	19980423 <--
	EP 977566	A1	20000209	EP 1998-917656	19980423 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002504893	T2	20020212	JP 1998-545475	19980423 <--
	US 6214855	B1	20010410	US 1999-402084	19990929 <--
PRAI	JP 1998-545402	A	19970424 <--		
	WO 1997-JP1421	A	19970424 <--		
	WO 1998-JP1880	W	19980423 <--		

OS MARPAT 129:326101

AB A method or compn. is disclosed for the treatment and/or prevention of stroke using N-heterocyclic glyoxylamide compds.

IT 172732-68-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 172733-42-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

L34 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:672466 HCAPLUS

DN 129:298393

TI Method for treatment of chronic bronchitis

IN Macias, William L.

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9842343	A1	19981001	WO 1998-US5791	19980324 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,				

GA, GN, ML, MR, NE, SN, TD, TG

US 5972988	A	19991026	US 1998-42686	19980312 <--
ZA 9802454	A	19990923	ZA 1998-2454	19980323 <--
AU 9867717	A1	19981020	AU 1998-67717	19980324 <--
EP 1007046	A1	20000614	EP 1998-913085	19980324 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI


JP 2001524962	T2	20011204	JP 1998-545925	19980324 <--
---------------	----	----------	----------------	--------------

PRAI US 1997-42101P P 19970326 <--

WO 1998-US5791 W 19980324 <--

OS MARPAT 129:298393

GI



AB Chronic bronchitis is treated in mammals by administering a therapeutically effective amt. of a 1H-indole-3-glyoxylamide [I; X = O, S; R11 = (substituted) C7-20 alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, etc., or any of these groups attached through a linking group; R12 = H, halo, C1-3 alkyl, C3-4 cycloalkyl or cycloalkenyl, OMe, OEt, SMe, SEt; R14, R15 = H, non-interfering substituent, acidic group attached through a linker; R16, R17 = H, alkyl, alkoxy, alkylcarbonyl, alkylamino, alkylthio, PhO, NH2, Br, Cl, CO2H, NHH2, SO3H, etc.] or a prodrug thereof. Thus, Na [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxylacetate (II), administered as a continuous i.v. infusion for 7 days to achieve a blood II level of 400 ng/mL, alleviated smoker's cough in a subject and increased the peak expiratory flow rate measured by spirometry. II was prepd. by reaction of N-tert-butoxycarbonyl-3-methoxy-2-methylaniline with sec-BuLi and N-methoxy-N-methylpropanamide followed by F3CCO2H to produce 2-ethyl-4-methoxy-1H-indole, benzylation with PhCH2Br, O-demethylation with BBr3, carboxymethylation with BrCH2CO2Me,, reaction with oxalyl chloride and NH3, and sapon.

IT 172732-68-2P 172733-42-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(treatment of chronic bronchitis with indoleglyoxylamides)

L34 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:604907 HCAPLUS

DN 129:189241

TI Preparation and formulation of indoledicarboxylic acid derivatives as sPLA2 inhibitors

IN Ohtani, Mitsuaki; Hagishita, Sanji

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9837069	A1	19980827	WO 1998-JP679	19980219 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,  
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,  
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,  
 UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG  
 AU 9862292 A1 19980909 AU 1998-62292 19980219 <--  
 EP 987250 A1 20000322 EP 1998-904379 19980219 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI  
 PRAI JP 1997-35984 19970220 <--  
 WO 1998-JP679 19980219 <--  
 OS MARPAT 129:189241  
 GI



- AB The title compds. I [R1 = (un)substituted alkyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, alkyl, et.] are prepd. In an in vitro test for **sPLA2** inhibition, the title compd. I [R1 = benzyl; R2 = ethyl; R3 = methyl] showed IC50 of 1.7 nM.
- IT **172732-68-2**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (prepn. of indoledicarboxylic acid derivs. as **sPLA2** inhibitors)
- IT **9001-84-7, Phospholipase A2**  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of indoledicarboxylic acid derivs. as **sPLA2** inhibitors)

## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eli Lilly And Co	1995			JP 07285933 A	HCAPLUS
Eli Lilly And Co	1995			CN 1098714 A	HCAPLUS
Eli Lilly And Co	1995			CN 1098715 A	HCAPLUS
Eli Lilly And Co	1995			CN 1114310 A	HCAPLUS
Eli Lilly And Co	1995			CA 2121321 A	HCAPLUS
Eli Lilly And Co	1995			CA 2121323 A	HCAPLUS
Eli Lilly And Co	1995			CA 2146097 A	HCAPLUS
Eli Lilly And Co	1995			NZ 260298 A	
Eli Lilly And Co	1995			NZ 260299 A	
Eli Lilly And Co	1995			TW 268942 A	
Eli Lilly And Co	1995			NZ 270848 A	
Eli Lilly And Co	1995			TW 306914 A	
Eli Lilly And Co	1995			US 5578634 A	HCAPLUS
Eli Lilly And Co	1995			US 5654326 A	HCAPLUS
Eli Lilly And Co	1995			US 5684034 A	HCAPLUS
Eli Lilly And Co	1995			EP 620214 A1	HCAPLUS
Eli Lilly And Co	1995			EP 620215 A1	HCAPLUS
Eli Lilly And Co	1995			EP 675110 A1	HCAPLUS
Eli Lilly And Co	1995			JP 710838 A	

Eli Lilly And Co	1995		JP 725850 A	
Eli Lilly And Co	1995		CZ 9400893 A	
Eli Lilly And Co	1995		CZ 9400894 A	
Eli Lilly And Co	1995		NO 9401360 A	HCAPLUS
Eli Lilly And Co	1995		NO 9401361 A	HCAPLUS
Eli Lilly And Co	1995		BR 9401482 A	HCAPLUS
Eli Lilly And Co	1995		BR 9401484 A	HCAPLUS
Eli Lilly And Co	1995		FI 9401766 A	HCAPLUS
Eli Lilly And Co	1995		FI 9401767 A	HCAPLUS
Eli Lilly And Co	1995		ZA 9402614 A	HCAPLUS
Eli Lilly And Co	1995		ZA 9402615 A	HCAPLUS
Eli Lilly And Co	1995		AU 9459486 A	HCAPLUS
Eli Lilly And Co	1995		AU 9459492 A	HCAPLUS
Eli Lilly And Co	1995		CZ 9500822 A	
Eli Lilly And Co	1995		NO 9501252 A	HCAPLUS
Eli Lilly And Co	1995		BR 9501404 A	HCAPLUS
Eli Lilly And Co	1995		FI 9501553 A	HCAPLUS
Eli Lilly And Co	1995		ZA 9502693 A	HCAPLUS
Eli Lilly And Co	1995		AU 9516217 A	HCAPLUS

L34 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:713060 HCAPLUS

DN 126:69724

TI Indole Inhibitors of Human Nonpancreatic Secretory **Phospholipase**

**A2. 3. Indole-3-glyoxamides**

AU Draheim, Susan E.; Bach, Nicholas J.; Dillard, Robert D.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.

CS Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SO Journal of Medicinal Chemistry (1996), 39(26), 5159-5175

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnps-**PLA2**. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxamide derivs. Functionalized indole-3-glyoxamides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepd. and tested as inhibitors of hnps-**PLA2**. It was found that the indole-3-glyoxamides with a 4-oxyacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-acetamides, and **LY315920** (6m) was selected for evaluation clin. as an hnps-**PLA2** inhibitor.

IT **172732-68-2P, LY 315920**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

L34 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2002 ACS

AN 1995:994542 HCAPLUS

DN 124:117083

TI Preparation of indole-3-glyoxylamides as **sPLA2** inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 78 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 675110	A1	19951004	EP 1995-302166	19950331	<--
	EP 675110	B1	20020710			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
	CA 2146097	AA	19951002	CA 1995-2146097	19950331	<--
	FI 9501553	A	19951002	FI 1995-1553	19950331	<--
	NO 9501252	A	19951002	NO 1995-1252	19950331	<--
	AU 9516217	A1	19951012	AU 1995-16217	19950331	<--
	AU 688458	B2	19980312			
	JP 07285933	A2	19951031	JP 1995-76117	19950331	<--
	JP 3109974	B2	20001120			
	CN 1114310	A	19960103	CN 1995-103320	19950331	<--
	CN 1067054	B	20010613			
	BR 9501404	A	19960305	BR 1995-1404	19950331	<--
	HU 72048	A2	19960328	HU 1995-957	19950331	<--
	ZA 9502693	A	19960930	ZA 1995-2693	19950331	<--
	RU 2128169	C1	19990327	RU 1995-104885	19950331	<--
	TW 383302	B	20000301	TW 1995-84103168	19950331	<--
	IL 113210	A1	20010128	IL 1995-113210	19950331	<--
	PL 180523	B1	20010228	PL 1995-307951	19950331	<--
	EP 1081135	A2	20010307	EP 2000-203897	19950331	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT					
	EP 1197484	A2	20020417	EP 2001-130290	19950331	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT					
	AT 220394	E	20020715	AT 1995-302166	19950331	<--
	US 5654326	A	19970805	US 1995-469954	19950606	<--
	US 5733923	A	19980331	US 1997-825453	19970328	<--
	US 5919810	A	19990706	US 1997-856271	19970514	<--
	US 5919943	A	19990706	US 1997-991149	19971216	<--
	US 6175021	B1	20010116	US 1999-258680	19990226	<--
	US 6433001	B1	20020813	US 2000-714364	20001116	<--
PRAI	US 1994-221916	A	19940401			<--
	EP 1995-302166	A3	19950331			<--
	US 1995-469954	A3	19950606			<--
	US 1997-825453	A1	19970328			<--
	US 1997-856271	A1	19970514			<--
	US 1999-258680	A1	19990226			<--
OS	MARPAT 124:117083					
GI						



AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr3 to give 69% 1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole. This was O-alkylated with NaH/BrCH2CO2Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)<sub>2</sub> followed by amidation with NH<sub>3</sub> and ester hydrolysis to give title compd. (II). II inhibited human secreted **PLA2** with IC<sub>50</sub> = 4.33 nM.

IT **172732-68-2P 172733-42-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

IT **9001-84-7, Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(secretory; prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

=> fil embase

FILE 'EMBASE' ENTERED AT 14:40:25 ON 17 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 10 Oct 2002 (20021010/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L82 ANSWER 1 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN **1999289982** EMBASE

TI **Secretory** event in intestinal grafts during preservation  
**ischemia.**

AU Arcuni J.; Wang L.; Yousef K.; Chiu S.; Mikkelsen K.; Franson R.D.;  
Sonnino R.E.

CS Dr. R.E. Sonnino, University of Kansas Medical Center, 3901 Rainbow Blvd.,  
Kansas City, KS 66160, United States. rsonnino@kumc.edu

SO Journal of Surgical Research, (15 Jun 1999) 84/2 (233-239).

Refs: 25  
ISSN: 0022-4804 CODEN: JSGRA2  
CY United States  
DT Journal; Article  
FS 009 Surgery  
037 Drug Literature Index  
048 Gastroenterology  
LA English  
SL English  
AB Background. **Ischemia** triggers secretion of proteins from the intestine, including type H **secretory phospholipase A2 (sPLA2)**. This '**secretory** event' was studied in intestinal grafts during the first few hours of preservation by measuring total protein, **sPLA2**, and other enzymes in the UW preservation solution over time. The effect of PX-13, a **PLA2 inhibitor**, was also studied. Materials and methods. Twenty-five centimeter intestinal grafts were harvested from Lewis rats, flushed, and preserved in UW solution .+-. PX-13 at 4.degree.C. UW samples from 0 to 48 h (n = 5 each) were analyzed for total protein, **sPLA2**, lactate dehydrogenase (LDH), N-acetylglucosamine (NAGA), and lysozyme. Nonpreserved grafts were homogenized in PBS as tissue controls. Standard biochemical methods were used for all assays. Results. Total protein increased rapidly by 5 min, continued to rise more slowly until 30 min, and then stabilized. The most significant increase in **sPLA2** activity occurred between 90 and 180 min. NAGA increased most markedly between 30 and 180 min, while LDH increased in the first 30 min, although the level of both enzymes was negligible compared to tissue enzyme. Lysozyme levels were minimal at all times. PX-13 decreased **sPLA2** activity markedly at all time points. Conclusion. Total protein levels increased before **sPLA2**, suggesting that **sPLA2** may be secreted in response to other proteins or enzymes released even earlier during preservation (e.g., cytokines). These elevations do not appear to be caused by cell death. **Phospholipase A2** secretion may be **blocked**, and this may greatly improve the outcome of intestinal preservation.  
CT Medical Descriptors:  
    \*intestine ischemia  
    \*intestine graft  
    protein secretion  
    treatment outcome  
    postoperative complication  
    nonhuman  
    rat  
    animal experiment  
    animal tissue  
    article  
    priority journal  
Drug Descriptors:  
    \*phospholipase a2  
    \*phospholipase a2 inhibitor: DV, drug development  
    \*phospholipase a2 inhibitor: PD, pharmacology  
px 13  
RN (phospholipase a2) 9001-84-7  
CN Px 13  
  
L82 ANSWER 2 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 97169782 EMBASE  
DN 1997169782  
TI **Phospholipase A2** secretion during intestinal graft ischemia.  
AU Sonnino R.E.; Pigatt L.; Schrama A.; Burchett S.; Franson R.  
CS Dr. R.E. Sonnino, Division of Pediatric Surgery, P.O. Box 980015, Richmond, VA 23298, United States

SO Digestive Diseases and Sciences, (1997) 42/5 (972-981).  
Refs: 36  
ISSN: 0163-2116 CODEN: DDSCDJ

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy  
048 Gastroenterology

LA English

SL English

AB The time-dependent appearance of **phospholipase A<sub>2</sub>** (**PLA<sub>2</sub>**) activity in the preservation media of **ischemic** rat intestinal grafts is described. In controls, **Ca<sup>2+</sup>-dependent**, **secretory PLA<sub>2</sub>** activity accumulated rapidly during the first 6 hr of **ischemia**, followed by a linear increase for up to 48 hr. LDH levels, by contrast, increased linearly throughout the 48 hr of **ischemia**. Addition of **inhibitors** of **PLA<sub>2</sub>**, cyclooxygenase, and lipooxygenase **blocked** accumulation of **PLA<sub>2</sub>** but not LDH. PX-13, a novel **PEA<sub>2</sub> inhibitor**, was most effective: 40. $\mu$ M **inhibited** release by 86%, while 25 . $\mu$ M indomethacin (cyclooxygenase **blocker**) or nordihydroguaiaretic acid (lipooxygenase **blocker**) **inhibited** 41 and 36%, respectively. That appearance of **PLA<sub>2</sub>** activity, but not LDH, is attenuated by **inhibitors** of the eicosanoid cascade suggests a **secretory** event rather than leakage from dying cells. The secreted **PLA<sub>2</sub>** is most likely the proinflammatory **sPLA<sub>2</sub>** that has been implicated as a stress- induced protein and priming agent in **ischemia-reperfusion injury**.

CT Medical Descriptors:  
\*intestine graft  
    **\*intestine ischemia**  
animal experiment  
animal model  
animal tissue  
article  
controlled study  
disease association  
enzyme release  
male  
nonhuman  
pathogenesis  
priority journal  
rat  
Drug Descriptors:  
    **\*phospholipase a<sub>2</sub>**  
indometacin  
lactate dehydrogenase  
prostaglandin synthase

RN (**phospholipase a<sub>2</sub>**) 9001-84-7; (indometacin)  
53-86-1, 74252-25-8, 7681-54-1; (lactate dehydrogenase) 9001-60-9;  
(prostaglandin synthase) 39391-18-9, 59763-19-8, 9055-65-6

L82 ANSWER 3 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 96086570 EMBASE

DN 1996086570

TI Glyburide-reversible cardioprotective effects of calcium-independent **phospholipase A<sub>2</sub> inhibition** in **ischemic** rat hearts.

AU Sargent C.A.; wilde M.W.; Dzwonczyk S.; Tuttle J.G.; Murray H.N.; Atwal K.; Grover G.J.

CS Department of Pharmacology, Bristol-Myers Squibb Pharm. Res Inst, PO Box 4000, Princeton, NJ 08543, United States

SO Cardiovascular Research, (1996) 31/2 (270-277).  
ISSN: 0008-6363 CODEN: CVREAU



CY Netherlands  
DT Journal; Article  
FS 002 Physiology  
018 Cardiovascular Diseases and Cardiovascular Surgery  
030 Pharmacology  
037 Drug Literature Index  
LA English  
SL English  
AB Objectives: A myocardial calcium-independent **PLA2** has been described, that is activated during myocardial **ischemia** and this enzyme may modulate ATP-sensitive potassium channels (K(ATP)). The aim of this study was to determine the effect of an **inhibitor** of this enzyme, a bromoenol lactone, in isolated globally **ischemic** rat hearts. Methods: Isolated rat hearts were treated for 10 min with 0.3-6 .mu.M bromoenol lactone and then subjected to 25 min **ischemia** and 30 min **reperfusion**. Results: The bromoenol lactone significantly increased coronary flow in **nonischemic** myocardium, and slightly reduced cardiac function at 6 .mu.M. During global **ischemia**, time to contracture was significantly increased from vehicle group values in the presence of the bromoenol lactone (EC50 - 1.2 .mu.M) During **reperfusion**, a concentration-dependent increase in function and a reduction in LDH release were observed for the **PLA2** , **inhibitor**. The concentrations of the **PLA2** **inhibitor** which were significantly cardioprotective, **inhibited** this enzyme in membrane fractions of rat myocardium (IC50 - 0.87 .mu.M). The K(ATP) **blocker** sodium 5-hydroxydecanoate (5-HD) **inhibited** the increase in time to contracture observed for the bromoenol lactone. During **reperfusion** , 5-HD abolished the protective effects of the bromoenol lactone on cardiac function and LDH release. Glyburide had similar effects on the cardioprotective activity of the bromoenol lactone, although it only partially abolished the LDH reducing effect of this agent. Conclusions: The bromoenol lactone protects **ischemic** myocardium at concentrations which also **inhibit** calcium-independent **PLA2**. This cardioprotection can be attenuated by **blockers** of K(ATP), suggesting a potential mechanism for modulation of myocardial K(ATP).  
CT Medical Descriptors:  
    \*heart muscle ischemia  
    \*reperfusion injury  
animal tissue  
article  
controlled study  
male  
nonhuman  
priority journal  
rat  
Drug Descriptors:  
    \*glibenclamide: PD, pharmacology  
5 hydroxydecanoic acid: PD, pharmacology  
bromoenol lactone: PD, pharmacology  
lactate dehydrogenase: EC, endogenous compound  
    phospholipase a2: EC, endogenous compound  
unclassified drug  
RN (glibenclamide) 10238-21-8; (lactate dehydrogenase) 9001-60-9; (  
    phospholipase a2) 9001-84-7  
CO Bristol myers squibb  
  
L82 ANSWER 4 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 95370070 EMBASE  
DN 1995370070  
TI Reducing **ischemia-reperfusion injury** in rat  
island groin flaps by dexamethasone and BW755C.

AU Dolan R.W.; Kerr D.; Arena S.  
 CS Department of Otolaryngology, Boston University School of Medicine, 720  
 Harrison Ave., Boston, MA 02118, United States  
 SO Laryngoscope, (1995) 105/12 I (1322-1325).  
 ISSN: 0023-852X CODEN: LARYA8  
 CY United States  
 DT Journal; Article  
 FS 011 Otorhinolaryngology  
 030 Pharmacology  
 037 Drug Literature Index  
 LA English  
 SL English  
 AB Despite the known effectiveness of anti-inflammatory therapy in reducing  
**reperfusion injury**, no studies to date involve the use  
 of anti-inflammatory therapy in reducing **ischemia-**  
**reperfusion injury** in fasciocutaneous flaps.  
 Dexamethasone (a **phospholipase A2 inhibitor**)  
 and specific cyclooxygenase and lipoxxygenase **inhibitors**  
 (indomethacin and BW755C) were administered to rats with **ischemic**  
 island groin (fasciocutaneous) flaps. Significant improvement in  
**ischemic** flap survival was found with dexamethasone and BW755C.  
 The mode of action of dexamethasone was not specifically investigated in  
 our study; however, it may suppress neutrophil function and reduce  
**ischemia-reperfusion injury** in its shared  
 ability with BW755C to reduce the formation of leukotrienes. Dexamethasone  
 could be applied in the clinical setting to reduce **ischemic** flap  
 loss by attenuating the systemic inflammatory response to  
**reperfused ischemic**-damaged tissue.  
 CT Medical Descriptors:  
 \*inguinal flap  
   **\*ischemia**  
   **\*reperfusion injury**  
 animal experiment  
 animal model  
 article  
 cell viability  
 controlled study  
 drug efficacy  
 endothelium cell  
   **enzyme inhibition**  
 fasciocutaneous flap  
 island flap  
 lymphocyte activation  
 macrophage function  
 neutrophil  
 nonhuman  
 priority journal  
 rat  
   **tissue injury**  
 Drug Descriptors:  
 \*3 amino 1 (3 trifluoromethylphenyl) 2 pyrazoline: PD, pharmacology  
 \*dexamethasone: PD, pharmacology  
 \*indometacin: PD, pharmacology  
 RN (3 amino 1 (3 trifluoromethylphenyl) 2 pyrazoline) 66000-40-6;  
 (dexamethasone) 50-02-2; (indometacin) 53-86-1, 74252-25-8, 7681-54-1  
 CN Bw 755c  
 L82 ANSWER 5 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 95306757 EMBASE  
 DN 1995306757  
 TI The role of oxygen free radicals and **phospholipase A2**  
 in **ischemia-reperfusion injury** to the liver.  
 AU Park M.-J.; Cho T.-S.; Lee S.-M.

CS College of Pharmacy, Sung Kyung Kwan University, Suwon 440-746, Korea, Republic of

SO Archives of Pharmacal Research, (1995) 18/3 (189-194).  
ISSN: 0253-6269 CODEN: APHRDQ

CY Korea, Republic of

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy  
029 Clinical Biochemistry  
048 Gastroenterology  
030 Pharmacology  
037 Drug Literature Index

LA English

SL English

AB The focus of this study was to investigate the influences of enzymatic scavengers of active oxygen metabolites and **phospholipase A2 inhibitor** on hepatic **secretory** and microsomal function during hepatic **ischemia/reperfusion**. Rats were pretreated with free radical scavengers such as superoxide dismutase (SOD), catalase, deferoxamine and **phospholipase A2 inhibitor** such as quinacrine and then subjected to 60 min. no-flow hepatic **ischemia** in vivo. After 1, 5 hr of **reperfusion**, bile was collected, blood was obtained from the abdominal aorta, and liver microsomes were isolated. Serum aminotransferase (ALT) level was increased at 1 hr and peaked at 5 hr. The increase in ALT was significantly attenuated by SOD plus catalase, deferoxamine and quinacrine especially at 5 hr of **reperfusion**. The wet weight-to-dry weight ratio of the liver was significantly increased by **ischemia/reperfusion**. SOD and catalase treatment minimized the increase in this ratio. Hepatic lipid peroxidation was elevated by **ischemia/reperfusion**, and this elevation was **inhibited** by free radical scavengers and quinacrine. Bile flow and cholate output, but not bilirubin output, were markedly decreased by **ischemia/reperfusion** and quinacrine restored the secretion. Cytochrome P450 content was decreased by **ischemia/reperfusion** and restored by free radical scavengers and quinacrine to the level of that of the sham operated group. Aminopyrine N-demethylase activity was decreased and aniline p-hydroxylase was increased by **ischemia/reperfusion**. The changes in the activities of the two enzymes were prevented by free radical scavengers and quinacrine. Our findings suggest that **ischemia/reperfusion** diminishes hepatic **secretory** functions as well as microsomal drug metabolizing systems by increasing lipid peroxidation, and in addition to free radicals, other factors such as **phospholipase A2** are involved in pathogenesis of hepatic dysfunction after **ischemia/reperfusion**.

CT Medical Descriptors:  
\*liver function  
  \***liver ischemia**  
  \***reperfusion injury**: DT, drug therapy  
  \***reperfusion injury**: PC, prevention  
animal model  
article  
bile flow  
controlled study  
intravenous drug administration  
lipid peroxidation  
liver weight  
male  
nonhuman  
rat  
Drug Descriptors:  
\*aminotransferase: EC, endogenous compound  
\*bilirubin: EC, endogenous compound

\*cholic acid: EC, endogenous compound  
 \*liver enzyme: EC, endogenous compound  
 \*phospholipase a2: EC, endogenous compound  
 \*radical: EC, endogenous compound  
 \*scavenger: CM, drug comparison  
 \*scavenger: DT, drug therapy  
 \*scavenger: PD, pharmacology  
 aminopyrine n demethylase: EC, endogenous compound  
 catalase: CM, drug comparison  
 catalase: DT, drug therapy  
 catalase: PD, pharmacology  
 catalase: CB, drug combination  
 deferoxamine: CM, drug comparison  
 deferoxamine: DT, drug therapy  
 mepacrine: DT, drug therapy  
 mepacrine: CM, drug comparison

**phospholipase a2 inhibitor**

**phospholipase inhibitor**

superoxide dismutase: CM, drug comparison  
 superoxide dismutase: DT, drug therapy  
 superoxide dismutase: PD, pharmacology  
 superoxide dismutase: CB, drug combination  
 unspecific monooxygenase: EC, endogenous compound  
 RN (aminotransferase) 9031-66-7; (bilirubin) 18422-02-1, 635-65-4; (cholic acid) 32500-01-9, 361-09-1, 81-25-4; (**phospholipase a2**) **9001-84-7**; (aminopyrine n demethylase) 9037-69-8; (catalase) 9001-05-2; (deferoxamine) 70-51-9; (mepacrine) 69-05-6, 83-89-6; (superoxide dismutase) 37294-21-6, 9016-01-7, 9054-89-1; (unspecific monooxygenase) 9012-80-0, 9037-52-9, 9038-14-6

CO Sigma

L82 ANSWER 6 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 93270524 EMBASE

DN 1993270524

TI **Reperfusion injury after intestinal ischemia**

AU Schoenberg M.H.; Beger H.G.

CS Department of General Surgery, University of Ulm, Steinhovelstr. 9, 7900 Ulm, Germany

SO Critical Care Medicine, (1993) 21/9 (1376-1386).

ISSN: 0090-3493 CODEN: CCMDC7

CY United States

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

024 Anesthesiology

048 Gastroenterology

LA English

SL English

AB Objective: Review the histologic and pathophysiologic alterations seen after intestinal **ischemia** and **reperfusion**. Data Source: Current literature review. Study Selection: The most pertinent, current, and representative articles describing results from both animal and human investigations are utilized and discussed. Data Synthesis: **Postischemic** intestinal tissue damage appears to be due to the formation of oxygen radicals and the activation of **phospholipase A2**. The initial source of oxygen radicals seems to be the hypoxanthine-xanthine oxidase system. Oxygen radicals react directly with polyunsaturated fatty acids, leading to lipid peroxidation within the cell membranes. Indirectly, the radicals trigger the accumulation of neutrophils within the affected tissue initiating inflammatory processes that lead to severe mucosal lesions. Similarly, **phospholipase A2** also initiates **postischemic** mucosal lesions. **Phospholipase A2** is a hydrolytic enzyme capable of

increasing formation of cytotoxic lysophospholipids within the tissue. Enhanced activity of **phospholipase A2** also stimulates the production of prostaglandins and leukotrienes. Various substances (superoxide dismutase, catalase, dimethyl sulfoxide, allopurinol, and deferoxamine, etc.) are able to detoxify oxygen radicals or **inhibit** the mechanisms leading to their enhanced generation, thus attenuating the **postischemic** lesions of the mucosa. Conclusions: Oxygen radicals and the activation of **phospholipase A2** during **reperfusion** seem to be instrumental for the development of hemorrhagic mucosal lesions after intestinal **ischemia**. Radical scavengers and **phospholipase A2 inhibitors** may prevent **reperfusion** damage of the intestine, even when the treatment starts during **ischemia** but before **reperfusion**.

CT Medical Descriptors:

- \*intestine ischemia: ET, etiology
- \*reperfusion injury: CO, complication
- \*reperfusion injury: ET, etiology

article  
enzyme activation  
enzyme activity  
histopathology  
human  
intestine mucosa  
intestine ulcer  
nonhuman  
oxidation  
pathophysiology  
priority journal

L82 ANSWER 7 OF 7 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 93060528 EMBASE

DN 1993060528

TI **Reperfusion** mucosal damage after complete intestinal **ischemia** in the dog: The effects of antioxidant and **phospholipase A2 inhibitor** therapy.

AU Boros M.; Karacsony G.; Kaszaki J.; Nagy S.

CS Institute of Experimental Surgery, Szent-Gyorgyi Albert Medical Univ., P.O. Box 464, H-6701 Szeged, Hungary

SO Surgery, (1993) 113/2 (184-191).

ISSN: 0039-6060 CODEN: SURGAZ

CY United States

DT Journal; Article

FS 002 Physiology

009 Surgery

LA English

SL English

AB In a recent study, **reperfusion** mucosal injury was demonstrated in a rat model of total **ischemia** if venous congestion was avoided. The aims were to examine the possibility of **reperfusion** damage in a canine model involving 2 hours of complete segmental **ischemia** and to investigate the effects of antioxidant therapy or pretreatment with nonspecific **phospholipase A2 inhibitors** on postocclusive mucosal changes. Tissue samples were evaluated histologically in a blind manner, according to a 0 to V grade scale. The degree of mucosal damage was statistically significantly increased during the 30-minute **reperfusion** period. Similarly, 2 hours of total **ischemia** followed by 30 minutes of **reperfusion** produced significantly more tissue lesions than did 2 1/2 hours of **ischemia** without **reperfusion**. Oral allopurinol pretreatment supplemented by an intravenous dose, or oral allopurinol in combination with a superoxide radical scavenger, resulted in a significant amelioration of **postischemic** histologic

changes. Pretreatment with a nonspecific **phospholipase A2 inhibitor** (methylprednisolone, dexamethasone, or quinacrine) was ineffective in diminishing the **reperfusion injury** in either case. The results suggest that **reperfusion injury** may develop even after complete intestinal **ischemia**, and this damage can be attenuated by **inhibiting** the capacity of xanthine oxidase to generate reactive oxygen intermediates.

CT Medical Descriptors:

\***intestine ischemia**

\***reperfusion injury**

animal experiment

animal model

animal tissue

article

controlled study

dog

female

**ischemia**

male

mucosa

nonhuman

priority journal

**tissue injury: ET, etiology**

vein occlusion: ET, etiology

Drug Descriptors:

\***allopurinol**

\***antioxidant**

\***dexamethasone**

\***mepacrine**

\***methylprednisolone**

\***phospholipase a2**

\***xanthine oxidase**

RN (allopurinol) 315-30-0; (dexamethasone) 50-02-2; (mepacrine) 69-05-6, 83-89-6; (methylprednisolone) 6923-42-8, 83-43-2; (**phospholipase a2**) 9001-84-7; (xanthine oxidase) 9002-17-9

=> fil medline

FILE 'MEDLINE' ENTERED AT 14:53:42 ON 17 OCT 2002

FILE LAST UPDATED: 15 OCT 2002 (20021015/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> d all tot

L101 ANSWER 1 OF 8 MEDLINE

AN 97292997 MEDLINE

DN 97292997 PubMed ID: 9149050

TI **Phospholipase A2** secretion during intestinal graft **ischemia**.

AU Sonnino R E; Pigatt L; Schrama A; Burchett S; Franson R

CS Department of Biochemistry and Molecular Biophysics, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.

SO DIGESTIVE DISEASES AND SCIENCES, (1997 May) 42 (5) 972-81.  
Journal code: 7902782. ISSN: 0163-2116.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199706  
 ED Entered STN: 19970612  
 Last Updated on STN: 19970612  
 Entered Medline: 19970604  
 AB The time-dependent appearance of **phospholipase A2 (PLA2)** activity in the preservation media of **ischemic** rat intestinal grafts is described. In controls,  $\text{Ca}^{2+}$ -dependent, secretory **PLA2** activity accumulated rapidly during the first 6 hr of **ischemia**, followed by a linear increase for up to 48 hr. LDH levels, by contrast, increased linearly throughout the 48 hr of **ischemia**. Addition of inhibitors of **PLA2**, cyclooxygenase, and lipooxygenase blocked accumulation of **PLA2**, but not LDH. PX-13, a novel **PLA2** inhibitor, was most effective: 40 microM inhibited release by 86%, while 25 microM indomethacin (cyclooxygenase blocker) or nordihydroguaiaretic acid (lipooxygenase blocker) inhibited 41 and 36%, respectively. That appearance of **PLA2** activity, but not LDH, is attenuated by inhibitors of the eicosanoid cascade suggests a secretory event rather than leakage from dying cells. The secreted **PLA2** is most likely the proinflammatory **sPLA2** that has been implicated as a stress-induced protein and priming agent in **ischemia-reperfusion injury**.  
 CT Check Tags: Animal; Male; Support, Non-U.S. Gov't  
 Alkanesulfonates: PD, pharmacology  
 Cyclooxygenase Inhibitors: PD, pharmacology  
 Enzyme Inhibitors: PD, pharmacology  
 Indomethacin: PD, pharmacology  
 Intestinal Mucosa: EN, enzymology  
 \*Jejunum: TR, transplantation  
 Lactate Dehydrogenase: ME, metabolism  
 Lipooxygenase Inhibitors: PD, pharmacology  
 Organ Preservation Solutions  
 Phospholipases A: AI, antagonists & inhibitors  
 \*Phospholipases A: ME, metabolism  
 Rats  
 Rats, Inbred Lew  
 \*Reperfusion Injury: EN, enzymology  
 Time Factors  
 RN 53-86-1 (Indomethacin)  
 CN 0 (Alkanesulfonates); 0 (Cyclooxygenase Inhibitors); 0 (Enzyme Inhibitors); 0 (Lipooxygenase Inhibitors); 0 (Organ Preservation Solutions); 0 (PX 13); EC 1.1.1.27 (Lactate Dehydrogenase); EC 3.1.1.- (Phospholipases A)  
 L101 ANSWER 2 OF 8 MEDLINE  
 AN 95208760 MEDLINE  
 DN 95208760 PubMed ID: 7900800  
 TI Gut **phospholipase A2** mediates neutrophil priming and lung **injury** after mesenteric **ischemia-reperfusion**.  
 AU Koike K; Moore E E; Moore F A; Kim F J; Carl V S; Banerjee A  
 CS Department of Surgery, Denver General Hospital, Colorado.  
 NC P50GM-49222 (NIGMS)  
 R29HL-43696 (NHLBI)  
 T32GM-08315 (NIGMS)  
 SO AMERICAN JOURNAL OF PHYSIOLOGY, (1995 Mar) 268 (3 Pt 1) G397-403.  
 Journal code: 0370511. ISSN: 0002-9513.  
 CY United States

DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199504  
ED Entered STN: 19950504  
Last Updated on STN: 19970203  
Entered Medline: 19950425

AB Intestinal **ischemia-reperfusion** (I/R) provokes polymorphonuclear neutrophil (PMN)-mediated lung **injury** via a process characterized by circulating PMN priming, pulmonary PMN sequestration, and increased microvascular leak in the lung. We found in rats subjected to intestinal I/R (**ischemia** 45 min and **reperfusion** 6 h) that 1) intestinal **phospholipase A2 (PLA2)** was activated during **ischemia**, 2) circulating PMN priming (assessed by superoxide production with N-formyl-Met-Leu-Phe) occurred after 1 h **reperfusion**, and 3) exaggerated 125I-labeled albumin lung leak occurred after 2 h **reperfusion**, compared with sham-treated animals ( $P < 0.05$ ). Treatment with a **PLA2** inhibitor, quinacrine, within 15 min of **reperfusion** reversed the exaggerated gut **PLA2** activity and abrogated subsequent PMN priming and lung leak ( $P < 0.05$ ). However, when quinacrine was administered after 2 h of **reperfusion**, circulating PMN priming and lung leak continued to evolve despite suppression of intestinal **PLA2** activity. We conclude that intestinal **PLA2** activation may be a prerequisite for the sequelae of circulating PMN priming and pulmonary microvascular leak observed after intestinal I/R.

CT Check Tags: Animal; Male; Support, U.S. Gov't, P.H.S.  
Enzyme Activation  
Intestines: BS, blood supply  
\*Intestines: EN, enzymology  
\***Ischemia**  
Kinetics  
\*Lung Diseases: ET, etiology  
N-Formylmethionine Leucyl-Phenylalanine: PD, pharmacology  
\*Neutrophils: PH, physiology  
\***Phospholipases A: AI, antagonists & inhibitors**  
\***Phospholipases A: PH, physiology**  
Quinacrine: PD, pharmacology  
Rats  
Rats, Sprague-Dawley  
\***Reperfusion Injury: PP, physiopathology**  
Serum Albumin, Radio-Iodinated: ME, metabolism  
\*Splanchnic Circulation  
Superoxides: BL, blood

RN 11062-77-4 (Superoxides); 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine); 83-89-6 (Quinacrine)

CN 0 (Serum Albumin, Radio-Iodinated); **EC 3.1.1.- (Phospholipases A)**

L101 ANSWER 3 OF 8 MEDLINE  
AN **93342635** MEDLINE  
DN **93342635** PubMed ID: **8342134**  
TI Platelet-activating factor-induced polymorphonuclear neutrophil priming independent of CD11b adhesion.  
AU Read R A; Moore E E; Moore F A; Carl V S; Banerjee A  
CS Department of Surgery, Denver General Hospital, University of Colorado Health Sciences Center 80204-4507.  
SO SURGERY, (1993 Aug) 114 (2) 308-13.  
Journal code: 0417347. ISSN: 0039-6060.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals



EM 199308  
ED Entered STN: 19930917  
Last Updated on STN: 19930917  
Entered Medline: 19930831  
AB BACKGROUND. Our previous studies have implicated **phospholipase A2**-dependent platelet-activating factor (PAF) production in the genesis of polymorphonuclear neutrophil (PMN)-mediated tissue **injury** after gut **ischemia-reperfusion**. Further, these studies have suggested a discordance of PMN sequestration and tissue **injury**. CD11B-dependent PMN-endothelial cell adhesion has been purported to play a dominant role in PMN-mediated tissue **injury**. We therefore undertook this study with the hypothesis that PAF-induced PMN superoxide production requires CD11B-mediated PMN-endothelial cell adherence. METHODS. Human PMNs, isolated by Percoll gradient centrifugation, were exposed to PAF (10 ng/ml). At fixed times of exposure during 120 minutes, (1) superoxide production, (2) CD11B receptor expression, and (3) PMN adhesion to unstimulated human umbilical vein endothelial cell cultures were assayed. RESULTS. PAF induced prompt changes in PMN priming (increased superoxide production after N-formyl-methyl-leucyl-phenylalanine activation), adhesion to unstimulated endothelial cells, and CD11B receptor expression. Priming was temporally concordant with the rise and fall of CD11B expression but appeared to precede adhesion. CD11B blockade (F(Ab') 2 anti-CD11B [60.1] antibodies), before or at maximal PAF priming, reduced PMN adhesion but had no effect on superoxide production. CONCLUSIONS. In summary, PAF-induced PMN priming occurs in temporal concordance with the expression of CD11B and subsequent endothelial cell adherence, but CD11B-mediated adherence is not essential for this process.  
CT Check Tags: Human  
Cell Adhesion  
Cells, Cultured  
Endothelium, Vascular: DE, drug effects  
Endothelium, Vascular: PH, physiology  
Macrophage-1 Antigen: AN, analysis  
\*Macrophage-1 Antigen: PH, physiology  
\*Neutrophils: DE, drug effects  
Neutrophils: PH, physiology  
\*Platelet Activating Factor: PD, pharmacology  
CN 0 (Macrophage-1 Antigen); 0 (Platelet Activating Factor)  
L101 ANSWER 4 OF 8 MEDLINE  
AN 93157904 MEDLINE  
DN 93157904 PubMed ID: 8430367  
TI **Reperfusion** mucosal damage after complete intestinal **ischemia** in the dog: the effects of antioxidant and **phospholipase A2** inhibitor therapy.  
AU Boros M; Karacsony G; Kaszaki J; Nagy S  
CS Institute of Experimental Surgery, Szent-Gyorgyi Albert Medical University, Szeged, Hungary.  
SO SURGERY, (1993 Feb) 113 (2) 184-91.  
Journal code: 0417347. ISSN: 0039-6060.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199303  
ED Entered STN: 19930326  
Last Updated on STN: 19930326  
Entered Medline: 19930308  
AB In a recent study, **reperfusion** mucosal **injury** was demonstrated in a rat model of total **ischemia** if venous congestion was avoided. The aims were to examine the possibility of **reperfusion** damage in a canine model involving 2 hours of complete

segmental **ischemia** and to investigate the effects of antioxidant therapy or pretreatment with nonspecific **phospholipase A2** inhibitors on postocclusive mucosal changes. Tissue samples were evaluated histologically in a blind manner, according to a 0 to V grade scale. The degree of mucosal damage was statistically significantly increased during the 30-minute **reperfusion** period. Similarly, 2 hours of total **ischemia** followed by 30 minutes of **reperfusion** produced significantly more tissue lesions than did 2 1/2 hours of **ischemia** without **reperfusion**. Oral allopurinol pretreatment supplemented by an intravenous dose, or oral allopurinol in combination with a superoxide radical scavenger, resulted in a significant amelioration of **postischemic** histologic changes. Pretreatment with a nonspecific **phospholipase A2** inhibitor (methylprednisolone, dexamethasone, or quinacrine) was ineffective in diminishing the **reperfusion injury** in either case. The results suggest that **reperfusion injury** may develop even after complete intestinal **ischemia**, and this damage can be attenuated by inhibiting the capacity of xanthine oxidase to generate reactive oxygen intermediates.

CT Check Tags: Animal; Female; Male; Support, Non-U.S. Gov't  
 Allopurinol: TU, therapeutic use  
 \*Antioxidants: PD, pharmacology  
 Dexamethasone: PD, pharmacology  
 Dogs  
 \*Ileum: BS, blood supply  
 Ileum: PA, pathology  
 \*Intestinal Mucosa: DE, drug effects  
 Intestinal Mucosa: PA, pathology  
 \*Ischemia: DT, drug therapy  
 Ischemia: PA, pathology  
 Methylprednisolone: PD, pharmacology  
 \*Phospholipases A: AI, antagonists & inhibitors  
 Quinacrine: PD, pharmacology  
 \*Quinolines: PD, pharmacology  
 \*Reperfusion Injury: DT, drug therapy  
 RN 315-30-0 (Allopurinol); 50-02-2 (Dexamethasone); 83-43-2 (Methylprednisolone); 83-89-6 (Quinacrine); 90829-56-4 (6,6'-methylenebis(2,2-dimethyl-4-methanesulfonic acid-1,2-dihydroquinoline))  
 CN 0 (Antioxidants); 0 (Quinolines); EC 3.1.1.- (Phospholipases A)

L101 ANSWER 5 OF 8 MEDLINE

AN 92351281 MEDLINE

DN 92351281 PubMed ID: 1322564

TI **Phospholipase A2** inhibition decouples lung injury from gut **ischemia-reperfusion**.

AU Koike K; Moore E E; Moore F A; Carl V S; Pitman J M; Banerjee A

CS Department of Surgery, Denver General Hospital, Colo.

NC P50-HL40784 (NHLBI)

R29-HL43696 (NHLBI)

T32-GM08315 (NIGMS)

SO SURGERY, (1992 Aug) 112 (2) 173-80.

Journal code: 0417347. ISSN: 0039-6060.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199208

ED Entered STN: 19920911

Last Updated on STN: 19920911

Entered Medline: 19920828

AB BACKGROUND. **Phospholipase A2** (PLA2) has recently been implicated as a key enzyme of local inflammation after gut

**ischemia-reperfusion (I/R)**. The hypothesis of this study is that **PLA2** inhibition decouples remote organ injury from gut I/R. **METHODS**. Sprague-Dawley rats were pretreated with a **PLA2** inhibitor, quinacrine (10 mg/kg, intravenously), before the induction of gut **ischemia** (45 minutes of superior mesenteric artery occlusion) followed by 6 hours of **reperfusion**. <sup>125</sup>I-labeled albumin leak was employed as a marker of pulmonary endothelial permeability and myeloperoxidase as a monitor of neutrophil (PMN) traffic in the gut and lung. To further characterize the impact of **PLA2** inhibition, PMNs were harvested at 6 hours of **reperfusion** and superoxide production was measured in the presence or absence of an activating stimulus, N-formyl-methionyl-leucyl-phenylalanine. **RESULTS**. Gut I/R increased gut **PLA2** activity, elicited gut PMN influx, and produced lung leak; these events were prevented by **PLA2** blockade. Gut I/R also markedly enhanced PMN superoxide production with N-formyl-methionyl-leucyl-phenylalanine, and this priming was ablated by **PLA2** inhibition. **CONCLUSION**. These data suggest that **PLA2** activation is a proximal step in the pathogenesis of distant organ injury after splanchnic **hypoperfusion**, a process that appears to involve PMN priming in the gut bed.

CT Check Tags: Animal; Male; Support, U.S. Gov't, P.H.S.

Capillary Permeability

\*Intestines: BS, blood supply

\***Ischemia: PA, pathology**

Lung: ME, metabolism

\*Lung: PA, pathology

Neutrophils: ME, metabolism

Peroxidase: ME, metabolism

\***Phospholipases A: AI, antagonists & inhibitors**

**Phospholipases A: ME, metabolism**

Rats

Rats, Inbred Strains

\***Reperfusion Injury: PA, pathology**

Serum Albumin: ME, metabolism

Superoxides: ME, metabolism

RN 11062-77-4 (Superoxides)

CN 0 (Serum Albumin); EC 1.11.1.7 (Peroxidase); EC 3.1.1.-  
(**Phospholipases A**)

L101 ANSWER 6 OF 8 MEDLINE

AN 92272636 MEDLINE

DN 92272636 PubMed ID: 1590734

TI Changes in phosphoinositide-specific phospholipase C and  
**phospholipase A2** activity in **ischemic** and  
**reperfused** rat heart.

AU Schwertz D W; Halverson J

CS Department of Pharmacology and Medical Surgical Nsg, University of  
Illinois, Chicago.

NC NR 02203 (NINR)

SO BASIC RESEARCH IN CARDIOLOGY, (1992 Mar-Apr) 87 (2) 113-27.

Journal code: 0360342. ISSN: 0300-8428.

CY GERMANY: Germany, Federal Republic of

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199206

ED Entered STN: 19920710

Last Updated on STN: 19960129

Entered Medline: 19920625

AB Phospholipid metabolism is altered during **ischemia** and post-  
**ischemic reperfusion**. Past studies demonstrating  
elevated myocardial free fatty acid and lysophospholipid content infer

accelerated phospholipid degradation involving **phospholipase A** activity. Recently, **ischemic** and **post-ischemic reperfusion (reperfusion)** have been shown to affect levels of phosphoinositide (PPI) degradation products. Considering the role of PPI turnover in regulation of cellular calcium homeostasis, our laboratory and others have suggested that alteration in the metabolism of the inositol phospholipids could play a role in the development of **ischemia-induced calcium overload injury**. Using an isolated rat heart model (**Langendorff perfusion**), this study examines the effect of global **ischemia** and **reperfusion** on ventricular phosphoinositide-specific phospholipase C (PLC) activity and **PLA2** activity. The primary purpose was to determine if **ischemia** and **reperfusion**-induced changes in PLC activity could explain previously observed changes in PPI degradation products, and whether PLC and **PLA2** activities were similarly or differentially altered by **ischemia** and **reperfusion**. PLC and **PLA2** activities were measured in cytosolic and total membrane fractions from control (**perfused**), **ischemic** (5, 10, 30, and 60 min), and **post-ischemic reperfusion** ventricular tissue. Phospholipase activity was determined under optimal in vitro conditions using exogenous radiolabeled substrates. Alterations in membrane-associated PPI-PLC activity correlated with reported **ischemia** and **reperfusion**-induced changes in ventricular content of PPI metabolites. Membrane PLC activity increased slightly at 5 min of **ischemia**, decreased significantly at 10 min of **ischemia**, and continued to decrease with longer duration of **ischemia** (73% of control after 60 min). Cytosolic PPI-PLC activity was decreased at 5 min, and then significantly increased by longer durations of **ischemia**, while cytosolic **PLA2** activity was reduced at all time points. Pretreatment with muscarinic, alpha 1-adrenergic, beta-adrenergic, and adenosine receptor blockers did not alter **ischemia**-elicited changes in PLC activity. **Reperfusion** caused a 140% to 200% rise in the activities of all phospholipases in all fractions after 40 min of **ischemia**, but not after 10 min of **ischemia**. Results suggest 1) **ischemia** and **reperfusion**-elicited alterations in membrane-associated PPI-PLC activity can explain previously observed changes in phosphoinositide turnover metabolites, 2) cytosolic and membrane-associated PPI-PLC and **PLA2** activities are not uniformly affected by **ischemia**, 3) **reperfusion** following **ischemia** of sufficient duration initiates uniform activation of PIP2-PLC and **PLA2**, and 4) because **ischemia** and **reperfusion**-induced changes in phospholipase activity can be detected under optimal in vitro assay conditions (removed from the in vivo **ischemic** microenvironment), it is likely that the enzymes themselves have been altered.

CT Check Tags: Animal; Male; Support, U.S. Gov't, P.H.S.

\*Coronary Disease: EN, enzymology

Disease Models, Animal

Phospholipase C: AI, antagonists & inhibitors

\*Phospholipase C: ME, metabolism

Phospholipases A: AI, antagonists & inhibitors

\*Phospholipases A: ME, metabolism

Rats

Rats, Inbred Strains

\*Reperfusion Injury: EN, enzymology

Time Factors

CN EC 3.1.1.- (Phospholipases A); EC 3.1.4.3 (Phospholipase C)

L101 ANSWER 7 OF 8 MEDLINE

AN 90160664 MEDLINE

DN 90160664 PubMed ID: 2516320

TI Pharmacologic protection of **perfused** rat heart against global

**ischemia.**

AU Katsuoka M; Ohnishi S T  
 CS Membrane Research Institute, University City Science Center, Philadelphia, PA 19104.  
 SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, (1989 Dec) 38 (3) 151-6.  
 Journal code: 8802730. ISSN: 0952-3278.  
 CY SCOTLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199003  
 ED Entered STN: 19900601  
 Last Updated on STN: 19980206  
 Entered Medline: 19900327  
 AB Using a Langendorff rat heart model, studies were performed on the effects of three drugs in protecting the heart against global **ischemia**. The drugs used were: (a) MR-256, a prostaglandin oligomeric derivative, which is a calcium chelating agent and at the same time, is an inhibitor of **phospholipase A2** activity, (b) chlorpromazine which is not a calcium chelator, but is a calmodulin antagonist and is an inhibitor of **phospholipase A2** activity, and (c) BAPTA/AM, a calcium chelating agent, but which is not an inhibitor of **phospholipase A2** activity. The **perfused heart** was exposed to 15 minutes of global **ischemia**. In control experiments (no drug), the ventricular pressure recovered to 26.4 +/- 6.7% (n = 22) of the original level. With pretreatment of (a) MR-256 (b) chlorpromazine, and (c) BAPTA/AM, maximum recoveries were 0.5 +/- 6.7% (n = 5), 88.7 +/- 8.5% (n = 5), 45.3 +/- 26.6% (n = 5), respectively. MR-256 and chlorpromazine were found to react with free radicals. The modes of action of these three different types of drugs are discussed.  
 CT Check Tags: Animal; In Vitro; Male; Support, Non-U.S. Gov't  
 Chlorpromazine: TU, therapeutic use  
 \*Coronary Disease: PC, prevention & control  
 Egtazic Acid: TU, therapeutic use  
 Free Radicals  
 \*Heart: DE, drug effects  
 Myocardial Contraction: DE, drug effects  
 \*Myocardial Reperfusion Injury: PC, prevention & control  
 Phospholipases A: AI, antagonists & inhibitors  
 Prostaglandins: TU, therapeutic use  
 Rats  
 Rats, Inbred Strains  
 RN 119314-69-1 (MR 256); 50-53-3 (Chlorpromazine); 67-42-5 (Egtazic Acid); 85233-19-8 (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)  
 CN 0 (Free Radicals); 0 (Prostaglandins); EC 3.1.1.- (Phospholipases A)

L101 ANSWER 8 OF 8 MEDLINE

AN 89154777 MEDLINE

DN 89154777 PubMed ID: 3229863

TI The effects of **phospholipase A2** inhibition on experimental infarct size, left ventricular hemodynamics and regional myocardial blood flow.

AU Zalewski A; Goldberg S; Maroko P R

CS Cardiology Division, Thomas Jefferson University, Philadelphia, Pennsylvania.

SO INTERNATIONAL JOURNAL OF CARDIOLOGY, (1988 Dec) 21 (3) 247-57.

Journal code: 8200291. ISSN: 0167-5273.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198904  
ED Entered STN: 19900306  
Last Updated on STN: 19900306  
Entered Medline: 19890414  
AB It has been reported that activation of **phospholipase A2** and the subsequent degradation of membrane phospholipids are responsible for irreversible myocardial **injury**. Thus, we examined whether a **phospholipase A2** inhibitor 1-(benzylmethyl-amino)-3-[(alpha, alpha, alpha-trifluoro-m-tolyl)oxy]-2- propanol hydrochloride, can reduce myocardial necrosis after coronary artery occlusion. In 14 anesthetized dogs, 1 minute after coronary occlusion, 99mTc-labeled albumin microspheres (8 mCi) were injected into the left atrium for future assessment of the **hypoperfused** zone. After 15 minutes, the dogs were randomized to a control group (n = 7) and a treated group (n = 7, 2 mg/kg i.v.). After 6 hours, infarct size and **hypoperfused** zones were measured using triphenyltetrazolium chloride staining and autoradiography, respectively. The **hypoperfused** zone, as a percentage of the left ventricle, was 26 +/- 3% and 23 +/- 1% in the control and the treated groups (NS), respectively. The percentage of the **hypoperfused** zone that evolved to necrosis was 98 +/- 4% in the control group and 45 +/- 10% in the treated group (P less than 0.001) showing a reduction of 54%. By weight, in the control group, necrosis involved 26 +/- 4 g of the left ventricle while in the treated group it was 9 +/- 2 g (P less than 0.005). In 6 additional dogs, left ventricular hemodynamics and regional myocardial blood flow were studied before and after treatment i.e., 15 and 30 minutes after coronary occlusion, respectively. **Phospholipase A2** inhibitor did not acutely change heart rate, aortic pressure, left ventricular end-diastolic and systolic pressures, left ventricular dP/dt and regional myocardial blood flow. Thus, **phospholipase A2** inhibitor salvaged the acutely **ischemic** myocardium, reducing necrosis by over 50% in the canine model. It is postulated that since this effect was not related to the studied hemodynamic parameters and regional myocardial blood flow, it may be related to the preservation of membrane integrity.

CT Check Tags: Animal  
\*Coronary Circulation: DE, drug effects  
Dogs  
\*Hemodynamics: DE, drug effects  
\*Myocardial Infarction: DT, drug therapy  
\*Myocardial Infarction: EN, enzymology  
Myocardium: EN, enzymology  
\*Phospholipases: AI, antagonists & inhibitors  
\*Phospholipases A: AI, antagonists & inhibitors  
\*Propanolamines: PD, pharmacology

RN 5214-61-9 (1-(benzylmethlamino)-3-(alpha, alpha, alpha-trifluoro-3-tolyl)oxy-2-propanol)

CN 0 (Propanolamines); EC 3.1.- (Phospholipases); EC 3.1.1.- (Phospholipases A)

=> fil reg  
FILE 'REGISTRY' ENTERED AT 15:10:37 ON 17 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1  
DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.



Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que l122

L104 583311 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-C6/ES  
 L106 342395 SEA FILE=REGISTRY ABB=ON PLU=ON 333.151.57/RID  
 L108 STR



G1-G4  
 10 11





Ak @28

VAR G1=7/9  
 VAR G2=O/S  
 VAR G3=H/X/28  
 VAR G4=13/19  
 NODE ATTRIBUTES:  
 CONNECT IS E2 RC AT 23  
 CONNECT IS E1 RC AT 24  
 CONNECT IS E1 RC AT 28  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC 7  
 NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE  
 L115 STR



VAR G1=7/9  
 VAR G2=O/S  
 REP G3=(0-1) N  
 NODE ATTRIBUTES:  
 CONNECT IS E1 RC AT 32  
 DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 7

NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L118 1236 SEA FILE=REGISTRY SUB=L104 SSS FUL L115  
L119 1059 SEA FILE=REGISTRY ABB=ON PLU=ON L118 AND L106  
L121 421 SEA FILE=REGISTRY SUB=L118 SSS FUL L108  
L122 411 SEA FILE=REGISTRY ABB=ON PLU=ON L119 AND L121

=> d his l122-

(FILE 'REGISTRY' ENTERED AT 14:53:58 ON 17 OCT 2002)

SAV L121 KWON807A/A

L122 411 S L119 AND L121  
L123 10 S L121 NOT L122  
L124 409 S L122 NOT L13,L14

FILE 'HCAPLUS' ENTERED AT 15:06:15 ON 17 OCT 2002

L125 193 S L124  
L126 166 S L125 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L127 27 S L126 AND L22-L25,L27  
L128 6 S L126 AND L1,L4  
L129 2 S L126 AND (?ISCHEM? OR ?ISCHAEM?)  
L131 1 S L126 AND ?PERFUS?  
E ISCHEMIA/CT  
E E3+ALL  
L132 5203 S E5,E4+NT  
E E9+ALL  
L133 9519 S E3,E2+NT  
E E1+ALL  
L134 11377 S E1+NT  
L135 1 S L126 AND L132-L134  
L136 6 S L128-L131,L135  
L137 4 S L127 AND L136  
L138 6 S L136,L137  
L139 23 S L127 NOT L138

FILE 'REGISTRY' ENTERED AT 15:10:37 ON 17 OCT 2002

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:10:52 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16

FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)



This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d l138 bib abs hitrn fhitr retable tot

L138 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:283786 HCAPLUS

DN 134:290409

TI Preparation of V type and/or X type sPLA2 inhibitors

IN Ono, Takashi; Ueno, Masahiko; Hanasaki, Kohji

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 58 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001026653	A1	20010419	WO 2000-JP7024	20001010 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,				
	SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,				
	ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 1999-293273	A	19991015 <--		
OS	MARPAT 134:290409				
GI					



AB V type and/or X type **sPLA2** inhibitors which contain as the active ingredient compds. represented by general formulas [I; X = CHR<sup>2</sup>, N; X<sup>1</sup> = C, N; X<sup>2</sup> = C, N; Y = R<sup>6</sup>; Z = R<sup>7</sup>; YZ = C(CONH<sup>2</sup>):CHCH:CH; R<sup>1</sup> = OH, NHSO<sub>2</sub>C<sub>6</sub>H<sub>5</sub>; R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> independently = H, CH<sub>3</sub>, C<sub>6</sub>H<sub>5</sub>, F; ; R<sup>5</sup> = 4-C<sub>6</sub>H<sub>5</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>, cyclohexylmethyl, 2-cyclopentylphenyl; R<sup>6</sup> = H, C<sub>1</sub>-3 alkyl; R<sup>7</sup> = COCONH<sup>2</sup>, CH<sub>2</sub>CONH<sup>2</sup>; dotted bond = single, double], prodrugs thereof, and pharmaceutically acceptable salts of the same or solvates of the same are prepd. as V type and/or X type **sPLA2** inhibitors. Thus, the title compd. II was prepd. and tested for X type **sPLA2** inhibition with an IC<sub>50</sub> of 3 nM.

IT **258262-50-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of V type and/or X type **sPLA2** inhibitors)

IT **9001-84-7, Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of V type and/or X type **sPLA2** inhibitors)


IT **258262-50-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of V type and/or X type **sPLA2** inhibitors)

RN 258262-50-9 HCAPLUS

CN 1H-Indole-3-acetamide, 2-ethyl-.alpha.-oxo-4-[2-oxo-2-[(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eli Lilly And Company				JP 07285933 A	HCAPLUS
Eli Lilly And Company				EP 1043991 A1	HCAPLUS
Eli Lilly And Company				JP 10503208 A	
Eli Lilly And Company				JP 10505336 A	
Eli Lilly And Company				JP 10505584 A	
Eli Lilly And Company				CN 1098714 A	HCAPLUS
Eli Lilly And Company				CN 1098715 A	HCAPLUS
Eli Lilly And Company				CN 1114310 A	HCAPLUS
Eli Lilly And Company				CN 1158121 A	HCAPLUS
Eli Lilly And Company				CA 2121321 A	HCAPLUS
Eli Lilly And Company				CA 2121323 A	HCAPLUS
Eli Lilly And Company				CA 2146097 A	HCAPLUS
Eli Lilly And Company				CA 2195432 A	HCAPLUS
Eli Lilly And Company				CA 2195569 A	HCAPLUS
Eli Lilly And Company				CA 2195570 A	HCAPLUS
Eli Lilly And Company				US 5578634 A	HCAPLUS

Eli Lilly And Company				US 5641800 A	HCAPLUS
Eli Lilly And Company				US 5654326 A	HCAPLUS
Eli Lilly And Company				US 5684034 A	HCAPLUS
Eli Lilly And Company				US 5733923 A	HCAPLUS
Eli Lilly And Company				US 5919810 A	HCAPLUS
Eli Lilly And Company				US 5919943 A	HCAPLUS
Eli Lilly And Company				HU 70205 A	HCAPLUS
Eli Lilly And Company				HU 70836 A	HCAPLUS
Eli Lilly And Company				JP 710838 A	
Eli Lilly And Company				HU 72048 A	HCAPLUS
Eli Lilly And Company				JP 725850 A	
Eli Lilly And Company				EP 769940 A1	HCAPLUS
Eli Lilly And Company				EP 772592 A1	HCAPLUS
Eli Lilly And Company				EP 772596 A1	HCAPLUS
Eli Lilly And Company				HU 77867 A	HCAPLUS
Eli Lilly And Company				NO 9401360 A	HCAPLUS
Eli Lilly And Company				NO 9401361 A	HCAPLUS
Eli Lilly And Company				BR 9401482 A	HCAPLUS
Eli Lilly And Company				BR 9401484 A	HCAPLUS
Eli Lilly And Company				FI 9401766 A	HCAPLUS
Eli Lilly And Company				FI 9401767 A	HCAPLUS
Eli Lilly And Company				ZA 9402614 A	HCAPLUS
Eli Lilly And Company				ZA 9402615 A	HCAPLUS
Eli Lilly And Company				AU 9459486 A	HCAPLUS
Eli Lilly And Company				AU 9459492 A	HCAPLUS
Eli Lilly And Company				NO 9501252 A	HCAPLUS
Eli Lilly And Company				BR 9501404 A	HCAPLUS
Eli Lilly And Company				FI 9501553 A	HCAPLUS
Eli Lilly And Company				ZA 9502693 A	HCAPLUS
Eli Lilly And Company				BR 9508298 A	HCAPLUS
Eli Lilly And Company				AU 9516217 A	HCAPLUS
Eli Lilly And Company				AU 9531406 A	HCAPLUS
Eli Lilly And Company				AU 9531459 A	HCAPLUS
Eli Lilly And Company				AU 9531980 A	HCAPLUS
Eli Lilly And Company				AU 9914073 A	
Eli Lilly And Company	1994			EP 620214 A1	HCAPLUS
Eli Lilly And Company	1994			EP 620215 A1	HCAPLUS
Eli Lilly And Company	1995			EP 675110 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603120 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603376 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603383 A1	HCAPLUS
Eli Lilly And Company	1999			WO 9925340 A1	HCAPLUS
Sawada, H	1999	26	826	Eur J Biochem	
Shionogi & Co Ltd				AU 9862292 A	HCAPLUS
Shionogi & Co Ltd				EP 987250 A1	HCAPLUS
Shionogi & Co Ltd				AU 9930543 A	HCAPLUS
Shionogi & Co Ltd	1998			WO 9837069 A1	HCAPLUS
Shionogi & Co Ltd	1999			WO 9951605 A1	HCAPLUS

L138 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:260062 HCAPLUS

DN 132:284251

TI Remedies or preventives containing **sPLA2** inhibitors for  
**ischemic** reflow failure

IN **Todo, Satoru**PA **Shionogi & Co., Ltd., Japan**

SO PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	----	-----	-----	-----
-------	------	-------	-------	-------

PI WO 2000021563 A1 20000420 WO 1999-JP5528 19991007 <--  
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,  
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
 IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,  
 MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
 TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 9960047 A1 20000501 AU 1999-60047 19991007 <--  
 EP 1157704 A1 20011128 EP 1999-970328 19991007 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 PRAI JP 1998-292423 A 19981014 <--  
 WO 1999-JP5528 W 19991007 <--  
 OS MARPAT 132:284251  
 AB The invention relates to remedies or preventives for **ischemic**  
 reflow failure which contain an **sPLA2** inhibitor, e.g.  
 [[3-[2-Amino-1,2-dioxoethyl]-2-methyl-1-(phenylmethyl)-1H-indol-4-  
 yl]oxy]acetic acid, as active ingredient. Capsules were formulated contg.  
**sPLA2** inhibitor 250, starch 200 and magnesium stearate 10  
 mg/capsule.  
 IT 172732-60-4 172732-61-5 172732-62-6  
 172732-63-7 172732-64-8 172732-65-9  
 172732-66-0 172732-67-1 172732-69-3  
 172732-70-6 172732-71-7 172732-72-8  
 172732-73-9 211925-45-0 263910-31-2  
 263910-32-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (remedies or preventives contg. **sPLA2** inhibitors for  
**ischemic** reflow failure)  
 IT 9001-84-7, **Phospholipase A2**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (secretory, inhibitor of; remedies or preventives contg. **sPLA2**  
 inhibitors for **ischemic** reflow failure)  
 IT 172732-60-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (remedies or preventives contg. **sPLA2** inhibitors for  
**ischemic** reflow failure)  
 RN 172732-60-4 HCAPLUS  
 CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-  
 yl]oxy]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
=====	=====	=====	=====	=====	=====
Anon				JP 07285933 A	HCAPLUS
Anon				CN 1098714 A	HCAPLUS
Anon				CN 1114310 A	HCAPLUS
Anon				CA 2121321 A	HCAPLUS
Anon				CA 2146097 A	HCAPLUS
Anon				NZ 260299 A	
Anon				NZ 270848 A	
Anon				TW 306914 A	
Anon				US 5578634 A	HCAPLUS
Anon				US 5654326 A	HCAPLUS
Anon				US 5733923 A	HCAPLUS
Anon				US 5919774 A	HCAPLUS
Anon				US 5919810 A	HCAPLUS
Anon				US 5919943 A	HCAPLUS
Anon				JP 710838 A	
Anon				EP 779211 A1	
Anon				EP 779273 A1	HCAPLUS
Anon				CZ 9400894 A3	
Anon				NO 9401360 A	HCAPLUS
Anon				BR 9401484 A	HCAPLUS
Anon				FI 9401766 A	HCAPLUS
Anon				ZA 9402614 A	HCAPLUS
Anon				AU 9459486 A	HCAPLUS
Anon				EP 946495 A1	HCAPLUS
Anon				CZ 9500822 A3	
Anon				NO 9501252 A	HCAPLUS
Anon				BR 9501404 A	HCAPLUS
Anon				FI 9501553 A	HCAPLUS
Anon				MX 9501608 A	
Anon				ZA 9502693 A	HCAPLUS
Anon				AU 9516217 A	HCAPLUS
Anon				BR 9612347 A	HCAPLUS
Anon				AU 9711497 A	HCAPLUS
Anon				AU 9712897 A	HCAPLUS
Anon				AU 985592 A	
Anon				AU 9855983	HCAPLUS
Anon				HU 9901984 A2	
Eisai Co Ltd				JP 07285866 A	HCAPLUS
Eisai Co Ltd				CN 1112920 A	HCAPLUS
Eisai Co Ltd				CA 2141987 A	HCAPLUS
Eisai Co Ltd				ZA 9501467 A	HCAPLUS
Eisai Co Ltd				AU 9512374 A	HCAPLUS
Eisai Co Ltd	1995			EP 672415 A1	HCAPLUS
Eli Lilly And Company				JP 10503208 A	
Eli Lilly And Company				JP 10505336 A	
Eli Lilly And Company				JP 10505584 A	
Eli Lilly And Company				CN 1098715 A	HCAPLUS
Eli Lilly And Company				CA 2121323 A	HCAPLUS
Eli Lilly And Company				NZ 260298 A	
Eli Lilly And Company				TW 268942 A	
Eli Lilly And Company				US 5641800 A	HCAPLUS
Eli Lilly And Company				US 5684034 A	HCAPLUS
Eli Lilly And Company				US 5916922 A	HCAPLUS
Eli Lilly And Company				US 5972972 A	HCAPLUS
Eli Lilly And Company				JP 725850 A	
Eli Lilly And Company				EP 769940 A1	HCAPLUS
Eli Lilly And Company				EP 772592 A1	HCAPLUS
Eli Lilly And Company				EP 772596 A1	HCAPLUS
Eli Lilly And Company				EP 839806 A1	HCAPLUS
Eli Lilly And Company				EP 846687 A1	HCAPLUS

Eli Lilly And Company				CZ 9400893 A3	
Eli Lilly And Company				NO 9401361 A	HCAPLUS
Eli Lilly And Company				BR 9401482 A	HCAPLUS
Eli Lilly And Company				FI 9401767 A	HCAPLUS
Eli Lilly And Company				ZA 9402615 A	HCAPLUS
Eli Lilly And Company				EP 944636 A1	HCAPLUS
Eli Lilly And Company				AU 9459492 A	HCAPLUS
Eli Lilly And Company				BR 9508298 A	HCAPLUS
Eli Lilly And Company				AU 9531406 A	HCAPLUS
Eli Lilly And Company				AU 9531459	HCAPLUS
Eli Lilly And Company				AU 9531980 A	HCAPLUS
Eli Lilly And Company				MX 9700511 A1	
Eli Lilly And Company				ZA 9710878 A	HCAPLUS
Eli Lilly And Company				KR 97704695 A	
Eli Lilly And Company				AU 9851494 A	HCAPLUS
Eli Lilly And Company				AU 9853655 A	HCAPLUS
Eli Lilly And Company				AU 9854544 A	HCAPLUS
Eli Lilly And Company				NO 9901831 A	HCAPLUS
Eli Lilly And Company	1994			EP 620214 A1	HCAPLUS
Eli Lilly And Company	1994			EP 620215 A1	HCAPLUS
Eli Lilly And Company	1995			EP 675110 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603120 A1	HCAPLUS
Eli Lilly And Company	1996			WO 9603383 A1	HCAPLUS
Eli Lilly And Company	1996			WO 963376 A1	
Eli Lilly And Company	1997			WO 9721664 A1	HCAPLUS
Eli Lilly And Company	1997			WO 9721716 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9818464 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9824437 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9824794 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9824856 A1	HCAPLUS
Eli Lilly And Company	1998			WO 9825609 A1	HCAPLUS
Jun, T	1998	440	377	FEBS Letters	
Sargent, C	1992	262	1161	J Pharm Ther	HCAPLUS
Shionogi & Co Ltd	1999			WO 9951605 A1	HCAPLUS
Shionogi & Co Ltd	1999			WO 9959999 A1	HCAPLUS
Sonnino, R	1997	42	972	Dig Dis Sci	HCAPLUS
Windt, L	1998	180	65	Mol Cell Biochem	
Yoshihiro, S	1998	107		J Kyoto Pref Univ Me	

L138 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:576777 HCAPLUS

DN 131:204622

TI Pharmaceutical compositions containing the phospholipase inhibitor sodium  
 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate

IN Confer, William Lester; Tai, Hideaki

PA Shionogi &amp; Co., Ltd., Japan

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944604	A1	19990910	WO 1999-US4516	19990302 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

CA 2322796	AA 19990910	CA 1999-2322796	19990302 <--
AU 9927998	A1 19990920	AU 1999-27998	19990302 <--
BR 9908479	A 20001205	BR 1999-8479	19990302 <--
EP 1058547	A1 20001213	EP 1999-908612	19990302 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6166062	A 20001226	US 1999-260490	19990302 <--
JP 2002505282	T2 20020219	JP 2000-534206	19990302 <--
NO 2000004306	A 20001010	NO 2000-4306	20000829 <--
PRAI US 1998-76659P	A2 19980303 <--		
WO 1999-US4516	W 19990302 <--		

GI



I


AB A lyophilized pharmaceutical compn. is described which contains I, a solubilizer, and stabilizer. Such compns. are storage stable and readily dissolve in aq. medium to give injectable soln. for treatment of sepsis, etc. I was prepd. and addn. of tri-Na citrate solubilizer to I solns. improved stability of the soln.

IT **172733-08-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pharmaceuticals contg. the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate and stabilizers and solubilizers)

IT **172733-08-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (pharmaceuticals contg. the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl]-1H-indol-4-yl]oxy]acetate and stabilizers and solubilizers)

RN 172733-08-3 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Fiedler	1989	1	309	Lexikon Der Hilfssto	
Fiedler	1989	2	751	Lexikon Der Hilfssto	
Lilly Co Eli	1995			EP 0675110 A	HCAPLUS

L138 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:325791 HCAPLUS

DN 130:338017

TI Method for the treatment of disorders associated with apoptosis using  
N-heterocyclic glyoxylamide compounds

IN Yagami, Tatsuro; Takasu, Nobuo

PA Shionogi &amp; Co., Ltd., Japan

SO PCT Int. Appl., 104 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924033	A1	19990520	WO 1997-JP4104	19971112 <--
	W: JP, US				
	CA 2308269	AA	19990520	CA 1998-2308269	19981110 <--
	WO 9924026	A2	19990520	WO 1998-JP5042	19981110 <--
	WO 9924026	A3	19990715		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9897630	A1	19990531	AU 1998-97630	19981110 <--
	EP 1037630	A2	20000927	EP 1998-951749	19981110 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	WO 1997-JP4104	A	19971112	<--	
	WO 1998-JP5042	W	19981110	<--	
OS	MARPAT 130:338017				
GI					



I



II

AB A method is disclosed for the treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds. I [E, F = C, N; the dotted line indicates the presence or absence of a double bond; R11 = alkyl, etc.; R12 = H, halo, etc.; R14 = H, etc.; R15 = H, etc.; R16 = H,



carboxyl or ester thereof; R17 = H, alkyl, etc.; X = O, S]. Indole deriv.  
II (prepn. given) in vitro suppressed neuronal death depending on its  
concn.

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-69-3P  
172732-70-6P 172732-71-7P 172732-72-8P  
172732-73-9P 172732-74-0P 172733-08-3P  
211925-44-9P 211925-45-0P 211925-46-1P  
224581-09-3P 224581-10-6P 224581-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treatment of disorders assocd. with apoptosis using  
N-heterocyclic glyoxylamide compds.)

IT 9001-84-7, **Phospholipase A2**

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
(Biological study)

(method for treatment of disorders assocd. with apoptosis using  
N-heterocyclic glyoxylamide compds.)


IT 172732-60-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)

(method for treatment of disorders assocd. with apoptosis using  
N-heterocyclic glyoxylamide compds.)

RN 172732-60-4 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-  
yl]oxy]- (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Dillard, R	1996			WO 9603383 A	HCAPLUS
Draheim	1996  39	5159		J Med Chem	HCAPLUS
Gonzalo, J	1993  23	2372		European Journal of	HCAPLUS
Lilly Co Eli	1995			EP 0675110 A	HCAPLUS
Lilly Co Eli	1995			WO 9517183 A	HCAPLUS
Russel, R	1996			WO 9640982 A	HCAPLUS

L138 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:708940 HCAPLUS

DN 129:326101

TI Method for the treatment of stroke using N-heterocyclic glyoxylamide  
compounds

IN Genba, Takefumi; Hori, Yozo

PA **Shionogi & Co., Ltd., Japan**


SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent


LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847507	A1	19981029	WO 1997-JP1421	19970424 <--
	W: JP				
	WO 9847508	A1	19981029	WO 1998-JP1880	19980423 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9870807	A1	19981113	AU 1998-70807	19980423 <--
	EP 977566	A1	20000209	EP 1998-917656	19980423 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002504893	T2	20020212	JP 1998-545475	19980423 <--
	US 6214855	B1	20010410	US 1999-402084	19990929 <--
PRAI	JP 1998-545402	A	19970424 <--		
	WO 1997-JP1421	A	19970424 <--		
	WO 1998-JP1880	W	19980423 <--		
OS	MARPAT 129:326101				
AB	A method or compn. is disclosed for the treatment and/or prevention of stroke using N-heterocyclic glyoxylamide compds.				
IT	5548-10-7D, derivs. 172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8 172732-65-9 172732-66-0 172732-67-1 172732-69-3 172732-70-6 172732-71-7 172732-72-8 172732-73-9 172732-74-0				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)				
IT	172733-08-3P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and reaction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)				
IT	5548-10-7D, derivs.				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)				
RN	5548-10-7 HCAPLUS				
CN	1H-Indole-3-acetamide, .alpha.-oxo- (9CI) (CA INDEX NAME)				



AN 1998:604907 HCAPLUS  
 DN 129:189241  
 TI Preparation and formulation of indoledicarboxylic acid derivatives as  
**sPLA2** inhibitors  
 IN Ohtani, Mitsuaki; Hagishita, Sanji  
 PA Shionogi & Co., Ltd., Japan  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9837069	A1	19980827	WO 1998-JP679	19980219 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9862292	A1	19980909	AU 1998-62292	19980219 <--
	EP 987250	A1	20000322	EP 1998-904379	19980219 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	JP 1997-35984		19970220 <--		
	WO 1998-JP679		19980219 <--		
OS	MARPAT 129:189241				
GI					



AB The title compds. I [R1 = (un)substituted alkyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, alkyl, et.] are prepd. In an in vitro test for **sPLA2** inhibition, the title compd. I [R1 = benzyl; R2 = ethyl; R3 = methyl] showed IC50 of 1.7 nM.

IT 211925-44-9P 211925-45-0P 211925-46-1P 211925-47-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of indoledicarboxylic acid derivs. as **sPLA2** inhibitors)

IT 9001-84-7, Phospholipase A2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (prepn. of indoledicarboxylic acid derivs. as **sPLA2** inhibitors)


IT 211925-55-2P 211925-56-3P 211925-60-9P 211925-61-0P 211925-62-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of indoledicarboxylic acid derivs. as **sPLA2** inhibitors)

IT 211925-63-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of indoledicarboxylic acid derivs. as **sPLA2**  
 inhibitors)

IT 211925-44-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of indoledicarboxylic acid derivs. as **sPLA2**  
 inhibitors)

RN 211925-44-9 HCAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-  
 1-(phenylmethyl)-, 6-methyl ester (9CI) (CA INDEX NAME)



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Eli Lilly And Co	1995			JP 07285933 A	HCAPLUS
Eli Lilly And Co	1995			CN 1098714 A	HCAPLUS
Eli Lilly And Co	1995			CN 1098715 A	HCAPLUS
Eli Lilly And Co	1995			CN 1114310 A	HCAPLUS
Eli Lilly And Co	1995			CA 2121321 A	HCAPLUS
Eli Lilly And Co	1995			CA 2121323 A	HCAPLUS
Eli Lilly And Co	1995			CA 2146097 A	HCAPLUS
Eli Lilly And Co	1995			NZ 260298 A	
Eli Lilly And Co	1995			NZ 260299 A	
Eli Lilly And Co	1995			TW 268942 A	
Eli Lilly And Co	1995			NZ 270848 A	
Eli Lilly And Co	1995			TW 306914 A	
Eli Lilly And Co	1995			US 5578634 A	HCAPLUS
Eli Lilly And Co	1995			US 5654326 A	HCAPLUS
Eli Lilly And Co	1995			US 5684034 A	HCAPLUS
Eli Lilly And Co	1995			EP 620214 A1	HCAPLUS
Eli Lilly And Co	1995			EP 620215 A1	HCAPLUS
Eli Lilly And Co	1995			EP 675110 A1	HCAPLUS
Eli Lilly And Co	1995			JP 710838 A	
Eli Lilly And Co	1995			JP 725850 A	
Eli Lilly And Co	1995			CZ 9400893 A	
Eli Lilly And Co	1995			CZ 9400894 A	
Eli Lilly And Co	1995			NO 9401360 A	HCAPLUS
Eli Lilly And Co	1995			NO 9401361 A	HCAPLUS
Eli Lilly And Co	1995			BR 9401482 A	HCAPLUS
Eli Lilly And Co	1995			BR 9401484 A	HCAPLUS
Eli Lilly And Co	1995			FI 9401766 A	HCAPLUS
Eli Lilly And Co	1995			FI 9401767 A	HCAPLUS
Eli Lilly And Co	1995			ZA 9402614 A	HCAPLUS
Eli Lilly And Co	1995			ZA 9402615 A	HCAPLUS
Eli Lilly And Co	1995			AU 9459486 A	HCAPLUS
Eli Lilly And Co	1995			AU 9459492 A	HCAPLUS
Eli Lilly And Co	1995			CZ 9500822 A	

Eli Lilly And Co	1995		NO 9501252 A	HCAPLUS
Eli Lilly And Co	1995		BR 9501404 A	HCAPLUS
Eli Lilly And Co	1995		FI 9501553 A	HCAPLUS
Eli Lilly And Co	1995		ZA 9502693 A	HCAPLUS
Eli Lilly And Co	1995		AU 9516217 A	HCAPLUS

=> d l139 bib abs hitrn fhitrstr retable tot

L139 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:228857 HCAPLUS

DN 134:252258

TI Preparation of indole derivatives as human non-pancreatic secretory  
**phospholipase A2 (sPLA2)** inhibitors

IN Harper, Richard Waltz; Lin, Ho-Shen; Richett, Michael Enrico

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 117 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021587	A2	20010329	WO 2000-US20816	20000907 <--
	WO 2001021587	A3	20011011		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1220839	A2	20020710	EP 2000-959170	20000907 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI	US 1999-154836P	P	19990920 <--		
	WO 2000-US20816	W	20000907		
OS	MARPAT 134:252258				
GI					



AB A class of novel indole represented by formula [I; R1 is selected from groups (a), (b), and (c) wherein; (a) is C7-20 alkyl, C7-20 haloalkyl, C7-20 alkenyl, C7-20 alkynyl, carbocyclic radical, or heterocyclic radical, or (b) is a member of (a) substituted with one or more independently selected non-interfering substituents; or (c) is (a) or (b) group linked to a divalent linking group of 1 to 8 atoms; R2 is hydrogen, or a group contg. 1 to 4 nonhydrogen atoms plus any required hydrogen atoms; R3 is -(L3)-Z, where (L3) is a divalent linker group selected from a bond or a divalent group selected from: CH2, O, S, NH, CO and Z is

selected from a group represented by the formulas, C(:NORa)C(:X)NH<sub>2</sub>, C(:X)CONH<sub>2</sub>, C(Ra)C(:X)NH<sub>2</sub> or wherein, X is oxygen or sulfur; and Ra is selected from hydrogen, C1-8 alkyl, aryl, C1-8 alkaryl, C1-8 alkoxy, aralkyl and cyano; R4 is the group, -(Lh)-(hydroxyfunctional amide); wherein (Lh), is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8; R5 is selected from hydrogen, a non-interfering substituent, or the group, -(La)-(acidic group); wherein -(La)-, is an acid linker having an acid linker length of 1 to 8; R6 and R7 are selected from hydrogen, non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted with non-interfering substituent(s)] is prepd. These compds. inhibit **sPLA2**-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid Me ester was condensed with O-phenylhydroxylamine hydrochloride in the presence of collidine and benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate in DMF at ambient temp. for 2 h to give 2-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide (II). II in vitro showed IC<sub>50</sub> of 9.0.+-.2.0 nM against **sPLA2**.

IT 172733-08-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of indole derivs. as human non-pancreatic secretory **phospholipase A2 (sPLA2)** inhibitors and inhibitors of **sPLA2**-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock)

IT 331440-80-3P 331440-82-5P 331440-84-7P

331440-86-9P 331440-88-1P 331440-90-5P

331440-92-7P 331440-95-0P 331440-97-2P

331440-99-4P 331441-01-1P 331441-03-3P

331441-05-5P 331441-07-7P 331441-15-7P

331441-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole derivs. as human non-pancreatic secretory **phospholipase A2 (sPLA2)** inhibitors and inhibitors of **sPLA2**-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock)

IT 9001-84-7, **Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(recombinant human non-pancreatic secreted; prepn. of indole derivs. as human non-pancreatic secretory **phospholipase A2 (sPLA2)** inhibitors)


IT 172733-08-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of indole derivs. as human non-pancreatic secretory **phospholipase A2 (sPLA2)** inhibitors and inhibitors of **sPLA2**-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock)

RN 172733-08-3 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



L139 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:63970 HCAPLUS

DN 134:116236

TI Preparation of indole amino acid derivatives as secretory  
phospholipase A2 (sPLA2) inhibitors

IN Lin, Ho-Shen; Richett, Michael Enrico

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 142 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001005761	A1	20010125	WO 2000-US16319	20000711	<--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1202963	A1	20020508	EP 2000-944673	20000711	<--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-144502P	P	19990719			<--
	WO 2000-US16319	W	20000711			
OS	MARPAT 134:116236					
GI						



AB Indole derivs. I [R1 = (un)substituted alkyl, haloalkyl, alkenyl, alkynyl, carbocyclyl, or heterocyclyl connected directly or via a divalent linking group to the indole ring; R2 is H or a group contg. 1-4 non-hydrogen atoms plus any required hydrogen atoms; R3 is -L3-Z, where L3 is a bond, CH2, O, S, NH, or CO and Z is -C(:NORa)C(:X)NH2, -C(:X)CONH2, or CRa2C(:X)NH2 (X = O or S and Ra = alkyl, aryl, alkaryl, alkoxy, aralkyl, CN); R4 is the

group -(Lc)-(acylamino acid group), where Lc is an acylamino acid linker; R5 is H, a non-interfering substituent, or the group -(La)-(acidic group), where La is an acid linker; R6, R7 = H, a non-interfering substituent or (un)substituted carbocyclyl were prepd. for inhibiting **sPLA2** mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, treatment of N-tert-butoxycarbonyl-3-methoxy-2-methylaniline with N-methoxy-N-methylpropanamide and then trifluoroacetic acid afforded 2-ethyl-4-methoxy-1H-indole. N-benzylation, O-demethylation, alkylation with Me bromoacetate, reaction with oxalyl chloride and ammonia gave [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid Me ester (1). Reaction of 1 with glycine Me ester hydrochloride and sapon. afforded N-[[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]glycine (3a). Compds. 1 and 3a resp. showed IC50 = 49 and 71 nM for inhibition of human secreted **PLA2**.

IT 172733-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of indole amino acid derivs. as secretory **phospholipase A2 (sPLA2)** inhibitors)

IT 321153-17-7P 321153-19-9P 321153-21-3P  
321153-23-5P 321153-25-7P 321153-27-9P  
321153-29-1P 321153-31-5P 321153-33-7P  
321153-35-9P 321153-36-0P 321153-38-2P  
321153-40-6P 321153-42-8P 321153-44-0P  
321153-46-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole amino acid derivs. as secretory **phospholipase A2 (sPLA2)** inhibitors)

IT 9001-84-7, **Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of indole amino acid derivs. as secretory **phospholipase A2 (sPLA2)** inhibitors)


IT 172733-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of indole amino acid derivs. as secretory **phospholipase A2 (sPLA2)** inhibitors)

RN 172733-08-3 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RETABLE

Referenced Author | Year | VOL | PG | Referenced Work | Referenced



(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Bach, N	1997			US 5684034 A	HCAPLUS
Lilly Co Eli	1994			EP 0620215 A	HCAPLUS
Lilly Co Eli	1995			EP 0675110 A	HCAPLUS

L139 ANSWER 3 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:769082 HCAPLUS

DN 133:321890

TI Preparation of morpholinoethyl ester derivative of an indole **sPLA2** inhibitor

IN Sawyer, Jason Scott; Morin, John Michael, Jr.; Beight, Douglas Wade; Sall, Daniel Jon; Buben, John Andrew

PA Eli Lilly and Company, USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6140327	A	20001031	US 1999-310563	19990512 <--
	WO 2000069818	A1	20001123	WO 2000-US6704	20000508 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000010448	A	20020213	BR 2000-10448	20000508 <--
	EP 1181276	A1	20020227	EP 2000-930084	20000508 <--
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1999-310563 A 19990512 &lt;--

WO 2000-US6704 W 20000508

AB ((3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholinoethyl ester was prepd. Its use as a highly bioavailable indole compd. for inhibiting **sPLA2** mediated release of fatty acids for treatment of conditions such as septic shock was reported.

IT 172732-80-8 249730-08-3 249730-10-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

IT 172733-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

IT 249730-11-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

IT 9001-84-7, Phospholipase A2

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)


IT 172732-80-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. of morpholinoethyl ester deriv. of an indole **sPLA2** inhibitor)

RN 172732-80-8 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998			WO 9842343	HCAPLUS
Anon	1999			WO 9921559	HCAPLUS
Anon	1999			WO 9925339	HCAPLUS
Bach	1997			US 5654326	HCAPLUS
Lipsky	1996	348	1357	The Lancet	HCAPLUS

L139 ANSWER 4 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:441704 HCAPLUS

DN 133:79346

TI Preparation of indoles as secretory **phospholipase A2** inhibitors as anti-inflammatory agents

IN Bach, Nicholas James; Harper, Richard Waltz; Kinnick, Michael Dean; Lin, Ho-Shen; Morin, John Michael, Jr.; Richett, Michael Enrico

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000037358	A1	20000629	WO 1999-US30405	19991220 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144305	A1	20011017	EP 1999-967465	19991220 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002532571	T2	20021002	JP 2000-589439	19991220 <--
US 6391908	B1	20020521	US 2001-856942	20010530 <--

PRAI US 1998-113303P P 19981222 <--  
 WO 1999-US30405 W 19991220 <--  
 OS MARPAT 133:79346  
 AB Indole derivs. are disclosed together with the use of such compds. for inhibiting human nonpancreatic secretory **phospholipase A2 (sPLA2)**-mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, 2-[[3-[[2-(Aminooxo)-1-(N-hydroxyimino)ethyl]-2-ethyl-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid (I) was prep'd. by the hydrolysis of the corresponding ester with LiOH soln. in THF. Thus, tablets contained I 250, microcryst. cellulose 400, fumed siO<sub>2</sub> 10 and stearic acid 5 mg/tablet.  
 IT **172733-08-3 278601-79-9**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of indoles as secretory **phospholipase A2** inhibitors as anti-inflammatory agents)  
 IT **9001-84-7, Phospholipase A2**  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (secretory; prepn. of indoles as secretory **phospholipase A2** inhibitors as anti-inflammatory agents)  
 IT **172733-08-3**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of indoles as secretory **phospholipase A2** inhibitors as anti-inflammatory agents)  
 RN 172733-08-3 HCAPLUS  
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Tone	1993			US 5238938 A	HCAPLUS

L139 ANSWER 5 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:441578 HCAPLUS

DN 133:53700

TI Combination therapy for the treatment of sepsis with activated protein C and a secretory **phospholipase A2 (sPLA2)** inhibitor

IN Maciak, Ronald Steven

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037022	A2	20000629	WO 1999-US30433	19991220 <--
WO 2000037022	A3	20020613		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000019408 A1 20000712 AU 2000-19408 19991220 <--

EP 1214041 A2 20020619 EP 1999-963109 19991220 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

PRAI US 1998-113124P P 19981221 <--

WO 1999-US30433 W 19991220 <--

OS MARPAT 133:53700

AB The invention provides a method of prevention and treatment for sepsis for mammals. The treatment is a combination therapy of activated protein C and an **sPLA2** inhibitor.

IT 172733-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(activated protein C-secretory **phospholipase A2** inhibitor combination for sepsis treatment)

IT 5548-10-7D, derivs. 172732-60-4 172732-60-4D, prodrug derivs. 172732-61-5 172732-61-5D, prodrug derivs. 172732-62-6 172732-62-6D, prodrug derivs.

172732-63-7 172732-63-7D, prodrug derivs. 172732-64-8 172732-64-8D, prodrug derivs.

172732-65-9 172732-65-9D, prodrug derivs.

172732-66-0 172732-66-0D, prodrug derivs.

172732-67-1 172732-67-1D, prodrug derivs.

172732-69-3 172732-69-3D, prodrug derivs.

172732-70-6 172732-70-6D, prodrug derivs.

172732-71-7 172732-71-7D, prodrug derivs.

172732-72-8 172732-72-8D, prodrug derivs.

172732-73-9 172732-73-9D, prodrug derivs.

172732-74-0 172732-74-0D, prodrug derivs.

172733-08-3D, prodrug derivs. 249730-08-3

249730-08-3D, prodrug derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(activated protein C-secretory **phospholipase A2** inhibitor combination for sepsis treatment)

IT 9001-84-7, **Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(secretory; activated protein C-secretory **phospholipase A2** inhibitor combination for sepsis treatment)


IT 172733-08-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(activated protein C-secretory **phospholipase A2** inhibitor combination for sepsis treatment)

RN 172733-08-3 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



L139 ANSWER 6 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:260237 HCAPLUS

DN 132:279109

TI Process for preparing 4-substituted-1H-indole-3-glyoxamides

IN Anderson, Benjamin Alan; Harn, Nancy Kay; Miller, Richard Duane;  
Plocharczyk, Edward Francis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 62 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000021929	A1	20000420	WO 1999-US8325	19990415	<--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9935644	A1	20000501	AU 1999-35644	19990415	<--
	EP 1119549	A1	20010801	EP 1999-917552	19990415	<--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002527421	T2	20020827	JP 2000-575838	19990415	<--
	US 6380397	B1	20020430	US 2001-787587	20010319	<--
PRAI	US 1998-103604P	P	19981009	<--		
	WO 1999-US8325	W	19990415	<--		
OS	CASREACT 132:279109; MARPAT 132:279109					
GI						



AB The title compds. [I; R1 = alkyl, (un)substituted CH2Ph, (CH2)2Ph, etc.; R2 = H, halo, alkyl, etc.; R4 = CO2H, SO3H, PO(OH)2, etc.; R5 = H, alkyl, alkoxy, etc.], useful for inhibiting **sPLA2** (no data), were prepd. E.g., a multi-step synthesis of I [R1 = CH2Ph; R2 = Et; R4 =

COOMe; R5 = H], was given.

IT 172733-08-3P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)


IT 172733-08-3P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)

RN 172733-08-3 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Draheim	1996	39		Journal of Medicinal	HCAPLUS
Eli Lilly And Company	1995		37	EP 0675110 A1	HCAPLUS
Shionogi & Co Ltd	1998		6	WO 9837069 A1	HCAPLUS

L139 ANSWER 7 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:116896 HCAPLUS

DN 132:151679

TI Preparation of indole sPLA2 inhibitors

IN Mihelich, Edward David; Phillips, Michael Leroy; Warshawsky, Alan M.

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007591	A1	20000217	WO 1999-US17460	19990802 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9953314	A1	20000228	AU 1999-53314	19990802 <--
EP 1100493	A1	20010523	EP 1999-938937	19990802 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002522386	T2	20020723	JP 2000-563276	19990802 <--
PRAI US 1998-95109P	P	19980803 <--		
WO 1999-US17460	W	19990802 <--		

OS MARPAT 132:151679  
GI



AB The title compds. [I; R1 = alkyl, haloalkyl, alkenyl, etc.; R2 = H, a group contg. 1-4 non-hydrogen atoms; R3 = L3-Z (wherein L3 = CH<sub>2</sub>, O, S, NH, CO; Z = acetamide, thioacetamide, glyoxylamide, etc.); R4, R5 = H, non-interfering substituent, La-acylsulfonamide (La = a divalent linker having a linker length of 1-8; provided that at least one of R4 and R5 must be La-acylsulfonamide); R6, R7 = H, cycloalkyl, heterocyclyl, etc.], useful for inhibiting **sPLA2** mediated release of fatty acids for treatment of inflammatory diseases such as septic shock, were prepd. and formulated. Thus, reacting 1-benzyl-2-ethyl-4-carboxymethyloxy-indole-3-glyoxylamide (prepn. given) with methanesulfonamide in the presence of 4-dimethylaminopyridine and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH<sub>2</sub>Cl<sub>2</sub> afforded 19% II which showed IC<sub>50</sub> of 12 nM against human secreted **PLA2**.

IT 258262-49-6P 258262-50-9P 258262-51-0P  
258262-52-1P 258262-53-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole **sPLA2** inhibitors)

IT 9001-84-7, **Phospholipase A2**

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(prepn. of indole **sPLA2** inhibitors)

IT 172733-08-3P 258262-55-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of indole **sPLA2** inhibitors)

IT 258262-49-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole **sPLA2** inhibitors)

RN 258262-49-6 HCAPLUS

CN 1H-Indole-3-acetamide, 2-ethyl-4-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-.alpha.-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach	1997			US 5641800 A	HCAPLUS
Bach	1997			US 5654326 A	HCAPLUS

L139 ANSWER 8 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:723018 HCAPLUS

DN 131:332096

TI Secretory **phospholipase A2 (sPLA2)**

inhibitors for treatment of inflammatory bowel disease

IN Macias, William Louis

PA Eli Lilly and Co., USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9957100	A1	19991111	WO 1999-US8654	19990420 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2330856	AA	19991111	CA 1999-2330856	19990420 <--
AU 9936562	A1	19991123	AU 1999-36562	19990420 <--
BR 9910095	A	20001226	BR 1999-10095	19990420 <--
EP 1084108	A1	20010321	EP 1999-918711	19990420 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
US 6340699	B1	20020122	US 1999-673675	19990420 <--
JP 2002513783	T2	20020514	JP 2000-547070	19990420 <--
NO 2000005479	A	20001220	NO 2000-5479	20001031 <--
PRAI US 1998-83874P	P	19980501 <--		
WO 1999-US8654	W	19990420 <--		
OS MARPAT 131:332096				
AB	A method is disclosed for the treatment of inflammatory bowel disease by administering to a human in need thereof a therapeutically effective amt. of an <b>sPLA2</b> inhibitor, such as a 1H-indole-3-glyoxylamide <b>sPLA2</b> inhibitor.			
IT	<b>5548-10-7D</b> , derivs. <b>172732-60-4</b> <b>172732-60-4D</b> , derivs. <b>172732-61-5</b> <b>172732-61-5D</b> , derivs. <b>172732-62-6</b> <b>172732-62-6D</b> , derivs. <b>172732-63-7</b>			



172732-63-7D, derivs. 172732-64-8 172732-64-8D  
 , derivs. 172732-65-9 172732-65-9D, derivs.  
 172732-66-0D, derivs. 172732-66-0D, derivs.  
 172732-67-1 172732-67-1D, derivs. 172732-69-3  
 172732-69-3D, derivs. 172732-70-6 172732-70-6D  
 , derivs. 172732-71-7 172732-71-7D, derivs.  
 172732-72-8 172732-72-8D, derivs. 172732-73-9  
 172732-73-9D, derivs. 172732-74-0 172732-74-0D  
 , derivs. 172733-08-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(secretory **phospholipase A2** inhibitors for treatment of inflammatory bowel disease)

IT 9001-84-7, **Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(secretory **phospholipase A2** inhibitors for treatment of inflammatory bowel disease)


IT 5548-10-7D, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(secretory **phospholipase A2** inhibitors for treatment of inflammatory bowel disease)

RN 5548-10-7 HCAPLUS

CN 1H-Indole-3-acetamide, .alpha.-oxo- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Dillard, R		39	5137	J Med Chem	HCAPLUS
Dillard, R	1996	39	5119	J Med Chem	HCAPLUS
Draheim, S	1996	39	5159	Indole Inhibitors of	HCAPLUS
Eli Lilly And Company	1995			EP 675110 A1	HCAPLUS
Murthy, S	1992	16	259	Increased Phospholip	HCAPLUS
Peterson, J	1996	39	698	Gut	MEDLINE

L139 ANSWER 9 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:722903 HCAPLUS

DN 131:336938

TI Preparation of [(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid N-morpholino Et ester as **sPLA2** inhibitor ester

IN Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer, Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 18 pp.  
 CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9956752	A1	19991111	WO 1999-US8538	19990420 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331036	AA	19991111	CA 1999-2331036	19990420 <--
	AU 9936525	A1	19991123	AU 1999-36525	19990420 <--
	EP 1073440	A1	20010207	EP 1999-918666	19990420 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9910149	A	20011002	BR 1999-10149	19990420 <--
	JP 2002513761	T2	20020514	JP 2000-546777	19990420 <--
	US 6274578	B1	20010814	US 2000-673677	20001017 <--
	NO 2000005477	A	20001031	NO 2000-5477	20001031 <--
PRAI	US 1998-83873P	P	19980501 <--		
	WO 1999-US8538	W	19990420 <--		
AB	Prepn. of [(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid N-morpholino Et ester is disclosed, together with its use as a highly bioavailable indole <b>sPLA2</b> inhibitor compd.				
IT	<b>172732-80-8P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				
IT	<b>249730-08-3P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				
IT	<b>172733-08-3 249730-09-4 249730-10-7</b>				
	<b>249730-11-8 249730-12-9 249730-13-0</b>				
	<b>249730-14-1 249730-15-2 249730-16-3</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				
IT	<b>9001-84-7, Phospholipase A2</b>				
	RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				
IT	<b>172732-60-4P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				
IT	<b>172732-80-8P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as <b>sPLA2</b> inhibitor)				

acid N-morpholino Et ester as **sPLA2** inhibitor)

RN 172732-80-8 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Denny	1999			WO 99215545	

L139 ANSWER 10 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:350593 HCAPLUS

DN 131:5185

TI Preparation of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA2** inhibitors

IN Watanabe, August Masaru

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 56 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925339	A1	19990527	WO 1998-US24234	19981113 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2310249	AA	19990527	CA 1998-2310249	19981113 <--
	AU 9914058	A1	19990607	AU 1999-14058	19981113 <--
	EP 1039901	A1	20001004	EP 1998-957915	19981113 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2001522883	T2	20011120	JP 2000-520773	19981113 <--
	US 6436983	B1	20020820	US 2000-529247	20000410 <--
PRAI	US 1997-66036P	P	19971114	<--	
	WO 1998-US24234	W	19981113	<--	
OS	MARPAT 131:5185				
GI					



AB Title compds. (I; R = COCONH<sub>2</sub>) [II; R<sub>1</sub> = (un)substituted CH<sub>2</sub>Ph, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Ph-4, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>Ph)-4, etc.; R<sub>2</sub> = halo, Me, Et, Pr, cyclopropyl; 1 of R<sub>4</sub>, R<sub>5</sub> = ZR<sub>3</sub> and the other = H or ZR<sub>3</sub>; R<sub>3</sub> = CO<sub>2</sub>H, SO<sub>3</sub>H, P(O)(OH)<sub>2</sub>; R<sub>6</sub>, R<sub>7</sub> = H, halo, alkyl, alkoxy, etc.; when R<sub>4</sub> .noteq. H Z = CH<sub>2</sub>CH<sub>2</sub>, OCH<sub>2</sub>, OCHMe, etc.; when R<sub>5</sub> .noteq. H Z = OZ<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, NHZ<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, C<sub>6</sub>H<sub>4</sub>C<sub>6</sub>H<sub>4</sub>Z<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, etc.; Z<sub>1</sub> = (un)substituted CH<sub>2</sub>] were prepd. as **sPLA<sub>2</sub>** inhibitors (no data). Thus, II (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = Et, R<sub>4</sub> = OCH<sub>2</sub>CO<sub>2</sub>H, R<sub>5</sub>-R<sub>7</sub> = H) was prepd. starting from 2,3-Me(MeO)C<sub>6</sub>H<sub>3</sub>NHCO<sub>2</sub>CMe<sub>3</sub> and EtCON(OMe)Me.

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-69-3P  
172732-70-6P 172732-71-7P 172732-72-8P  
172732-73-9P 172733-08-3P 220862-20-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA<sub>2</sub>** inhibitors)

IT 9001-84-7, **Phospholipase A<sub>2</sub>**


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(secretory; mediated disorders; treatment; prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA<sub>2</sub>** inhibitors)

IT 172732-60-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as **sPLA<sub>2</sub>** inhibitors)

RN 172732-60-4 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach	1998			US 5733923 A	HCAPLUS

L139 ANSWER 11 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:297307 HCAPLUS

DN 130:311805

TI Preparation and formulation of an indolyloxyacetate **sPLA2**  
inhibitor prodrug

IN Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer,  
Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 28 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921559	A1	19990506	WO 1998-US22679	19981026 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2308443	AA	19990506	CA 1998-2308443	19981026 <--
	AU 9912008	A1	19990517	AU 1999-12008	19981026 <--
	EP 1039911	A1	20001004	EP 1998-955125	19981026 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2001520998	T2	20011106	JP 2000-517717	19981026 <--
	US 6177426	B1	20010123	US 2000-509755	20000329 <--
PRAI	US 1997-63646P	P	19971027 <--		
	WO 1998-US22679	W	19981026 <--		
AB	Title compd. 3-(2-amino-1,2-dioxoethyl)-1-(3-biphenylylmethyl)-2-methyl-4-indolyloxyacetic acid 2-morpholinoethyl ester (I) was prepd. as a highly bioavailable compd. for inhibiting <b>sPLA2</b> mediated release of, e.g., arachidonate. Data for bioavailability of I were given.				
IT	<b>214421-73-5P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and formulation of an indolyloxyacetate <b>sPLA2</b> inhibitor prodrug)				
IT	<b>172732-87-5P 172732-91-1P</b>				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and formulation of an indolyloxyacetate <b>sPLA2</b> inhibitor prodrug)				
IT	<b>9001-84-7, Phospholipase A2</b>				
	RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (secretory; prepn. and formulation of an indolyloxyacetate <b>sPLA2</b> inhibitor prodrug)				
IT	<b>214421-73-5P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and formulation of an indolyloxyacetate <b>sPLA2</b> inhibitor prodrug)				
RN	214421-73-5 HCAPLUS				
CN	Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)				



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998				HCAPLUS
Macias, W	1998			WO 9842343 A1	HCAPLUS

L139 ANSWER 12 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:297296 HCAPLUS

DN 130:311697

TI N,N-Diethylglycol amido ester prodrugs of indole **sPLA2**  
inhibitorsIN Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer,  
Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9921546	A1	19990506	WO 1998-US22690	19981026 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309135	AA	19990506	CA 1998-2309135	19981026 <--
AU 9912798	A1	19990517	AU 1999-12798	19981026 <--
EP 1030661	A1	20000830	EP 1998-956223	19981026 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001520991	T2	20011106	JP 2000-517704	19981026 <--

US 6274616 B1 20010814 US 2000-509754 20000329 <--  
 PRAI US 1997-63280P P 19971027 <--  
 WO 1998-US22690 W 19981026 <--  
 AB The compd. ((3-(2-amino-1,2-dioxoethyl)-1-((1,1'-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid N,N-diethylglycolamido ester was prepd. and its use as a highly bioavailable indole compd. for inhibiting **sPLA2** mediated release of fatty acids for treatment of conditions such as septic shock examd.  
 IT **214421-74-6P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of N,N-diethylglycol amido ester prodrugs of indole **sPLA2** inhibitors)  
 IT **9001-84-7, Phospholipase A2**  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (prepn. of N,N-diethylglycol amido ester prodrugs of indole **sPLA2** inhibitors)  
 IT **172732-63-7P 172732-87-5P 172732-91-1P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of N,N-diethylglycol amido ester prodrugs of indole **sPLA2** inhibitors)  
 IT **214421-74-6P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of N,N-diethylglycol amido ester prodrugs of indole **sPLA2** inhibitors)  
 RN 214421-74-6 HCAPLUS  
 CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]-, 2-(diethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)



## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach	1997			US 5654326 A	HCAPLUS

L139 ANSWER 13 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:297295 HCAPLUS

DN 130:311696

TI Preparation of isopropyl ester prodrugs of indole **sPLA2** inhibitors

IN Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer, Jason Scott

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921545	A1	19990506	WO 1998-US22678	19981026 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9912007	A1	19990517	AU 1999-12007	19981026 <--
PRAI	US 1997-63284P	P	19971027 <--		
	WO 1998-US22678	W	19981026 <--		
AB	The compd., ((3-(2-amino-1,2-dioxoethyl)-1-((1,1'-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid iso-Pr ester, is disclosed together with its use as a highly bioavailable indole compd. for inhibiting <b>sPLA2</b> mediated release of fatty acids for treatment of conditions such as septic shock.				
IT	<b>214421-73-5 214421-74-6 223676-72-0 223676-73-1</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of iso-Pr ester prodrugs of indole <b>sPLA2</b> inhibitors)				
IT	<b>214421-72-4P</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of iso-Pr ester prodrugs of indole <b>sPLA2</b> inhibitors)				
IT	<b>9001-84-7, Phospholipase A2</b> RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study) (prepn. of iso-Pr ester prodrugs of indole <b>sPLA2</b> inhibitors)				
IT	<b>172732-63-7P 172732-87-5P 172732-91-1P</b> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of iso-Pr ester prodrugs of indole <b>sPLA2</b> inhibitors)				
IT	<b>214421-73-5</b> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of iso-Pr ester prodrugs of indole <b>sPLA2</b> inhibitors)				
RN	214421-73-5 HCAPLUS				
CN	Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)				





## RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach	1997			US 5654326 A	HCAPLUS

L139 ANSWER 14 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:233807 HCAPLUS

DN 130:267344

TI Compounds for treatment of cystic fibrosis

IN Macias, William Louis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 260 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9916453	A1	19990408	WO 1998-US19906	19980923	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	CA 2304482	AA	19990408	CA 1998-2304482	19980923	<--
	AU 9896641	A1	19990423	AU 1998-96641	19980923	<--
	EP 1007056	A1	20000614	EP 1998-950654	19980923	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
	JP 2001517707	T2	20011009	JP 2000-513587	19980923	<--
PRAI	US 1997-60128P	P	19970926	<--		
	WO 1998-US19906	W	19980923	<--		
OS	MARPAT 130:267344					
AB	Title compds., <b>sPLA2</b> inhibitors (no data), were selected from indoleglyoxylamides, -acetamides, -acetic acid hydrazides, etc. Prepn. of					

[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl-1H-indol-4-yl]oxy]acetic acid was described.

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-69-3P  
172732-70-6P 172732-71-7P 172732-72-8P  
172732-73-9P 172732-74-0P 172733-08-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(comps. for treatment of cystic fibrosis)

IT 172732-60-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(comps. for treatment of cystic fibrosis)

RN 172732-60-4 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



# RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Blake	1995			US 5436258 A	HCAPLUS
Edwards	1996			US 5532366 A	HCAPLUS
Finke	1998			US 5719149 A	HCAPLUS
Gyorkos	1998			US 5807829 A	HCAPLUS
Perrier	1995			US 5453443 A	HCAPLUS
Talley	1996			US 5547975 A	HCAPLUS
Talley	1996			US 5565482 A	HCAPLUS
Veale	1995			US 5405852 A	HCAPLUS

L139 ANSWER 15 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:172589 HCAPLUS

DN 130:196575

TI Method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor.

IN Macias, William Louis

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 273 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909978	A1	19990304	WO 1998-US17778	19980827 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2301586 AA 19990304 CA 1998-2301586 19980827 <--  
 AU 9891231 A1 19990316 AU 1998-91231 19980827 <--  
 EP 1011670 A1 20000628 EP 1998-943430 19980827 <--  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 SI, FI  
 JP 2001513555 T2 20010904 JP 2000-507368 19980827 <--  
 ZA 9807867 A 20000228 ZA 1998-7867 19980828 <--  
 PRAI US 1997-57726P P 19970828 <--  
 WO 1998-US17778 W 19980827 <--  
 OS MARPAT 130:196575  
 GI



AB A method for treatment of non-rheumatoid arthritis by administration of of an **sPLA2** inhibitor is claimed (no data). Thus, preferred compd. (I) was prepd. in 6 steps via 2-ethyl-4-methoxy-1H-indole.

IT **9001-84-7, Phospholipase A2**  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (inhibitors; method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

IT 172732-60-4 172732-61-5 172732-62-6  
 172732-63-7 172732-64-8 172732-65-9  
 172732-66-0 172732-67-1 172732-69-3  
 172732-70-6 172732-71-7 172732-72-8  
 172732-73-9 172733-08-3 220862-20-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

IT **9001-84-7, Phospholipase A2**  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
 (inhibitors; method for treatment of non-rheumatoid arthritis by administration of an **sPLA2** inhibitor)

RN 9001-84-7 HCAPLUS  
 CN Phospholipase A2 (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
-------------------	------	-----	----	-----------------	------------

(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Chorvat	1979			US 4180666 A	HCAPLUS
Hinkley	1973			US 3732292 A	HCAPLUS
Kelley	1996		972	Preparation of indan	HCAPLUS
Shen	1976			US 3954852 A	HCAPLUS

L139 ANSWER 16 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:31976 HCAPLUS

DN 130:81400

TI Process for preparing 4-substituted-1H-indole-3-glyoxamides

IN Khau, Vien Van; Martinelli, Michael John; Pawlak, Joseph Matthew

PA Eli Lilly and Company, USA

SO Eur. Pat. Appl., 46 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 887342	A2	19981230	EP 1998-304994	19980625 <--
	EP 887342	A3	19990107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TW 455581	B	20010921	TW 1998-87109902	19980619 <--
	WO 9900360	A1	19990107	WO 1998-US12173	19980622 <--
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9879613	A1	19990119	AU 1998-79613	19980622 <--
	AU 735516	B2	20010712		
	BR 9810481	A	20000912	BR 1998-10481	19980622 <--
	JP 2002506460	T2	20020226	JP 1999-505568	19980622 <--
	US 5986106	A	19991116	US 1998-105381	19980626 <--
	NO 9906432	A	20000209	NO 1999-6432	19991223 <--
	CN 1343662	A	20020410	CN 2001-132979	20010907 <--
PRAI	US 1997-50877P	P	19970626 <--		
	US 1997-50891P	P	19970626 <--		
	WO 1998-US12173	W	19980622 <--		
OS	MARPAT 130:81400				
GI					



AB An 8-step process for prepg. 1H-indole-3-glyoxamides I [R1 = alkyl, aralkyl; R2 = H, halogen, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, aryl, aryloxy, heterocyclic; R3 = CO2H, SO3H, P(O)(OH)2; R4-R6 = H, alkyl, alkoxy, haloalkoxy, haloalkyl, Br, Cl, F, I, aryl], useful for inhibiting **sPLA2**, from R2COCH2CO2R7 [R7 = alkyl, aryl,

heterocyclic] is claimed. Thus, EtCOCH<sub>2</sub>CO<sub>2</sub>Me was treated with 1,3-cyclohexanedione to give 2-(2-oxobutyl)-1,3-cyclohexanedione which was cyclized to tetrahydroindole with PhCH<sub>2</sub>NH<sub>2</sub>. The tetrahydroindole was dehydrogenated over Pd-C, treated with BrCH<sub>2</sub>CO<sub>2</sub>Me, treated with oxalyl chloride and NH<sub>3</sub>, and subjected to ester hydrolysis to give I [R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = Et, R<sub>3</sub> = CO<sub>2</sub>H, R<sub>4</sub>-R<sub>6</sub> = H].

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
-inhibiting activity)

IT **172733-08-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
-inhibiting activity)

IT **218934-51-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
-inhibiting activity)

IT **9001-84-7, Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of 4-substituted-1H-indole-3-glyoxamides with **sPLA2**  
-inhibiting activity)

RN 9001-84-7 HCAPLUS

CN Phospholipase A2 (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L139 ANSWER 17 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:713060 HCAPLUS

DN 126:69724

TI Indole Inhibitors of Human Nonpancreatic Secretory **Phospholipase A2**. 3. Indole-3-glyoxamides

AU Draheim, Susan E.; Bach, Nicholas J.; Dillard, Robert D.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.

CS Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SO Journal of Medicinal Chemistry (1996), 39(26), 5159-5175  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnps-**PLA2**. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxamide derivs. Functionalized indole-3-glyoxamides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepd. and tested as inhibitors of hnps-**PLA2**. It was found that the indole-3-glyoxamides with a 4-oxyacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-acetamides, and LY315920 (6m) was selected for evaluation clin. as an hnps-**PLA2** inhibitor.

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-69-3P  
172732-70-6P 172732-71-7P 172732-72-8P  
172732-73-9P 172732-74-0P 172732-76-2P  
185298-58-2P 185298-61-7P 185298-62-8P  
185298-63-9P 185298-64-0P 185298-65-1P  
185298-66-2P 185298-67-3P 185298-68-4P  
185298-69-5P 185298-70-8P 185298-71-9P

185298-72-0P 185298-73-1P 185298-74-2P  
 185298-75-3P 185298-76-4P 185298-83-3P  
 185298-84-4P 185298-85-5P 185298-90-2P  
 185298-91-3P 185299-00-7P 185299-01-8P  
 185299-07-4P 185299-08-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

IT 9001-84-7, **Phospholipase A2**

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

IT 185298-18-4 185298-19-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

IT 172732-80-8P 172732-82-0P 172732-86-4P  
 172732-91-1P 172732-94-4P 172732-98-8P  
 172733-01-6P 172733-05-0P 172733-08-3P  
 172733-11-8P 172733-15-2P 172733-20-9P  
 172733-25-4P 172733-29-8P 172733-31-2P  
 172733-32-3P 172733-33-4P 172733-35-6P  
 172733-37-8P 172733-38-9P 172733-43-6P  
 185298-47-9P 185298-48-0P 185298-49-1P  
 185298-50-4P 185298-51-5P 185298-52-6P  
 185298-53-7P 185298-54-8P 185298-55-9P  
 185298-56-0P 185298-57-1P 185298-59-3P  
 185298-60-6P 185298-89-9P 185298-95-7P  
 185298-98-0P 185298-99-1P 185299-05-2P  
 185299-06-3P 185299-10-9P 185299-11-0P  
 185299-16-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)


IT 172732-60-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)

RN 172732-60-4 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



- TI Indole Inhibitors of Human Nonpancreatic Secretory **Phospholipase A2**. 2. Indole-3-acetamides with Additional Functionality
- AU Dillard, Robert D.; Bach, Nicholas J.; Draheim, Susan E.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.
- CS Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA
- SO Journal of Medicinal Chemistry (1996), 39(26), 5137-5158  
CODEN: JMCMAR; ISSN: 0022-2623
- PB American Chemical Society
- DT Journal
- LA English
- AB As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory **phospholipase A2** (hnps-PLA2) was developed. The design of these compds. was based on information derived from x-ray crystal structures detd. for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with addnl. functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.
- IT **163687-99-8P 185501-81-9P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)
- IT **9001-84-7, Phospholipase A2**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)
- IT **163734-57-4**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)
- IT **163687-89-6P 163735-19-1P 164082-87-5P 172733-37-8P 185501-28-4P 185501-43-3P 185501-68-2P 185501-73-9P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)
- IT **163687-99-8P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory **phospholipase A2**)
- RN 163687-99-8 HCAPLUS
- CN 1H-Indole-3-acetic acid, 5-(3-carboxypropoxy)-2-methyl-1-(phenylmethyl)-, .alpha.-hydrazide (9CI) (CA INDEX NAME)




L139 ANSWER 19 OF 23 HCAPLUS COPYRIGHT 2002 ACS  
AN 1996:713058 HCAPLUS  
DN 126:42246  
TI Indole Inhibitors of Human Nonpancreatic Secretory **Phospholipase A2**. 1. Indole-3-acetamides  
AU Dillard, Robert D.; Bach, Nicholas J.; Draheim, Susan E.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.  
CS Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA  
SO Journal of Medicinal Chemistry (1996), 39(26), 5119-5136  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
AB Phospholipases (PLAs) produce rate-limiting precursors in the biosynthesis of various types of biol. active lipids involved in inflammatory processes. Increased levels of human nonpancreatic secretory **phospholipase A2** (hnps-**PLA2**) have been detected in several pathol. conditions. An inhibitor of this enzyme could have therapeutic utility. A broad screening program was carried out to identify chem. structures which could inhibit hnps-**PLA2**. One of the lead compds. generated by the screening program was 5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid. We describe the syntheses, structure-activity relationships, and pharmacol. activities of a series of indole-3-acetamides and related compds. derived from this lead. This SAR was undertaken with the aid of X-ray crystal structures of complexes between the inhibitors and hnps-**PLA2** which were of great value in directing the SAR.  
IT 164082-87-5P 164082-89-7P 164083-71-0P  
185064-25-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; prepn. of and human nonpancreatic secretory **phospholipase A2** inhibition by indole-3-acetamides)  
IT 93871-13-7P 102174-35-6P 163687-72-7P  
163687-73-8P 163687-74-9P 163687-78-3P  
163687-84-1P 163687-96-5P 163734-44-9P  
163734-45-0P 163734-46-1P 163734-51-8P  
163734-55-2P 163734-57-4P 163734-58-5P  
163734-59-6P 163734-60-9P 163734-61-0P  
163734-62-1P 163734-65-4P 163734-66-5P  
163734-68-7P 163734-71-2P 163734-72-3P  
163734-75-6P 163734-76-7P 163734-77-8P  
163734-78-9P 163734-82-5P 163734-84-7P  
164082-81-9P 164082-97-7P 164083-24-3P  
164083-29-8P 164083-51-6P 164083-56-1P  
172733-31-2P 172733-37-8P 185063-73-4P  
185063-74-5P 185063-75-6P 185063-76-7P  
185063-77-8P 185063-80-3P 185064-11-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of and human nonpancreatic secretory **phospholipase A2** inhibition by indole-3-acetamides)  
IT 9001-84-7, **Phospholipase A2**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of and human nonpancreatic secretory **phospholipase A2** inhibition by indole-3-acetamides)  
IT 164082-87-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT



(Reactant or reagent)

(intermediate; prepn. of and human nonpancreatic secretory  
phospholipase A2 inhibition by indole-3-acetamides)

RN 164082-87-5 HCAPLUS

CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-2-ethyl-4-methoxy-  
.alpha.-oxo- (9CI) (CA INDEX NAME)

L139 ANSWER 20 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:340196 HCAPLUS

DN 125:10615

TI 1H-Indole-1-functional sPLA2 inhibitors and their pharmaceutical  
compositions and use

IN Bach, Nicholas J.; Dillard, Robert D.; Draheim, Susan E.

PA Lilly, Eli, and Co., USA

SO PCT Int. Appl., 114 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603376	A1	19960208	WO 1995-US9247	19950720 <--
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5641800	A	19970624	US 1995-421097	19950413 <--
	CA 2195569	AA	19960208	CA 1995-2195569	19950720 <--
	AU 9531406	A1	19960222	AU 1995-31406	19950720 <--
	EP 772592	A1	19970514	EP 1995-927352	19950720 <--
	R:	DE, ES, FR, GB, IT			
	JP 10503208	T2	19980324	JP 1995-505885	19950720 <--
PRAI	US 1994-278353		19940721 <--		
	WO 1995-US9247		19950720 <--		
OS	MARPAT 125:10615				
GI					



AB A class of novel 1H-indole-1-functional compds. is disclosed, together with their use for inhibiting release of fatty acids mediated by human non-pancreatic secretory **phospholipase A2** (**sPLA2**), and thereby for treatment of conditions such as septic shock. The compds. are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides, specifically I [X = O, S; R1 = H, alkyl; R2 = H, halo, alkyl, cycloalk(en)yl, alkoxy, alkylthio, etc.; R3 = (un)substituted alk(en/yn)yl, carbo- or heterocyclyl, etc.; R4, R5 = H, certain substituents, (un)substituted carbo- or heterocyclyl; R6, R7 = H, certain substituents (.gtoreq. 1 of R6 and R7 must be an acidic group bound by a linker)]. Examples include 4 syntheses, seven formulations, and 2 bioassays of 4 compds. For instance, 2-hydroxy-6-methylnitrobenzene was converted in 6 steps to 2-methyl-3-(phenylmethyl)-7-(benzyloxy)-1H-indole, which underwent N-alkylation with BrCH2CO2Et (58%), amidation with Me2AlNH2 (80%), hydrogenolytic debenzoylation (77%), etherification with BrCH2CO2Bu-tert (66%), and deprotection of the tert-Bu ester (76%), to give title compd. II. In an assay for inhibition of human recombinant **sPLA2** in vitro, II had IC50 of 0.013 .mu.M.

IT 9001-84-7, **Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(human non-pancreatic secretory; prepn. of indole derivs. as **sPLA2** inhibitors)

IT 177342-59-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole derivs. as **sPLA2** inhibitors)

IT 9001-84-7, **Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(human non-pancreatic secretory; prepn. of indole derivs. as **sPLA2** inhibitors)

RN 9001-84-7 HCAPLUS

CN Phospholipase A2 (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L139 ANSWER 21 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1995:994542 HCAPLUS

DN 124:117083

TI Preparation of indole-3-glyoxylamides as **sPLA2** inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI	EP 675110	A1	19951004	EP 1995-302166	19950331	<--
	EP 675110	B1	20020710			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
	CA 2146097	AA	19951002	CA 1995-2146097	19950331	<--
	FI 9501553	A	19951002	FI 1995-1553	19950331	<--
	NO 9501252	A	19951002	NO 1995-1252	19950331	<--
	AU 9516217	A1	19951012	AU 1995-16217	19950331	<--
	AU 688458	B2	19980312			
	JP 07285933	A2	19951031	JP 1995-76117	19950331	<--
	JP 3109974	B2	20001120			
	CN 1114310	A	19960103	CN 1995-103320	19950331	<--
	CN 1067054	B	20010613			
	BR 9501404	A	19960305	BR 1995-1404	19950331	<--
	HU 72048	A2	19960328	HU 1995-957	19950331	<--
	ZA 9502693	A	19960930	ZA 1995-2693	19950331	<--
	RU 2128169	C1	19990327	RU 1995-104885	19950331	<--
	TW 383302	B	20000301	TW 1995-84103168	19950331	<--
	IL 113210	A1	20010128	IL 1995-113210	19950331	<--
	PL 180523	B1	20010228	PL 1995-307951	19950331	<--
	EP 1081135	A2	20010307	EP 2000-203897	19950331	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT					
	EP 1197484	A2	20020417	EP 2001-130290	19950331	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT					
	AT 220394	E	20020715	AT 1995-302166	19950331	<--
	US 5654326	A	19970805	US 1995-469954	19950606	<--
	US 5733923	A	19980331	US 1997-825453	19970328	<--
	US 5919810	A	19990706	US 1997-856271	19970514	<--
	US 5919943	A	19990706	US 1997-991149	19971216	<--
	US 6175021	B1	20010116	US 1999-258680	19990226	<--
	US 6433001	B1	20020813	US 2000-714364	20001116	<--
PRAI	US 1994-221916	A	19940401	<--		
	EP 1995-302166	A3	19950331	<--		
	US 1995-469954	A3	19950606	<--		
	US 1997-825453	A1	19970328	<--		
	US 1997-856271	A1	19970514	<--		
	US 1999-258680	A1	19990226	<--		
OS	MARPAT 124:117083					
GI						



AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio,

non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr<sub>3</sub> to give 69% 1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole. This was O-alkylated with NaH/BrCH<sub>2</sub>CO<sub>2</sub>Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)<sub>2</sub> followed by amidation with NH<sub>3</sub> and ester hydrolysis to give title compd. (II). II inhibited human secreted **PLA2** with IC<sub>50</sub> = 4.33 nM.

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-69-3P  
172732-70-6P 172732-71-7P 172732-72-8P  
172732-73-9P 172732-74-0P 172732-75-1P  
172732-76-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

IT 172732-80-8P 172732-82-0P 172732-86-4P  
172732-87-5P 172732-91-1P 172732-94-4P  
172732-98-8P 172733-01-6P 172733-05-0P  
172733-08-3P 172733-11-8P 172733-15-2P  
172733-20-9P 172733-25-4P 172733-29-8P  
172733-31-2P 172733-32-3P 172733-33-4P  
172733-35-6P 172733-37-8P 172733-38-9P  
172733-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

IT 9001-84-7, **Phospholipase A2**


RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(secretory; prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

IT 172732-60-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole-3-glyoxylamides as **sPLA2** inhibitors)

RN 172732-60-4 HCAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



L139 ANSWER 22 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1995:621499 HCAPLUS


DN 123:32954

TI Preparation of 1H-indole-3-acetamides as **sPLA2** inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth;

Hermann, Robert Bell; Schevitz, Richard Walter  
 PA Lilly, Eli, and Co., USA  
 SO Eur. Pat. Appl., 123 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 620215	A1	19941019	EP 1994-302666	19940414	<--
	EP 620215	B1	19990818			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
	HU 70836	A2	19951128	HU 1994-1060	19940413	<--
	CA 2121323	AA	19941017	CA 1994-2121323	19940414	<--
	BR 9401482	A	19941018	BR 1994-1482	19940414	<--
	AT 183503	E	19990915	AT 1994-302666	19940414	<--
	ES 2138648	T3	20000116	ES 1994-302666	19940414	<--
	CZ 289750	B6	20020313	CZ 1994-893	19940414	<--
	FI 9401767	A	19941017	FI 1994-1767	19940415	<--
	NO 9401361	A	19941017	NO 1994-1361	19940415	<--
	AU 9459492	A1	19941020	AU 1994-59492	19940415	<--
	AU 676884	B2	19970327			
	JP 07025850	A2	19950127	JP 1994-77650	19940415	<--
	CN 1098715	A	19950215	CN 1994-104434	19940415	<--
	CN 1068588	B	20010718			
	ZA 9402615	A	19951016	ZA 1994-2615	19940415	<--
	RU 2162463	C2	20010127	RU 1994-12930	19940415	<--
	PL 181319	B1	20010731	PL 1994-303028	19940415	<--
	US 5684034	A	19971104	US 1995-435256	19950505	<--
	US 6252084	B1	20010626	US 1997-962603	19971031	<--
PRAI	US 1993-48629	A	19930416	<--		
	US 1994-208721	A	19940315	<--		
	US 1995-435256	A1	19950505	<--		
OS	MARPAT 123:32954					
GI						



I

AB Title compds. [I; R1 = (cyclo)alkyl, alkenyl, aryl, alkylamino, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, halo, Me; R4-R7 = H, (cyclo)alkyl, aryl(alkyl), alkoxy, etc.; X = O or S] were prepd. Thus, 1-(2-tert-butoxycarbonylamino-5-methoxyphenyl)-2-butanone (prepn. from 4-methoxy-2-methylaniline given) was cyclized and the product alkylated by BrCH<sub>2</sub>CO<sub>3</sub>Me to give, in 4 addnl. steps, I (R1 = CH<sub>2</sub>Ph, R2 = Et, R3 = R4 = R6 = R7 = H, R5 = OR, X = O) (II; R = H) which was condensed with Br(CH<sub>2</sub>)<sub>3</sub>P(O)(OMe)<sub>2</sub> to give, after sapon., II [R = (CH<sub>2</sub>)<sub>3</sub>P(O)(OH)<sub>2</sub>]. The latter had IC<sub>50</sub> of 0.02.μM against human sPLA<sub>2</sub> in vitro.

IT 93871-13-7P 163687-98-7P 163734-44-9P  
 163734-46-1P 163734-55-2P 163734-57-4P

163734-59-6P 163734-62-1P 163734-65-4P  
 163734-78-9P 164082-81-9P 164082-87-5P  
 164082-89-7P 164082-97-7P 164083-24-3P  
 164083-29-8P 164083-41-4P 164083-51-6P  
 164083-56-1P 164083-71-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of 1H-indole-3-acetamides as **sPLA2** inhibitors.)

IT **9001-84-7, Phospholipase A2**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)

(secreted; prepn. of 1H-indole-3-acetamides as **sPLA2**  
 inhibitors.)


IT **93871-13-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(prepn. of 1H-indole-3-acetamides as **sPLA2** inhibitors.)

RN 93871-13-7 HCAPLUS

CN 1H-Indole-3-acetic acid, 5-methoxy-1-(phenylmethyl)-, hydrazide (9CI) (CA  
 INDEX NAME)



L139 ANSWER 23 OF 23 HCAPLUS COPYRIGHT 2002 ACS

AN 1995:605380 HCAPLUS

DN 123:32955

TI Preparation of 1H-indole-3-acetic acid hydrazides as **sPLA2**  
 inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth;  
 Hermann, Robert Bell; Schevitz, Richard Walter

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 620214	A1	19941019	EP 1994-302646	19940414 <--
	EP 620214	B1	19990303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	IL 109309	A1	20000629	IL 1994-109309	19940412 <--
	HU 70205	A2	19950928	HU 1994-1058	19940413 <--
	HU 220221	B	20011128		
	CA 2121321	AA	19941017	CA 1994-2121321	19940414 <--
	BR 9401484	A	19941122	BR 1994-1484	19940414 <--
	AT 177081	E	19990315	AT 1994-302646	19940414 <--
	ES 2128510	T3	19990516	ES 1994-302646	19940414 <--
	CZ 289791	B6	20020417	CZ 1994-894	19940414 <--
	FI 9401766	A	19941017	FI 1994-1766	19940415 <--
	NO 9401360	A	19941017	NO 1994-1360	19940415 <--
	AU 9459486	A1	19941020	AU 1994-59486	19940415 <--
	AU 669782	B2	19960620		
	JP 07010838	A2	19950113	JP 1994-77646	19940415 <--

CN 1098714	A	19950215	CN 1994-104433	19940415 <--
CN 1067986	B	20010704		
ZA 9402614	A	19951016	ZA 1994-2614	19940415 <--
RU 2127725	C1	19990320	RU 1994-12931	19940415 <--
PL 179472	B1	20000929	PL 1994-303027	19940415 <--
US 5578634	A	19961126	US 1995-440154	19950512 <--
PRAI US 1993-48608	A	19930416	<--	
OS MARPAT 123:32955				
GI				



I

AB Title compds. I (X = O, S; R1 = (halo)C4-20 alkenyl, C4-20 alkenyl, C4-20 alkynyl, C4-12 cycloalkyl, (substituted)aryl, arylalkyl, (substituted)heterocyclyl; R2 = halo, C1-3 alkyl, ethenyl, C1-2 alkylthio, C1-2 alkylthio, C1-2 alkoxy, OHC, NC; R3 = H, C1-3 alkyl, halo; R4-7 = H, C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C3-8 cycloalkyl, aryl, aralkyl, any two of R4-7 with the C to which they are attached form a 5-6-membered (substituted)carbocyclyl, heterocyclyl, etc.) and a salt thereof, useful as **sPLA2** (secretory **phospholipase A2**) inhibitors, are prepd. 3-Methyl-4-nitrophenol, ICH2Me and K2CO3 in AcCOEt were refluxed for 16 h to give 4,2-(EtO)MeC6H3NO2 which in 6 steps was converted to I (X = O, R1 = PhCH2, R2 = Me, R3 = R4 = R6 = R7 = H, R5 = EtO) (II). In human **sPLA2** inhibition test, the IC50 of II was 0.80 .mu.M. Pharmaceutical formulations of I are given.

IT 163687-72-7P 163687-73-8P 163687-74-9P  
 163687-75-0P 163687-76-1P 163687-77-2P  
 163687-78-3P 163687-79-4P 163687-80-7P  
 163687-81-8P 163687-82-9P 163687-83-0P  
 163687-84-1P 163687-85-2P 163687-86-3P  
 163687-87-4P 163687-88-5P 163687-89-6P  
 163687-90-9P 163687-91-0P 163687-96-5P  
 163687-97-6P 163687-98-7P 163687-99-8P  
 163734-42-7P 163734-43-8P 163734-44-9P  
 163734-45-0P 163734-46-1P 163734-47-2P  
 163734-48-3P 163734-49-4P 163734-50-7P  
 163734-51-8P 163734-52-9P 163734-53-0P  
 163734-54-1P 163734-55-2P 163734-56-3P  
 163734-57-4P 163734-58-5P 163734-59-6P  
 163734-60-9P 163734-61-0P 163734-62-1P  
 163734-63-2P 163734-64-3P 163734-65-4P  
 163734-66-5P 163734-67-6P 163734-68-7P  
 163734-69-8P 163734-70-1P 163734-71-2P  
 163734-72-3P 163734-73-4P 163734-74-5P  
 163734-75-6P 163734-76-7P 163734-77-8P  
 163734-78-9P 163734-79-0P 163734-80-3P  
 163734-81-4P 163734-82-5P 163734-83-6P  
 163734-84-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1H-indole-3-acetic acid hydrazides as **sPLA2**  
inhibitors.)


IT **9001-84-7, Phospholipase A2**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
(Biological study); PROC (Process)  
(prepn. of 1H-indole-3-acetic acid hydrazides as **sPLA2**  
inhibitors.)

IT **163735-19-1P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of 1H-indole-3-acetic acid hydrazides as **sPLA2**  
inhibitors.)

IT **163687-72-7P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of 1H-indole-3-acetic acid hydrazides as **sPLA2**  
inhibitors.)

RN 163687-72-7 HCAPLUS

CN 1H-Indole-3-acetic acid, 2-bromo-5-methoxy-1-(phenylmethyl)-, hydrazide  
(9CI) (CA INDEX NAME)



=> fil reg

FILE 'REGISTRY' ENTERED AT 15:12:28 ON 17 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1  
DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot



RN 263910-32-3 REGISTRY  
 CN Butanoic acid, 3-[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H22 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:284251

L140 ANSWER 2 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 263910-31-2 REGISTRY  
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H22 N2 O5  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:40417

REFERENCE 2: 132:284251

L140 ANSWER 3 OF 33 REGISTRY COPYRIGHT 2002 ACS  
 RN 258262-50-9 REGISTRY

CN 1H-Indole-3-acetamide, 2-ethyl-.alpha.-oxo-4-[2-oxo-2-  
 [(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C27 H25 N3 O6 S  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1962 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:64164  
 REFERENCE 2: 136:64151  
 REFERENCE 3: 136:64112  
 REFERENCE 4: 134:290409  
 REFERENCE 5: 132:151679

L140 ANSWER 4 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 224581-11-7 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-  
 1-(phenylmethyl)-, 6-cyclopropyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H24 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:338017

L140 ANSWER 5 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 224581-10-6 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)-, 6-propyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H26 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:338017

L140 ANSWER 6 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 224581-09-3 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)-, 6-ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H24 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 130:338017

L140 ANSWER 7 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 211925-63-2 REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-6-(hydroxymethyl)-1-

(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H22 N2 O6  
 SR CA  
 LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 8 OF 33 REGISTRY COPYRIGHT 2002 ACS  
 RN 211925-62-1 REGISTRY  
 CN Acetic acid, [[6-[(acetyloxy)methyl]-3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C25 H26 N2 O7  
 SR CA  
 LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 9 OF 33 REGISTRY COPYRIGHT 2002 ACS  
 RN 211925-61-0 REGISTRY  
 CN 1H-Indole-3-acetamide, 6-[(acetyloxy)methyl]-2-ethyl-4-hydroxy-.alpha.-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H22 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 10 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 211925-60-9 REGISTRY


CN 1H-Indole-3-acetamide, 6-[(acetyloxy)methyl]-2-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C29 H28 N2 O5

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 11 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 211925-56-3 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-2-ethyl-4-[2-(1-methylethoxy)-2-oxoethoxy]-1-(phenylmethyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H32 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 12 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 211925-55-2 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-2-ethyl-4-(2-methoxy-2-oxoethoxy)-1-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H24 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 13 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 211925-47-2 REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)-, disodium salt (9CI) (CA INDEX NAME)

MF C22 H20 N2 O7 . 2 Na

SR CA

LC STN Files: CA, CAPLUS

CRN (211925-45-0)



● 2 Na

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 129:189241

L140 ANSWER 14 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **211925-46-1** REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)-, 6-(1-methylethyl) ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C25 H26 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:338017

REFERENCE 2: 129:189241

L140 ANSWER 15 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **211925-45-0** REGISTRY

CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C22 H20 N2 O7

CI COM

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:284251

REFERENCE 2: 130:338017

REFERENCE 3: 129:189241

L140 ANSWER 16 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **211925-44-9** REGISTRY


CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)-, 6-methyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C23 H22 N2 O7

SR CA

LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 130:338017

REFERENCE 2: 129:189241

L140 ANSWER 17 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172733-08-3** REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C22 H22 N2 O5

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

28 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 28 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:331344

REFERENCE 3: 135:236446

REFERENCE 4: 135:236432

REFERENCE 5: 135:152715

REFERENCE 6: 135:46087

REFERENCE 7: 135:46086

REFERENCE 8: 135:46085

REFERENCE 9: 134:252258

REFERENCE 10: 134:116236

L140 ANSWER 18 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172732-74-0** REGISTRY


CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C23 H24 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

12 REFERENCES IN FILE CA (1962 TO DATE)  
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
12 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:236446

REFERENCE 3: 135:236432

REFERENCE 4: 135:40417

REFERENCE 5: 133:53700

REFERENCE 6: 131:332096

REFERENCE 7: 130:338017

REFERENCE 8: 130:267344

REFERENCE 9: 129:326101

REFERENCE 10: 129:298393

L140 ANSWER 19 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-73-9 REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H24 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:236446

REFERENCE 3: 135:236432

REFERENCE 4: 135:152715

REFERENCE 5: 135:87174

REFERENCE 6: 135:40417

REFERENCE 7: 133:53700  
REFERENCE 8: 132:284251  
REFERENCE 9: 131:332096  
REFERENCE 10: 131:5185

L140 ANSWER 20 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-72-8 REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C22 H20 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715  
REFERENCE 5: 135:87174  
REFERENCE 6: 135:40417  
REFERENCE 7: 133:53700  
REFERENCE 8: 132:284251  
REFERENCE 9: 131:332096  
REFERENCE 10: 131:5185

L140 ANSWER 21 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-71-7 REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H26 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
 REFERENCE 2: 135:236446  
 REFERENCE 3: 135:236432  
 REFERENCE 4: 135:152715  
 REFERENCE 5: 135:87174  
 REFERENCE 6: 135:40417  
 REFERENCE 7: 133:53700  
 REFERENCE 8: 132:284251  
 REFERENCE 9: 131:332096  
 REFERENCE 10: 131:5185

L140 ANSWER 22 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172732-70-6** REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C27 H24 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
21 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 136:64164  
REFERENCE 3: 136:64151  
REFERENCE 4: 136:64112  
REFERENCE 5: 135:236446  
REFERENCE 6: 135:236432  
REFERENCE 7: 135:152715  
REFERENCE 8: 135:87174  
REFERENCE 9: 135:40417  
REFERENCE 10: 133:53700

L140 ANSWER 23 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-69-3 REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C21 H19 Cl N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715

REFERENCE 5: 135:87174  
REFERENCE 6: 135:40418  
REFERENCE 7: 135:40417  
REFERENCE 8: 133:53700  
REFERENCE 9: 132:284251  
REFERENCE 10: 131:332096

L140 ANSWER 24 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172732-67-1** REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C24 H20 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715  
REFERENCE 5: 135:87174  
REFERENCE 6: 135:40418  
REFERENCE 7: 135:40417  
REFERENCE 8: 133:53700  
REFERENCE 9: 132:284251

REFERENCE 10: 131:332096

L140 ANSWER 25 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-66-0 REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H17 F N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)

6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:236446

REFERENCE 3: 135:236432

REFERENCE 4: 135:152715

REFERENCE 5: 135:87174

REFERENCE 6: 135:40417

REFERENCE 7: 133:53700

REFERENCE 8: 132:284251

REFERENCE 9: 131:332096

REFERENCE 10: 131:5185

L140 ANSWER 26 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-65-9 REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H16 Cl2 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL





17 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715  
REFERENCE 5: 135:87174  
REFERENCE 6: 135:40417  
REFERENCE 7: 133:53700  
REFERENCE 8: 132:284251  
REFERENCE 9: 131:332096  
REFERENCE 10: 131:5185

L140 ANSWER 28 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-63-7 REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C26 H22 N2 O5

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715  
REFERENCE 5: 135:87174  
REFERENCE 6: 135:40417

REFERENCE 7: 133:53700

REFERENCE 8: 132:284251

REFERENCE 9: 131:332096

REFERENCE 10: 131:5185

L140 ANSWER 29 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172732-62-6** REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C26 H22 N2 O5

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:236446

REFERENCE 3: 135:236432

REFERENCE 4: 135:152715

REFERENCE 5: 135:87174

REFERENCE 6: 135:40417

REFERENCE 7: 133:53700

REFERENCE 8: 132:284251

REFERENCE 9: 131:332096


REFERENCE 10: 131:5185

L140 ANSWER 30 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **172732-61-5** REGISTRY

CN Propanoic acid, 2-[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD  
MF C21 H20 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
16 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669  
REFERENCE 2: 135:236446  
REFERENCE 3: 135:236432  
REFERENCE 4: 135:152715  
REFERENCE 5: 135:87174  
REFERENCE 6: 133:53700  
REFERENCE 7: 132:284251  
REFERENCE 8: 131:332096  
REFERENCE 9: 131:5185  
REFERENCE 10: 130:338017

L140 ANSWER 31 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN 172732-60-4 REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C20 H18 N2 O5

CI COM

SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 20 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:134669

REFERENCE 2: 135:331344

REFERENCE 3: 135:236446

REFERENCE 4: 135:236432

REFERENCE 5: 135:152715

REFERENCE 6: 135:87174

REFERENCE 7: 135:40418

REFERENCE 8: 135:40417

REFERENCE 9: 133:53700

REFERENCE 10: 132:284251

L140 ANSWER 32 OF 33 REGISTRY COPYRIGHT 2002 ACS

RN **9001-84-7** REGISTRY

CN Phospholipase A2 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Acanthoxin A1

CN Agelotoxin

CN Ammodytoxin C

CN Calcium-dependent phospholipase A2

CN Conodipine-M

CN E.C. 3.1.1.4

CN Lecitase

CN Lecitase 10L

CN Lecithinase A

CN Nigroxin C1

CN Nigroxin C2

CN Nigroxin C3

CN Phosphatidase

CN Phosphatide acyl-hydrolase

CN Phosphatidolipase

CN Phospholipase A

CN Phospholipase III

CN Phospholipin

CN PLA2


CN Superbin

CN Superbin a  
CN Superbin b  
CN Superbin c  
CN Superbin d  
CN Superbin I  
CN Superbin II  
DR 195159-59-2, 195159-60-5  
MF Unspecified  
CI COM, MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CABA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM,  
EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS, NAPRALERT, PROMT, RTECS\*,  
TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*  
(\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
11790 REFERENCES IN FILE CA (1962 TO DATE)  
108 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
11808 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:230679  
REFERENCE 2: 137:230482  
REFERENCE 3: 137:230417  
REFERENCE 4: 137:229772  
REFERENCE 5: 137:228256  
REFERENCE 6: 137:226804  
REFERENCE 7: 137:217139  
REFERENCE 8: 137:215484  
REFERENCE 9: 137:214098  
REFERENCE 10: 137:212737

L140 ANSWER 33 OF 33 REGISTRY COPYRIGHT 2002 ACS  
RN 5548-10-7 REGISTRY  
CN 1H-Indole-3-acetamide, .alpha.-oxo- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Indole-3-glyoxylamide (6CI, 7CI, 8CI)  
OTHER NAMES:  
CN 2-(1H-Indol-3-yl)-2-oxoethanamide  
CN 3-Indoleglyoxamide  
FS 3D CONCORD  
MF C10 H8 N2 O2  
LC STN Files: BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT,  
CHEMCATS, CSCHEM, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

27 REFERENCES IN FILE CA (1962 TO DATE)  
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 27 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:325715  
 REFERENCE 2: 136:37822  
 REFERENCE 3: 135:236446  
 REFERENCE 4: 135:236432  
 REFERENCE 5: 135:152715  
 REFERENCE 6: 133:78999  
 REFERENCE 7: 133:53700  
 REFERENCE 8: 131:332096  
 REFERENCE 9: 129:326101  
 REFERENCE 10: 129:81881

=> d his

(FILE 'HOME' ENTERED AT 13:54:16 ON 17 OCT 2002)  
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:54:27 ON 17 OCT 2002

E TODO S/AU  
 L1 165 S E3,E5-E8,E10  
 E WO99-JP5528/AP, PRN  
 L2 1 S E3,E4  
 E JP98-292423/AP, PRN  
 L3 1 S E4  
 E SHIONOGI/PA,CS  
 L4 8797 S SHIONOG?/PA,CS  
 L5 1 S L1,L4 AND L2,L3  
 SEL RN

FILE 'REGISTRY' ENTERED AT 13:56:45 ON 17 OCT 2002

L6 28 S E1-E28  
 L7 1 S L6 AND PHOSPHOLIPASE  
 L8 27 S L6 NOT L7  
 L9 23 S L8 AND 46.150.18/RID  
 L10 16 S L9 AND NC4-C6/ES  
 L11 9 S L10 AND 3/NR

L12 2 S L11 AND C21H20N2O5  
L13 1 S L12 NOT 172732-61-5  
L14 1 S 172732-68-2/CRN

FILE 'HCAPLUS' ENTERED AT 14:04:51 ON 17 OCT 2002

L15 36 S L13 OR L14  
L16 6 S LY315920 OR LY() (315920 OR 315 920 OR 315920NA OR 315 920NA)  
L17 38 S L15,L16  
L18 2 S 3 2 AMINO 1 2 DIOXOETHYL 2 METHYL 1 PHENYLMETHYL 1H INDOL 4 Y  
L19 39 S L17,L18  
L20 25 S L19 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L21 6 S L20 AND L1-L5  
L22 11809 S L7  
L23 14337 S PHOSPHOLIPASE A2  
L24 497 S SPLA2  
L25 2964 S PHOSPHOLIPASE A  
L26 1431 S L22 AND L25  
L27 4209 S PLA2 OR LECITHINASE A OR (EC OR "E") () 3 1 1 4  
L28 18 S L20 AND L22-L27  
L29 25 S L20,L21,L28  
L30 2 S L20 AND ?ISCHEM?  
L31 1 S L20 AND ?PERFUS?  
L32 25 S L29,L30,L31  
L33 1 S 3 AMINOXOACETYL 2 ETHYL 1 PHENYLMETHYL 1H INDOL 4 YL OXY ACE  
L34 25 S L32,L33

FILE 'REGISTRY' ENTERED AT 14:12:24 ON 17 OCT 2002

FILE 'HCAPLUS' ENTERED AT 14:12:59 ON 17 OCT 2002

FILE 'EMBASE' ENTERED AT 14:13:46 ON 17 OCT 2002

L35 0 S L13 OR L14  
L36 12 S L16 OR L18 OR L33  
L37 7 S L36 AND PY<=1999  
L38 0 S L37 AND (?ISCHEM? OR ?PERFUS?)  
E PHOSPHOLIPASE A2 INHIBITOR/CT  
E E3+ALL  
L39 526 S E1  
E PHOSPHOLIPASE A2 INHIBITOR/CT  
E PHOSPHOLIPASE A2 INHIBITOR?/CT  
L40 526 S PHOSPHOLIPASE A2 INHIBITOR?/CT  
L41 526 S L39,L40  
L42 7283 S L7  
L43 12629 S L23,L24,L25,L27  
L44 12629 S L42,L43  
E ISCHEMIA/CT  
E E3+ALL  
L45 161133 S E8+NT  
E REPERFUSION/CT  
E E3+ALL  
L46 17140 S E5+NT  
L47 64355 S E3+NT  
L48 16 S L41 AND L45  
L49 12 S L41 AND L46,L47  
L50 273 S L44 AND L45  
L51 187 S L44 AND L46,L47  
L52 22 S L48,L49 AND L50,L51  
L53 22 S L48,L49,L52  
L54 12 S L53 AND PY<=1999  
L55 3 S L54 NOT AB/FA  
L56 9 S L54 NOT L55  
E REPERFUSION INJURY/CT  
E E3+ALL

```

L57      8523 S E1+NT
L58      6 S L57 AND L41
L59      56 S L57 AND L44
L60      46 S L58,L59 AND L45
L61      37 S L60 AND PY<=1999
L62      9 S L61 NOT AB/FA
L63      28 S L61 NOT L62
L64      14 S L63 AND INHIBIT?
          SEL DN AN 5 8 9 12 14
L65      5 S L64 AND E1-E10
L66      284 S L24
L67      21 S L66 AND L41
L68      6 S L66 AND L45
L69      3 S L66 AND L46,L47
L70      6 S L68,L69
L71      5 S L70 NOT 2000/PY
L72      5 S L71 AND L39-L71
          SEL DN AN 2
L73      1 S E11 AND L72
L74      6 S L65,L73
L75      773 S L44 AND SECRETORY
L76      16 S L75 AND L50,L51
L77      10 S L76 AND PY<=1999
L78      1 S L77 NOT AB/FA
L79      9 S L77 NOT L78
          SEL DN AN 2 5
L80      2 S L79 AND E12-E14
L81      7 S L74,L80 AND L35-L80
L82      7 S L81 AND (?PERFUS? OR INJUR? OR ?ISCHEM? OR INHIBIT? OR BLOCK?

```

FILE 'EMBASE' ENTERED AT 14:40:25 ON 17 OCT 2002

FILE 'MEDLINE' ENTERED AT 14:40:37 ON 17 OCT 2002

```

          E PHOSPHOLIPASE/CT
          E E5+ALL
          E E2+ALL
L83      9318 S E20+NT
L84      9318 S E20/CN
L85      13994 S L23 OR L24 OR L25 OR L27
L86      13994 S L83-L85
L87      12239 S L86 AND PY<=1999
L88      296 S L87 AND ?ISCHEM?
          E ISCHEM/CT
          E E4+ALL
L89      250 S L87 AND E4+NT
L90      354 S L88,L89
L91      134 S L90 AND ?PERFUS?
          E REPERFUSION/CT
          E E9+ALL
L92      11940 S E9+NT
L93      49 S L92 AND L90
L94      49 S L91 AND L93
L95      89 S L91 AND INJUR?
L96      89 S L93-L95
L97      6 S L96 NOT AB/FA
L98      83 S L96 NOT L97
          SEL DN AN 22 42 52 54 57 58 68 75
L99      8 S L98 AND E1-E24
L100     8 S L99 AND L83-L99
L101     8 S L100 AND (?ISCHAEM? OR ?ISCHEM? OR ?PERFUS? OR INJUR?)

```

FILE 'MEDLINE' ENTERED AT 14:53:42 ON 17 OCT 2002



FILE 'REGISTRY' ENTERED AT 14:53:58 ON 17 OCT 2002

L102 STR  
L103 50 S L102  
L104 583311 S NC4-C6/ES  
L105 50 S L102 SAM SUB=L104  
L106 342395 S 333.151.57/RID  
L107 50 S L102 SAM SUB=L106  
L108 STR L102  
L109 0 S L108 SAM  
L110 0 S L108 SAM SUB=L104  
L111 0 S L108 SAM SUB=L106  
L112 11 S L6 NOT L104  
L113 17 S L6 NOT L112  
L114 0 S L113 NOT L106  
L115 STR L108  
L116 0 S L115 SAM SUB=L106  
L117 1 S L115 SAM SUB=L104  
L118 1236 S L115 FUL SUB=L104  
SAV L118 KWON807/A  
L119 1059 S L118 AND L106  
L120 177 S L118 NOT L119  
L121 421 S L108 FUL SUB=L118  
SAV L121 KWON807A/A  
L122 411 S L119 AND L121  
L123 10 S L121 NOT L122  
L124 409 S L122 NOT L13, L14

FILE 'HCAPLUS' ENTERED AT 15:06:15 ON 17 OCT 2002

L125 193 S L124  
L126 166 S L125 AND (PY<=1999 OR PRY<=1999 OR AY<=1999)  
L127 27 S L126 AND L22-L25, L27  
L128 6 S L126 AND L1, L4  
L129 2 S L126 AND (?ISCHEM? OR ?ISCHAEM?)  
L131 1 S L126 AND ?PERFUS?  
E ISCHEMIA/CT  
E E3+ALL  
L132 5203 S E5, E4+NT  
E E9+ALL  
L133 9519 S E3, E2+NT  
E E1+ALL  
L134 11377 S E1+NT  
L135 1 S L126 AND L132-L134  
L136 6 S L128-L131, L135  
L137 4 S L127 AND L136  
L138 6 S L136, L137  
L139 23 S L127 NOT L138

FILE 'REGISTRY' ENTERED AT 15:10:37 ON 17 OCT 2002

FILE 'HCAPLUS' ENTERED AT 15:10:52 ON 17 OCT 2002  
SEL HIT RN L138FILE 'REGISTRY' ENTERED AT 15:12:02 ON 17 OCT 2002  
L140 33 S E1-E33

FILE 'REGISTRY' ENTERED AT 15:12:28 ON 17 OCT 2002

L Number	Hits	Search Text	DB	Time stamp
1	1	"5986106" .pn.	USPAT; US-PGPUB	2002/10/17 21:05
2	1	"5733923" .pn.	USPAT; US-PGPUB	2002/10/17 21:06
-	909	ischemia adj reperfusion adj injury	USPAT; US-PGPUB	2002/10/17 07:05
-	1301124	prevent or inhibit	USPAT; US-PGPUB	2002/10/17 07:06
-	833	(ischemia adj reperfusion adj injury ) and (prevent or inhibit)	USPAT; US-PGPUB	2002/10/17 07:06
-	610	((ischemia adj reperfusion adj injury ) and (prevent or inhibit)) and organ	USPAT; US-PGPUB	2002/10/17 07:06
-	406	((((ischemia adj reperfusion adj injury ) and (prevent or inhibit)) and organ) and transplantation	USPAT; US-PGPUB	2002/10/17 10:23
-	1	"6214855" .pn.	USPAT; US-PGPUB	2002/10/17 11:04
-	1	"5654326" .pn.	USPAT; US-PGPUB	2002/10/17 11:04
-	1	"5986106" .pn.	USPAT; US-PGPUB	2002/10/17 21:05

1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
RN 219315-98-7 REGISTRY  
CN **PX 13 (9CI)** (CA INDEX NAME)  
ENTE A phospholipase A2 inhibitor  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

FILE 'CAPLUS' ENTERED AT 10:14:47 ON 17 OCT 2002

L1 22 S 263910-31-2/RN OR 263910-32-3/RN OR 211925-45-0/RN OR 172732-  
E ISCHEMIA REPERFUSION  
E ISCHEMIA REPERFUSION INJURY/CT  
L2 0 S E5+E6  
L3 0 S E5-E6  
E E6  
L4 0 S E3  
L5 4146 S ISCHEMIA-REPERFUSION INJURY  
L6 9372 S ISCHEMIA-REPERFUSION OR ISCHEMIA REPERFUSION  
L7 9372 S L5 OR L6  
L8 0 S L1 AND L7

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, JAPIO, USPATFULL' ENTERED AT  
10:19:24 ON 17 OCT 2002

L9 34 S L1  
L10 34 DUP REM L9 (0 DUPLICATES REMOVED)  
L11 2 S L10 AND ISCHEMIA  
L12 32792 S L7  
L13 0 S L9 AND L12

=>

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS  
RE

- (1) Anon; JP 07285933 A CAPLUS
- (2) Anon; CN 1098714 A CAPLUS
- (3) Anon; CN 1114310 A CAPLUS
- (4) Anon; CA 2121321 A CAPLUS
- (5) Anon; CA 2146097 A CAPLUS
- (6) Anon; NZ 260299 A
- (7) Anon; NZ 270848 A
- (8) Anon; TW 306914 A
- (9) Anon; US 5578634 A CAPLUS
- (10) Anon; US 5654326 A CAPLUS
- (11) Anon; US 5733923 A CAPLUS
- (12) Anon; US 5919774 A CAPLUS
- (13) Anon; US 5919810 A CAPLUS
- (14) Anon; US 5919943 A CAPLUS
- (15) Anon; JP 710838 A
- (16) Anon; EP 779211 A1
- (17) Anon; EP 779273 A1 CAPLUS
- (18) Anon; CZ 9400894 A3
- (19) Anon; NO 9401360 A CAPLUS
- (20) Anon; BR 9401484 A CAPLUS
- (21) Anon; FI 9401766 A CAPLUS
- (22) Anon; ZA 9402614 A CAPLUS
- (23) Anon; AU 9459486 A CAPLUS
- (24) Anon; EP 946495 A1 CAPLUS
- (25) Anon; CZ 9500822 A3
- (26) Anon; NO 9501252 A CAPLUS
- (27) Anon; BR 9501404 A CAPLUS
- (28) Anon; FI 9501553 A CAPLUS
- (29) Anon; MX 9501608 A
- (30) Anon; ZA 9502693 A CAPLUS
- (31) Anon; AU 9516217 A CAPLUS
- (32) Anon; BR 9612347 A CAPLUS
- (33) Anon; AU 9711497 A CAPLUS
- (34) Anon; AU 9712897 A CAPLUS
- (35) Anon; AU 985592 A
- (36) Anon; AU 9855983 CAPLUS
- (37) Anon; HU 9901984 A2
- (38) Eisai Co Ltd; JP 07285866 A CAPLUS
- (39) Eisai Co Ltd; CN 1112920 A CAPLUS
- (40) Eisai Co Ltd; CA 2141987 A CAPLUS
- (41) Eisai Co Ltd; ZA 9501467 A CAPLUS
- (42) Eisai Co Ltd; AU 9512374 A CAPLUS
- (43) Eisai Co Ltd; EP 672415 A1 1995 CAPLUS
- (44) Eli Lilly And Company; JP 10503208 A
- (45) Eli Lilly And Company; JP 10505336 A
- (46) Eli Lilly And Company; JP 10505584 A
- (47) Eli Lilly And Company; CN 1098715 A CAPLUS
- (48) Eli Lilly And Company; CA 2121323 A CAPLUS
- (49) Eli Lilly And Company; NZ 260298 A
- (50) Eli Lilly And Company; TW 268942 A
- (51) Eli Lilly And Company; US 5641800 A CAPLUS
- (52) Eli Lilly And Company; US 5684034 A CAPLUS
- (53) Eli Lilly And Company; US 5916922 A CAPLUS
- (54) Eli Lilly And Company; US 5972972 A CAPLUS
- (55) Eli Lilly And Company; JP 725850 A
- (56) Eli Lilly And Company; EP 769940 A1 CAPLUS
- (57) Eli Lilly And Company; EP 772592 A1 CAPLUS
- (58) Eli Lilly And Company; EP 772596 A1 CAPLUS
- (59) Eli Lilly And Company; EP 839806 A1 CAPLUS
- (60) Eli Lilly And Company; EP 846687 A1 CAPLUS

(61) Eli Lilly And Company; CZ 9400893 A3  
 (62) Eli Lilly And Company; NO 9401361 A CAPLUS  
 (63) Eli Lilly And Company; BR 9401482 A CAPLUS  
 (64) Eli Lilly And Company; FI 9401767 A CAPLUS  
 (65) Eli Lilly And Company; ZA 9402615 A CAPLUS  
 (66) Eli Lilly And Company; EP 944636 A1 CAPLUS  
 (67) Eli Lilly And Company; AU 9459492 A CAPLUS  
 (68) Eli Lilly And Company; BR 9508298 A CAPLUS  
 (69) Eli Lilly And Company; AU 9531406 A CAPLUS  
 (70) Eli Lilly And Company; AU 9531459 CAPLUS  
 (71) Eli Lilly And Company; AU 9531980 A CAPLUS  
 (72) Eli Lilly And Company; MX 9700511 A1  
 (73) Eli Lilly And Company; ZA 9710878 A CAPLUS  
 (74) Eli Lilly And Company; KR 97704695 A  
 (75) Eli Lilly And Company; AU 9851494 A CAPLUS  
 (76) Eli Lilly And Company; AU 9853655 A CAPLUS  
 (77) Eli Lilly And Company; AU 9854544 A CAPLUS  
 (78) Eli Lilly And Company; NO 9901831 A CAPLUS  
 (79) Eli Lilly And Company; EP 620214 A1 1994 CAPLUS  
 (80) Eli Lilly And Company; EP 620215 A1 1994 CAPLUS  
 (81) Eli Lilly And Company; EP 675110 A1 1995 CAPLUS  
 (82) Eli Lilly And Company; WO 9603120 A1 1996 CAPLUS  
 (83) Eli Lilly And Company; WO 9603383 A1 1996 CAPLUS  
 (84) Eli Lilly And Company; WO 963376 A1 1996  
 (85) Eli Lilly And Company; WO 9721664 A1 1997 CAPLUS  
 (86) Eli Lilly And Company; WO 9721716 A1 1997 CAPLUS  
 (87) Eli Lilly And Company; WO 9818464 A1 1998 CAPLUS  
 (88) Eli Lilly And Company; WO 9824437 A1 1998 CAPLUS  
 (89) Eli Lilly And Company; WO 9824794 A1 1998 CAPLUS  
 (90) Eli Lilly And Company; WO 9824856 A1 1998 CAPLUS  
 (91) Eli Lilly And Company; WO 9825609 A1 1998 CAPLUS  
 (92) Jun, T; FEBS Letters 1998, V440(3), P377  
 (93) Sargent, C; J Pharm Ther 1992, V262(3), P1161 CAPLUS  
 (94) Shionogi & Co Ltd; WO 9951605 A1 1999 CAPLUS  
 (95) Shionogi & Co Ltd; WO 9959999 A1 1999 CAPLUS  
 (96) Sonnino, R; Dig Dis Sci 1997, V42(5), P972 CAPLUS  
 (97) Windt, L; Mol Cell Biochem 1998, V180(1&2), P65  
 (98) Yoshihiro, S; J Kyoto Pref Univ Med 1998, V107(4)


=>

For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s 263910-33-4  
L2 1 263910-33-4  
(263910-33-4/RN)

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **263910-33-4** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethylene)-1H-inden-4-yl]oxy]- (9CI) (CA INDEX NAME)  
MF C22 H19 N O5  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 263910-31-2  
L3 1 263910-31-2  
(263910-31-2/RN)

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **263910-31-2** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H22 N2 O5  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 263910-32-3  
L4 1 263910-32-3  
(263910-32-3/RN)

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **263910-32-3** REGISTRY  
CN Butanoic acid, 3-[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H22 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 263910-34-5  
L5 1 263910-34-5  
(263910-34-5/RN)

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **263910-34-5** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(1-naphthalenylmethylene)-1H-inden-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C26 H21 N O5  
SR CA  
LC STN Files: CA, CAPLUS






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 263910-35-6  
L6 1 263910-35-6  
(263910-35-6/RN)

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **263910-35-6** REGISTRY  
CN Acetic acid, [[8-(aminooxoacetyl)-6-(cyclopropylmethyl)-7-ethyl-3-methylpyrrolo[1,2-a]pyrazin-1-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H21 N3 O5  
SR CA  
LC STN Files: CA, CAPLUS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 245757-15-7 245756-93-8 245756-89-2  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED '45757-15-7(W)245756-93-'  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED '45756-93-8(W)245756-89-'  
1 245757-15-7  
(245757-15-7/RN)

1 245756-93-8  
 (245756-93-8/RN)  
 1 245756-89-2  
 (245756-89-2/RN)  
 L7 0 245757-15-7 245756-93-8 245756-89-2  
 (245757-15-7 (W) 245756-93-8 (W) 245756-89-2)

=> d

L7 HAS NO ANSWERS

L7 0 SEA FILE=REGISTRY ABB=ON PLU=ON 245757-15-7 245756-93-8  
 245756-89-2

=> s 245757-15-7

L8 1 245757-15-7  
 (245757-15-7/RN)

=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **245757-15-7** REGISTRY


CN Acetic acid, [[8-(aminooxoacetyl)-7-ethyl-3-phenyl-6-(phenylmethyl)pyrrolo[1,2-a]pyrazin-1-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C26 H23 N3 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1962 TO DATE)

7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 245756-89-2

L9 1 245756-89-2  
 (245756-89-2/RN)

=> d

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **245756-89-2** REGISTRY


CN Acetic acid, [[8-(aminooxoacetyl)-7-ethyl-3-methyl-6-(phenylmethyl)pyrrolo[1,2-a]pyrazin-1-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C21 H21 N3 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 245756-93-8  
L10 1 245756-93-8  
(245756-93-8/RN)

=> d

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **245756-93-8** REGISTRY  
CN Acetic acid, [[8-(aminooxoacetyl)-6-({1,1'-biphenyl}-2-ylmethyl)-7-ethyl-3-methylpyrrolo[1,2-a]pyrazin-1-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C27 H25 N3 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


=> s 220862-64-6  
L11 1 220862-64-6  
(220862-64-6/RN)

=> d

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **220862-64-6** REGISTRY  
CN Acetic acid, [[5-(aminocarbonyl)-9-(cyclohexylmethyl)-9H-carbazol-4-yl]oxy]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN [[9-[(Cyclohexyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid  
 MF C22 H24 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


11 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 12 REFERENCES IN FILE CAPLUS (1962 TO DATE)


=> s 219925-45-0  
 L12 0 219925-45-0  
 (219925-45-0/RN)

=> s 211925-45-0  
 L13 1 211925-45-0  
 (211925-45-0/RN)

=> d

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **211925-45-0** REGISTRY  
 CN 1H-Indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C22 H20 N2 O7  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 182116-01-4  
L14 1 182116-01-4  
(182116-01-4/RN)

=> d

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **182116-01-4** REGISTRY  
CN Acetic acid, [[1-(aminooxoacetyl)-3-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-8-indolizinyloxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C28 H24 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


4 REFERENCES IN FILE CA (1962 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 182115-97-5  
L15 1 182115-97-5  
(182115-97-5/RN)

=> d

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **182115-97-5** REGISTRY  
CN Acetic acid, [[1-(aminooxoacetyl)-3-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-8-indolizinyloxy]- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Indoxam

FS 3D CONCORD  
 MF C27 H24 N2 O5  
 CI COM  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1962 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 182115-96-4  
 L16 1 182115-96-4  
 (182115-96-4/RN)

=> d

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **182115-96-4** REGISTRY  
 CN Acetic acid, [[1-(aminooxoacetyl)-2-ethyl-3-(phenylmethyl)-8-indolizinyloxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C21 H20 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1962 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-73-9  
 L17 1 172732-73-9  
 (172732-73-9/RN)

=> d

L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **172732-73-9** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C28 H24 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-72-8  
L18 1 172732-72-8  
(172732-72-8/RN)

=> d

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **172732-72-8** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H20 N2 O5  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-71-7

L19 1 172732-71-7  
(172732-71-7/RN)

=> d

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **172732-71-7** REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C28 H26 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-70-6

L20 1 172732-70-6  
(172732-70-6/RN)

=> d

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **172732-70-6** REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C27 H24 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 21 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-69-3  
 L21 1 172732-69-3  
 (172732-69-3/RN)

=> d

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-69-3** REGISTRY  
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C21 H19 Cl N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


18 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-67-1  
 L22 1 172732-67-1  
 (172732-67-1/RN)

=> d

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-67-1** REGISTRY

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C24 H20 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

18 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 18 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-66-0  
 L23 1 172732-66-0  
 (172732-66-0/RN)

=> d

L23 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-66-0** REGISTRY  
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C20 H17 F N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-65-9

L24 1 172732-65-9  
(172732-65-9/RN)

=> d

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **172732-65-9** REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C20 H16 Cl2 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-64-8

L25 1 172732-64-8  
(172732-64-8/RN)

=> d

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN **172732-64-8** REGISTRY


CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


FS 3D CONCORD

MF C26 H22 N2 O5

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-63-7  
 L26 1 172732-63-7  
 (172732-63-7/RN)

=> d

L26 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-63-7** REGISTRY  
 CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C26 H22 N2 O5  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


19 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 19 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-62-6  
 L27 1 172732-62-6  
 (172732-62-6/RN)

=> d

L27 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-62-6** REGISTRY  
 CN Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

FS 3D CONCORD  
 MF C26 H22 N2 O5  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

17 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 17 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-61-5  
 L28 1 172732-61-5  
 (172732-61-5/RN)

=> d

L28 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
 RN **172732-61-5** REGISTRY  
 CN Propanoic acid, 2-[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C21 H20 N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

16 REFERENCES IN FILE CA (1962 TO DATE)  
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 16 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> s 172732-60-4  
L29 1 172732-60-4  
(172732-60-4/RN)

=> d

L29 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS  
RN **172732-60-4** REGISTRY  
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H18 N2 O5  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1962 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
20 REFERENCES IN FILE CAPLUS (1962 TO DATE)

IT Drug delivery systems  
(prodrugs; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Organ preservation  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(suppositories; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8  
 172732-65-9 172732-66-0 172732-67-1 172732-68-2 172732-69-3  
 172732-70-6 172732-71-7 172732-72-8 172732-73-9 182115-96-4  
 182115-97-5 182116-01-4 211925-45-0 220862-64-6 245756-89-2  
 245756-93-8 245757-15-7 263910-31-2 263910-32-3 263910-33-4  
 263910-34-5 263910-35-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 9001-84-7, Phospholipase A2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (secretory, inhibitor of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.70	2.91

FILE 'REGISTRY' ENTERED AT 09:49:31 ON 17 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1  
 DICTIONARY FILE UPDATES: 16 OCT 2002 HIGHEST RN 462058-01-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> 263910-33-4

263910-33-4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:48:21 ON 17 OCT 2002

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 09:48:28 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16

FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s wo2000021563/pn

L1 1 WO2000021563/PN  
(WO2000021563/PN)

=> d it

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

IT Drug delivery systems  
(aerosols; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(capsules; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(injections, i.v.; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Liver, disease  
(ischemia, ischemic reflow failure; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Reperfusion  
(ischemic, disorder of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)



IT Drug delivery systems  
(prodrugs; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Organ preservation  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(suppositories; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8  
 172732-65-9 172732-66-0 172732-67-1 172732-68-2 172732-69-3  
 172732-70-6 172732-71-7 172732-72-8 172732-73-9 182115-96-4  
 182115-97-5 182116-01-4 211925-45-0 220862-64-6 245756-89-2  
 245756-93-8 245757-15-7 263910-31-2 263910-32-3 263910-33-4  
 263910-34-5 263910-35-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 9001-84-7, Phospholipase A2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (secretory, inhibitor of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:48:21 ON 17 OCT 2002

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 09:48:28 ON 17 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Oct 2002 VOL 137 ISS 16

FILE LAST UPDATED: 16 Oct 2002 (20021016/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s wo2000021563/pn

L1 1 WO2000021563/PN

(WO2000021563/PN)

=> d it

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

IT Drug delivery systems

(aerosols; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(capsules; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(injections, i.v.; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Liver, disease

(ischemia, ischemic reflow failure; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Reperfusion

(ischemic, disorder of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS			October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

IT Drug delivery systems  
(aerosols; remedies or preventives contg. sPLA2 inhibitors for  
ischemic reflow failure)

IT Drug delivery systems  
(capsules; remedies or preventives contg. sPLA2 inhibitors for  
ischemic reflow failure)

IT Drug delivery systems  
(injections, i.v.; remedies or preventives contg. sPLA2 inhibitors for  
ischemic reflow failure)

IT Liver, disease  
(ischemia, ischemic reflow failure; remedies or preventives contg.  
sPLA2 inhibitors for ischemic reflow failure)

IT Reperfusion  
(ischemic, disorder of; remedies or preventives contg. sPLA2  
inhibitors  
for ischemic reflow failure)

IT Drug delivery systems  
(prodrugs; remedies or preventives contg. sPLA2 inhibitors for  
ischemic reflow failure)

IT Organ preservation  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow  
failure)

IT Drug delivery systems  
(suppositories; remedies or preventives contg. sPLA2 inhibitors for  
ischemic reflow failure)

IT Drug delivery systems  
(tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic  
reflow failure)

IT [ 172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8  
172732-65-9 172732-66-0 172732-67-1 172732-68-2 172732-69-3  
172732-70-6 172732-71-7 172732-72-8 172732-73-9 182115-96-4  
182115-97-5 182116-01-4 211925-45-0 220862-64-6 245756-89-2  
245756-93-8 245757-15-7 263910-31-2 263910-32-3 263910-33-4  
263910-34-5 263910-35-6 ]

RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow  
failure)

IT 9001-84-7, Phospholipase A2  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(secretory, inhibitor of; remedies or preventives contg. sPLA2  
inhibitors for ischemic reflow failure)

AB The invention relates to remedies or preventives for ischemic reflow  
failure which contain an sPLA2 inhibitor, e.g. [[3-[2-Amino-1,2-  
dioxoethyl]-2-methyl-1-[phenylmethyl]-1H-indol-4-yl]oxy]acetic acid, as  
active ingredient. Capsules were formulated contg. sPLA2 inhibitor 250,  
starch 200 and magnesium stearate 10 mg/capsule.

ACCESSION NUMBER: 2000:260062 CAPLUS  
DOCUMENT NUMBER: 132:284251  
TITLE: Remedies or preventives containing sPLA2 inhibitors  
for ischemic reflow failure  
INVENTOR(S): Todo, Satoru  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 97 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021563	A1	20000420	WO 1999-JP5528	19991007 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9960047	A1	20000501	AU 1999-60047	19991007
PRIORITY APPLN. INFO.:			JP 1998-292423	A 19981014
			WO 1999-JP5528	W 19991007
OTHER SOURCE(S):		MARPAT 132:284251		
REFERENCE COUNT:		98		
REFERENCE(S):		(1) Anon; JP 07285933 A CAPLUS (2) Anon; CN 1098714 A CAPLUS (3) Anon; CN 1114310 A CAPLUS (4) Anon; CA 2121321 A CAPLUS (5) Anon; CA 2146097 A CAPLUS		
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=>

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1616bsk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI  
NEWS 10 Aug 23 In-process records and more frequent updates now in  
MEDLINE  
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA  
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN  
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change  
to PHARMASEARCH  
NEWS 14 Oct 09 Korean abstracts now included in Derwent World Patents  
Index  
NEWS 15 Oct 09 Number of Derwent World Patents Index updates increased  
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File  
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT  
NEWS 18 Oct 22 DGENE GETSIM has been improved  
NEWS 19 Oct 29 AAASD no longer available  
  
NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,  
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),  
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:52:30 ON 09 NOV 2001

=> file caplus

IT Drug delivery systems  
(tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8  
172732-65-9 172732-66-0 172732-67-1 172732-68-2 172732-69-3  
172732-70-6 172732-71-7 172732-72-8 172732-73-9 182115-96-4  
182115-97-5 182116-01-4 211925-45-0 220862-64-6 245756-89-2  
245756-93-8 245757-15-7 263910-31-2 263910-32-3 263910-33-4  
263910-34-5 263910-35-6

RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 9001-84-7, Phospholipase A2

RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(secretory, inhibitor of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

AB The invention relates to remedies or preventives for ischemic reflow failure which contain an sPLA2 inhibitor, e.g. [[3-[2-Amino-1,2-dioxoethyl]-2-methyl-1-[phenylmethyl]-1H-indol-4-yl]oxy]acetic acid, as active ingredient. Capsules were formulated contg. sPLA2 inhibitor 250, starch 200 and magnesium stearate 10 mg/capsule.

ACCESSION NUMBER: 2000:260062 CAPLUS

DOCUMENT NUMBER: 132:284251

TITLE: Remedies or preventives containing sPLA2 inhibitors for ischemic reflow failure

INVENTOR(S): Todo, Satoru

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021563	A1	20000420	WO 1999-JP5528	19991007 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9960047	A1	20000501	AU 1999-60047	19991007
PRIORITY APPLN. INFO.:			JP 1998-292423	A 19981014
			WO 1999-JP5528	W 19991007

OTHER SOURCE(S): MARPAT 132:284251

REFERENCE COUNT: 98

REFERENCE(S): (1) Anon; JP 07285933 A CAPLUS  
(2) Anon; CN 1098714 A CAPLUS  
(3) Anon; CN 1114310 A CAPLUS  
(4) Anon; CA 2121321 A CAPLUS  
(5) Anon; CA 2146097 A CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(1) L8 1

E1 THROUGH E1 ASSIGNED

=> SET SMA LOGIN

SET COMMAND COMPLETED

=> S E1

L9 1 "1995:994542"/AN

=> D L9 BIB,ABS

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1995:994542 CAPLUS

DN 124:117083

TI Preparation of indole-3-glyoxylamides as sPLA2 inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 675110	A1	19951004	EP 1995-302166	19950331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2146097	AA	19951002	CA 1995-2146097	19950331
	FI 9501553	A	19951002	FI 1995-1553	19950331
	NO 9501252	A	19951002	NO 1995-1252	19950331
	AU 9516217	A1	19951012	AU 1995-16217	19950331
	AU 688458	B2	19980312		
	JP 07285933	A2	19951031	JP 1995-76117	19950331
	JP 3109974	B2	20001120		
	CN 1114310	A	19960103	CN 1995-103320	19950331
	CN 1067054	B	20010613		
	BR 9501404	A	19960305	BR 1995-1404	19950331
	HU 72048	A2	19960328	HU 1995-957	19950331
	ZA 9502693	A	19960930	ZA 1995-2693	19950331
	RU 2128169	C1	19990327	RU 1995-104885	19950331
	TW 383302	B	20000301	TW 1995-84103168	19950331
	IL 113210	A1	20010128	IL 1995-113210	19950331
	PL 180523	B1	20010228	PL 1995-307951	19950331
	EP 1081135	A2	20010307	EP 2000-203897	19950331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT				
	US 5654326	A	19970805	US 1995-469954	19950606
	US 5733923	A	19980331	US 1997-825453	19970328
	US 5919810	A	19990706	US 1997-856271	19970514
	US 5919943	A	19990706	US 1997-991149	19971216
	US 6175021	B1	20010116	US 1999-258680	19990226
PRAI	US 1994-221916	A	19940401		



EP 1995-302166	A3	19950331
US 1995-469954	A3	19950606
US 1997-825453	A1	19970328
US 1997-856271	A1	19970514

OS MARPAT 124:117083  
GI



AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr<sub>3</sub> to give 69% 1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole. This was O-alkylated with NaH/BrCH<sub>2</sub>CO<sub>2</sub>Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)<sub>2</sub> followed by amidation with NH<sub>3</sub> and ester hydrolysis to give title compd. (II). II inhibited human secreted PLA<sub>2</sub> with IC<sub>50</sub> = 4.33 nM.

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(2) L8 1

E2 THROUGH E2 ASSIGNED

=> SET SMA LOGIN

SET COMMAND COMPLETED

=> S E2


L10 1 "1995:605380"/AN

=> D L10 BIB,ABS

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1995:605380 CAPLUS  
 DN 123:32955  
 TI Preparation of 1H-indole-3-acetic acid hydrazides as sPLA2 inhibitors.  
 IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth;  
 Hermann, Robert Bell; Schevitz, Richard Walter  
 PA Lilly, Eli, and Co., USA  
 SO Eur. Pat. Appl., 66 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 620214	A1	19941019	EP 1994-302646	19940414
	EP 620214	B1	19990303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	IL 109309	A1	20000629	IL 1994-109309	19940412
	HU 70205	A2	19950928	HU 1994-1058	19940413
	CA 2121321	AA	19941017	CA 1994-2121321	19940414
	BR 9401484	A	19941122	BR 1994-1484	19940414
	AT 177081	E	19990315	AT 1994-302646	19940414
	ES 2128510	T3	19990516	ES 1994-302646	19940414
	FI 9401766	A	19941017	FI 1994-1766	19940415
	NO 9401360	A	19941017	NO 1994-1360	19940415
	AU 9459486	A1	19941020	AU 1994-59486	19940415
	AU 669782	B2	19960620		
	JP 07010838	A2	19950113	JP 1994-77646	19940415
	CN 1098714	A	19950215	CN 1994-104433	19940415
	CN 1067986	B	20010704		
	ZA 9402614	A	19951016	ZA 1994-2614	19940415
	RU 2127725	C1	19990320	RU 1994-12931	19940415
	PL 179472	B1	20000929	PL 1994-303027	19940415
	US 5578634	A	19961126	US 1995-440154	19950512
PRAI	US 1993-48608	A	19930416		
OS	MARPAT 123:32955				
GI					



I

AB Title compds. I (X = O, S; R1 = (halo)C4-20 alkenyl, C4-20 alkenyl, C4-20 alkynyl, C4-12 cycloalkyl, (substituted)aryl, arylalkyl, (substituted)heterocyclyl; R2 = halo, C1-3 alkyl, ethenyl, C1-2 alkylthio, C1-2 alkylthio, C1-2 alkoxy, OHC, NC; R3 = H, C1-3 alkyl, halo; R4-7 = H, C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C3-8 cycloalkyl, aryl, aralkyl, any two of R4-7 with the C to which they are attached form a 5-6-membered (substituted)carbocyclyl, heterocyclyl, etc.) and a salt thereof, useful as sPLA2 (secretory phospholipase A2) inhibitors, are prepd.

3-Methyl-4-nitrophenol, ICH<sub>2</sub>Me and K<sub>2</sub>CO<sub>3</sub> in AcCOEt were refluxed for 16 h to give 4,2-(EtO)MeC<sub>6</sub>H<sub>3</sub>NO<sub>2</sub> which in 6 steps was converted to I (X = O, R<sub>1</sub> = PhCH<sub>2</sub>, R<sub>2</sub> = Me, R<sub>3</sub> = R<sub>4</sub> = R<sub>6</sub> = R<sub>7</sub> = H, R<sub>5</sub> = EtO) (II). In human sPLA<sub>2</sub> inhibition test, the IC<sub>50</sub> of II was 0.80 .mu.M. Pharmaceutical formulations of I are given.

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(3) L8 1

E3 THROUGH E3 ASSIGNED

=> SET SMA LOGIN

SET COMMAND COMPLETED

=> S E3

L11 1 "1995:994542"/AN

=> D L11 BIB,ABS

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1995:994542 CAPLUS

DN 124:117083

TI Preparation of indole-3-glyoxylamides as sPLA<sub>2</sub> inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 675110	A1	19951004	EP 1995-302166	19950331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2146097	AA	19951002	CA 1995-2146097	19950331
	FI 9501553	A	19951002	FI 1995-1553	19950331
	NO 9501252	A	19951002	NO 1995-1252	19950331
	AU 9516217	A1	19951012	AU 1995-16217	19950331
	AU 688458	B2	19980312		
	JP 07285933	A2	19951031	JP 1995-76117	19950331
	JP 3109974	B2	20001120		
	CN 1114310	A	19960103	CN 1995-103320	19950331
	CN 1067054	B	20010613		
	BR 9501404	A	19960305	BR 1995-1404	19950331
	HU 72048	A2	19960328	HU 1995-957	19950331
	ZA 9502693	A	19960930	ZA 1995-2693	19950331
	RU 2128169	C1	19990327	RU 1995-104885	19950331
	TW 383302	B	20000301	TW 1995-84103168	19950331
	IL 113210	A1	20010128	IL 1995-113210	19950331
	PL 180523	B1	20010228	PL 1995-307951	19950331
	EP 1081135	A2	20010307	EP 2000-203897	19950331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT				

	US 5654326	A	19970805	US 1995-469954	19950606
	US 5733923	A	19980331	US 1997-825453	19970328
	US 5919810	A	19990706	US 1997-856271	19970514
	US 5919943	A	19990706	US 1997-991149	19971216
	US 6175021	B1	20010116	US 1999-258680	19990226
PRAI	US 1994-221916	A	19940401		
	EP 1995-302166	A3	19950331		
	US 1995-469954	A3	19950606		
	US 1997-825453	A1	19970328		
	US 1997-856271	A1	19970514		
OS	MARPAT 124:117083				
GI					



I



II

AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr3 to give 69% 1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole. This was O-alkylated with NaH/BrCH2CO2Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)2 followed by amidation with NH3 and ester hydrolysis to give title compd. (II). II inhibited human secreted PLA2 with IC50 = 4.33 nM.

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(4) L8 1

E4 THROUGH E4 ASSIGNED

=> SET SMA LOGIN

SET COMMAND COMPLETED

=> S E4

L12 1 "1995:605380"/AN

=> D L12 BIB,ABS

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1995:605380 CAPLUS

DN 123:32955

TI Preparation of 1H-indole-3-acetic acid hydrazides as sPLA2 inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth; Hermann, Robert Bell; Schevitz, Richard Walter

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 66 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 620214	A1	19941019	EP 1994-302646	19940414
	EP 620214	B1	19990303		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	IL 109309	A1	20000629	IL 1994-109309	19940412
	HU 70205	A2	19950928	HU 1994-1058	19940413
	CA 2121321	AA	19941017	CA 1994-2121321	19940414
	BR 9401484	A	19941122	BR 1994-1484	19940414
	AT 177081	E	19990315	AT 1994-302646	19940414
	ES 2128510	T3	19990516	ES 1994-302646	19940414
	FI 9401766	A	19941017	FI 1994-1766	19940415
	NO 9401360	A	19941017	NO 1994-1360	19940415
	AU 9459486	A1	19941020	AU 1994-59486	19940415
	AU 669782	B2	19960620		
	JP 07010838	A2	19950113	JP 1994-77646	19940415
	CN 1098714	A	19950215	CN 1994-104433	19940415
	CN 1067986	B	20010704		
	ZA 9402614	A	19951016	ZA 1994-2614	19940415
	RU 2127725	C1	19990320	RU 1994-12931	19940415
	PL 179472	B1	20000929	PL 1994-303027	19940415
	US 5578634	A	19961126	US 1995-440154	19950512
PRAI	US 1993-48608	A	19930416		
OS	MARPAT 123:32955				
GI					



I

AB Title compds. I (X = O, S; R1 = (halo)C4-20 alkenyl, C4-20 alkenyl, C4-20 alkynyl, C4-12 cycloalkyl, (substituted)aryl, arylalkyl, (substituted)heterocyclyl; R2 = halo, C1-3 alkyl, ethenyl, C1-2 alkylthio,

C1-2 alkylthio, C1-2 alkoxy, OHC, NC; R3 = H, C1-3 alkyl, halo; R4-7 = H, C1-10 alkyl, C1-10 alkenyl, C1-10 alkynyl, C3-8 cycloalkyl, aryl, aralkyl, any two of R4-7 with the C to which they are attached form a 5-6-membered (substituted)carbocyclyl, heterocyclyl, etc.) and a salt thereof, useful as sPLA2 (secretory phospholipase A2) inhibitors, are prepd. 3-Methyl-4-nitrophenol, ICH2Me and K2CO3 in AcCOEt were refluxed for 16 h to give 4,2-(EtO)MeC6H3NO2 which in 6 steps was converted to I (X = O, R1 = PhCH2, R2 = Me, R3 = R4 = R6 = R7 = H, R5 = EtO) (II). In human sPLA2 inhibition test, the IC50 of II was 0.80 .mu.M. Pharmaceutical formulations of I are given.

=> SET SMA OFF

SET COMMAND COMPLETED

=> SEL RAN.CAPLUS(5) L8 1

E5 THROUGH E5 ASSIGNED

=> SET SMA LOGIN

SET COMMAND COMPLETED

=> S E5

L13 1 "1995:994542"/AN

=> D L13 BIB,ABS

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AN 1995:994542 CAPLUS

DN 124:117083

TI Preparation of indole-3-glyoxylamides as sPLA2 inhibitors.

IN Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 675110	A1	19951004	EP 1995-302166	19950331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2146097	AA	19951002	CA 1995-2146097	19950331
	FI 9501553	A	19951002	FI 1995-1553	19950331
	NO 9501252	A	19951002	NO 1995-1252	19950331
	AU 9516217	A1	19951012	AU 1995-16217	19950331
	AU 688458	B2	19980312		
	JP 07285933	A2	19951031	JP 1995-76117	19950331
	JP 3109974	B2	20001120		
	CN 1114310	A	19960103	CN 1995-103320	19950331
	CN 1067054	B	20010613		
	BR 9501404	A	19960305	BR 1995-1404	19950331
	HU 72048	A2	19960328	HU 1995-957	19950331
	ZA 9502693	A	19960930	ZA 1995-2693	19950331
	RU 2128169	C1	19990327	RU 1995-104885	19950331

TW 383302	B	20000301	TW 1995-84103168	19950331
IL 113210	A1	20010128	IL 1995-113210	19950331
PL 180523	B1	20010228	PL 1995-307951	19950331
EP 1081135	A2	20010307	EP 2000-203897	19950331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT				
US 5654326	A	19970805	US 1995-469954	19950606
US 5733923	A	19980331	US 1997-825453	19970328
US 5919810	A	19990706	US 1997-856271	19970514
US 5919943	A	19990706	US 1997-991149	19971216
US 6175021	B1	20010116	US 1999-258680	19990226
PRAI US 1994-221916	A	19940401		
EP 1995-302166	A3	19950331		
US 1995-469954	A3	19950606		
US 1997-825453	A1	19970328		
US 1997-856271	A1	19970514		
OS MARPAT 124:117083				
GI				



I



II

AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr<sub>3</sub> to give 69% 1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole. This was O-alkylated with NaH/BrCH<sub>2</sub>CO<sub>2</sub>Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)<sub>2</sub> followed by amidation with NH<sub>3</sub> and ester hydrolysis to give title compd. (II). II inhibited human secreted PLA<sub>2</sub> with IC<sub>50</sub> = 4.33 nM.

AB The title compds. I [R1 = (un)substituted alkyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, alkyl, et.] are prepd. In an in vitro test for sPLA2 inhibition, the title compd. I [R1 = benzyl; R2 = ethyl; R3 = methyl] showed IC50 of 1.7 nM.

IT Anti-inflammatory drugs  
Septic shock  
(prepn. and effect of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 172732-68-2  
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 211925-44-9P 211925-45-0P 211925-46-1P 211925-47-2P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 9001-84-7, Phospholipase A2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 67-63-0, Isopropanol, reactions 79-03-8, Propionyl chloride 79-37-8, Oxalyl chloride 96-32-2, Methyl bromoacetate 100-39-0, Benzyl bromide 108-24-7, Acetic anhydride 6638-79-5, N,O-Dimethylhydroxylamine hydrochloride 7664-41-7, Ammonia, reactions 24424-99-5, Di-tert-butyl dicarbonate 69660-37-3  
RL: RCT (Reactant)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 104863-65-2P 211925-48-3P 211925-49-4P 211925-50-7P 211925-51-8P  
211925-52-9P 211925-53-0P 211925-54-1P 211925-55-2P 211925-56-3P  
211925-57-4P 211925-58-5P 211925-59-6P 211925-60-9P 211925-61-0P  
211925-62-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

IT 211925-63-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of indoledicarboxylic acid derivs. as sPLA2 inhibitors)

L108 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:713060 CAPLUS

DOCUMENT NUMBER: 126:69724

TITLE: Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3. Indole-3-glyoxamides

AUTHOR(S): Draheim, Susan E.; Bach, Nicholas J.; Dillard, Robert D.; Berry, Dennis R.; Carlson, Donald G.; Chirgadze, Nickolay Y.; Clawson, David K.; Hartley, Lawrence W.; Johnson, Lea M.; et al.

CORPORATE SOURCE: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: J. Med. Chem. (1996), 39(26), 5159-5175

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The preceding papers of this series detail the development of functionalized indole-3-acetamides as inhibitors of hnp-PLA2. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxamide derivs. Functionalized indole-3-glyoxamides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepd. and tested as inhibitors of



hnps-PLA2. It was found that the indole-3-glyoxamides with a 4-oxyacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-acetamides, and LY315920 (6m) was selected for evaluation clin. as an hnps-PLA2 inhibitor.

IT Structure-activity relationship

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory phospholipase A2)

IT 172732-60-4P 172732-61-5P 172732-62-6P

172732-63-7P 172732-64-8P 172732-65-9P

172732-66-0P 172732-67-1P 172732-68-2P, LY

315920 172732-69-3P 172732-70-6P 172732-71-7P

172732-72-8P 172732-73-9P 172732-74-0P 172732-76-2P

185298-58-2P 185298-61-7P 185298-62-8P 185298-63-9P 185298-64-0P

185298-65-1P 185298-66-2P 185298-67-3P 185298-68-4P 185298-69-5P

185298-70-8P 185298-71-9P 185298-72-0P 185298-73-1P 185298-74-2P

185298-75-3P 185298-76-4P 185298-83-3P 185298-84-4P 185298-85-5P

185298-90-2P 185298-91-3P 185299-00-7P 185299-01-8P 185299-07-4P

185299-08-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory phospholipase A2)

IT 9001-84-7, Phospholipase A2

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory phospholipase A2)

IT 1006-94-6 4837-90-5 17897-50-6 163688-10-6 164082-79-5

172732-78-4 172733-06-1 172733-07-2 172733-16-3 172733-21-0

185298-18-4 185298-19-5 185299-09-6

RL: RCT (Reactant)

(prepn. and SAR of indoleglyoxamides as inhibitors of human nonpancreatic secretory phospholipase A2)

IT 6872-06-6P 16382-21-1P 27866-64-4P 73246-45-4P 90811-56-6P

164082-80-8P 172732-77-3P 172732-79-5P 172732-80-8P 172732-81-9P

172732-82-0P 172732-83-1P 172732-84-2P 172732-85-3P 172732-86-4P

172732-88-6P 172732-89-7P 172732-90-0P 172732-91-1P 172732-92-2P

172732-93-3P 172732-94-4P 172732-95-5P 172732-96-6P 172732-97-7P

172732-98-8P 172732-99-9P 172733-00-5P 172733-01-6P 172733-02-7P

172733-03-8P 172733-04-9P 172733-05-0P 172733-08-3P 172733-09-4P

172733-10-7P 172733-11-8P 172733-12-9P 172733-13-0P 172733-14-1P

172733-15-2P 172733-17-4P 172733-18-5P 172733-19-6P 172733-20-9P

172733-22-1P 172733-24-3P 172733-25-4P 172733-27-6P 172733-28-7P

172733-29-8P 172733-31-2P 172733-32-3P 172733-33-4P 172733-35-6P

172733-37-8P 172733-38-9P 172733-43-6P 185298-21-9P 185298-22-0P

185298-23-1P 185298-25-3P 185298-26-4P 185298-27-5P 185298-28-6P

185298-29-7P 185298-30-0P 185298-31-1P 185298-32-2P 185298-33-3P

185298-34-4P 185298-35-5P 185298-36-6P 185298-37-7P 185298-38-8P

185298-39-9P 185298-40-2P 185298-41-3P 185298-42-4P 185298-43-5P

185298-45-7P 185298-46-8P 185298-47-9P 185298-48-0P 185298-49-1P

185298-50-4P 185298-51-5P 185298-52-6P 185298-53-7P 185298-54-8P

185298-55-9P 185298-56-0P 185298-57-1P 185298-59-3P 185298-60-6P

185298-77-5P 185298-78-6P 185298-79-7P 185298-80-0P 185298-81-1P

185298-82-2P 185298-86-6P 185298-87-7P 185298-88-8P 185298-89-9P

185298-92-4P 185298-93-5P 185298-94-6P 185298-95-7P 185298-96-8P

185298-97-9P 185298-98-0P 185298-99-1P 185299-02-9P 185299-03-0P

185299-04-1P 185299-05-2P 185299-06-3P 185299-10-9P 185299-11-0P

185299-12-1P 185299-13-2P 185299-14-3P 185299-15-4P 185299-16-5P


185299-17-6P 185299-18-7P 185299-19-8P 185303-39-3P 185303-40-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)


(prepn. and SAR of indoleglyoxamides as inhibitors of human  
nonpancreatic secretory phospholipase A2)

L108 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1995:994542 CAPLUS  
DOCUMENT NUMBER: 124:117083  
TITLE: Preparation of indole-3-glyoxylamides as sPLA2  
inhibitors.  
INVENTOR(S): Bach, Nicholas James; Dillard, Robert Delane;  
Draheim,  
Susan Elizabeth  
PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA  
SOURCE: Eur. Pat. Appl., 78 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 675110	A1	19951004	EP 1995-302166	19950331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2146097	AA	19951002	CA 1995-2146097	19950331
FI 9501553	A	19951002	FI 1995-1553	19950331
NO 9501252	A	19951002	NO 1995-1252	19950331
AU 9516217	A1	19951012	AU 1995-16217	19950331
AU 688458	B2	19980312		
JP 07285933	A2	19951031	JP 1995-76117	19950331
JP 3109974	B2	20001120		
CN 1114310	A	19960103	CN 1995-103320	19950331
CN 1067054	B	20010613		
BR 9501404	A	19960305	BR 1995-1404	19950331
HU 72048	A2	19960328	HU 1995-957	19950331
ZA 9502693	A	19960930	ZA 1995-2693	19950331
RU 2128169	C1	19990327	RU 1995-104885	19950331
TW 383302	B	20000301	TW 1995-84103168	19950331
IL 113210	A1	20010128	IL 1995-113210	19950331
PL 180523	B1	20010228	PL 1995-307951	19950331
EP 1081135	A2	20010307	EP 2000-203897	19950331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT				
US 5654326	A	19970805	US 1995-469954	19950606
US 5733923	A	19980331	US 1997-825453	19970328
US 5919810	A	19990706	US 1997-856271	19970514
US 5919943	A	19990706	US 1997-991149	19971216
US 6175021	B1	20010116	US 1999-258680	19990226
PRIORITY APPLN. INFO.:			US 1994-221916	A 19940401
			EP 1995-302166	A3 19950331
			US 1995-469954	A3 19950606
			US 1997-825453	A1 19970328
			US 1997-856271	A1 19970514
OTHER SOURCE(S):	MARPAT 124:117083			
GI				



I



II

AB Title compds. [I; X, X1 = O, S; R1 = (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, optionally connected to N by a linking group; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, non-interfering substituent; R4, R5 = H, non-interfering substituent, linker-acidic group; R6, R7 = H, non-interfering substituent, (substituted) carbocyclyl, heterocyclyl; with provisos], were prepd. Thus, 2-ethyl-4-methoxy-1H-indole was N-alkylated with NaH/2-(bromomethyl)biphenyl (37%) and the product was O-demethylated with BBr3 to give 69%

1-(1,1'-biphenyl-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole.

This was O-alkylated with NaH/BrCH2CO2Me to give 59% 4-indolyloxyacetate ester, which was 3-acylated with (COCl)2 followed by amidation with NH3 and ester hydrolysis to give title compd. (II). II inhibited human secreted PLA2 with IC50 = 4.33 nM.

IT Allergy inhibitors

(prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Respiratory distress syndrome

(adult, treatment; prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Inflammation inhibitors

(antiarthritics, prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Bronchodilators

(antiasthmatics, prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Pancreas, disease

(pancreatitis, treatment; prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Shock

(septic, treatment; prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT Injury

(trauma, treatment; prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT 172732-60-4P 172732-61-5P 172732-62-6P

172732-63-7P 172732-64-8P 172732-65-9P

172732-66-0P 172732-67-1P 172732-68-2P

172732-69-3P 172732-70-6P 172732-71-7P

172732-72-8P 172732-73-9P 172732-74-0P 172732-75-1P

172732-76-2P 172733-42-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT 79-37-8, Oxalyl chloride 86-52-2, 1-(Chloromethyl)naphthalene 96-32-2,

Methyl bromoacetate 100-39-0, Benzyl bromide 102-50-1,  
 4-Methoxy-2-methylaniline 459-46-1, 4-Fluorobenzyl bromide 620-20-2,  
 3-Chlorobenzyl chloride 1006-94-6, 5-Methoxyindole 1667-11-4,  
 4-(Chloromethyl)biphenyl 2014-83-7, .alpha.,2,6-Trichlorotoluene  
 2969-81-5, Ethyl 4-bromobutyrate 5445-17-0, Methyl 2-bromopropionate  
 19500-02-8, 3-Methoxy-2-methylaniline 19853-09-9, 2-  
 (Bromomethyl)biphenyl 38580-82-4 87885-87-8, 2-Ethyl-4-nitroindole  
 104863-65-2, N-Methoxy-N-methylpropanamide 109480-78-6,  
 N-Methoxy-N-methylbutanamide 147356-78-3 172732-78-4 172733-39-0  
 RL: RCT (Reactant)

(prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT	16382-21-1P	17897-50-6P	129822-42-0P	142769-36-6P	163688-09-3P
	163688-10-6P	164082-77-3P	164082-79-5P	164082-80-8P	164082-86-4P
	164083-26-5P	172732-77-3P	172732-79-5P	172732-80-8P	172732-81-9P
	172732-82-0P	172732-83-1P	172732-84-2P	172732-85-3P	172732-86-4P
	172732-87-5P	172732-88-6P	172732-89-7P	172732-90-0P	172732-91-1P
	172732-92-2P	172732-93-3P	172732-94-4P	172732-95-5P	172732-96-6P
	172732-97-7P	172732-98-8P	172732-99-9P	172733-00-5P	172733-01-6P
	172733-02-7P	172733-03-8P	172733-04-9P	172733-05-0P	172733-06-1P
	172733-07-2P	172733-08-3P	172733-09-4P	172733-10-7P	172733-11-8P
	172733-12-9P	172733-13-0P	172733-14-1P	172733-15-2P	172733-16-3P
	172733-17-4P	172733-18-5P	172733-19-6P	172733-20-9P	172733-21-0P
	172733-22-1P	172733-23-2P	172733-24-3P	172733-25-4P	172733-26-5P
	172733-27-6P	172733-28-7P	172733-29-8P	172733-30-1P	172733-31-2P
	172733-32-3P	172733-33-4P	172733-34-5P	172733-35-6P	172733-36-7P
	172733-37-8P	172733-38-9P	172733-40-3P	172733-41-4P	172733-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT 9001-84-7, Phospholipase A2

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC  
 (Miscellaneous); BIOL (Biological study); PROC (Process)

(secretory; prepn. of indole-3-glyoxylamides as sPLA2 inhibitors)

IT 172732-68-2P 172733-08-3P  
 RL: BAC (Biological activity or effector, except adverse); RCT  
 (Reactant);  
 SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)

IT 249730-11-8P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
 preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)

IT 9001-84-7, Phospholipase A2  
 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
 (Biological study)  
 (prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)

IT 96-32-2, Methyl bromoacetate 3647-69-6, 4-(2-Chloroethyl)morpholine  
 hydrochloride 104863-65-2 164082-77-3  
 RL: RCT (Reactant)  
 (prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)

IT 164082-78-4P 164082-79-5P 164082-80-8P 172733-06-1P 172733-07-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)

REFERENCE COUNT:

5

REFERENCE(S):

- (1) Anon; WO 9842343 1998 CAPLUS
- (2) Anon; WO 9921559 1999 CAPLUS
- (3) Anon; WO 9925339 1999 CAPLUS
- (4) Bach; US 5654326 1997 CAPLUS
- (5) Lipsky; The Lancet 1996, V348, P1357 CAPLUS

L108 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:441578 CAPLUS

DOCUMENT NUMBER: 133:53700

TITLE: Combination therapy for the treatment of sepsis with  
 activated protein C and a secretory phospholipase A2  
 (sPLA2) inhibitor

INVENTOR(S): Maciak, Ronald Steven

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037022	A2	20000629	WO 1999-US30433	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000019408	A1	20000712	AU 2000-19408	19991220
PRIORITY APPLN. INFO.:			US 1998-113124	P 19981221
			WO 1999-US30433	W 19991220

OTHER SOURCE(S): MARPAT 133:53700

AB The invention provides a method of prevention and treatment for sepsis  
 for

mammals. The treatment is a combination therapy of activated protein C and an sPLA2 inhibitor.

IT Drug delivery systems  
Sepsis  
(activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(aerosols; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(capsules; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(injections, i.v.; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(nasal; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(oral; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(parenterals; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(prodrugs; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(suppositories; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(suspensions; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(tablets; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(transdermal; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT Drug delivery systems  
(unit doses; activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT 172733-08-3P  
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);  
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT 172732-68-2DP, prodrug derivs. 172732-68-2P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

IT 86-74-8D, Carbazole, derivs. 5548-10-7D, derivs. 42617-41-4,  
Activated  
protein C 172732-60-4 172732-60-4D, prodrug derivs.  
172732-61-5 172732-61-5D, prodrug derivs.  
172732-62-6 172732-62-6D, prodrug derivs. 172732-63

-7 172732-63-7D, prodrug derivs. 172732-64-8  
 172732-64-8D, prodrug derivs. 172732-65-9  
 172732-65-9D, prodrug derivs. 172732-66-0  
 172732-66-0D, prodrug derivs. 172732-67-1  
 172732-67-1D, prodrug derivs. 172732-69-3  
 172732-69-3D, prodrug derivs. 172732-70-6  
 172732-70-6D, prodrug derivs. 172732-71-7  
 172732-71-7D, prodrug derivs. 172732-72-8  
 172732-72-8D, prodrug derivs. 172732-73-9 172732-73-9D,  
 prodrug derivs. 172732-74-0 172732-74-0D, prodrug derivs.  
 172733-08-3D, prodrug derivs. 172733-42-5 172733-42-5D, prodrug  
 derivs. 207340-66-7 207340-66-7D, prodrug derivs. 207340-77-0  
 207340-77-0D, prodrug derivs. 207340-78-1 207340-78-1D, prodrug  
 derivs. 207340-79-2 207340-79-2D, prodrug derivs. 207340-81-6  
 207340-81-6D, prodrug derivs. 207340-82-7 207340-82-7D, prodrug  
 derivs. 207340-85-0 207340-85-0D, prodrug derivs. 207340-86-1D,  
 prodrug derivs. 207340-94-1 207340-94-1D, prodrug derivs.  
 220862-21-5 220862-21-5D, prodrug derivs. 220862-22-6 220862-22-6D,  
 prodrug derivs. 220862-23-7 220862-23-7D, prodrug derivs.  
 220862-24-8 220862-24-8D, prodrug derivs. 220862-25-9 220862-25-9D,  
 prodrug derivs. 220862-26-0 220862-26-0D, prodrug derivs.  
 220862-27-1 220862-27-1D, prodrug derivs. 220862-28-2 220862-28-2D,  
 prodrug derivs. 220862-30-6 220862-30-6D, prodrug derivs.  
 220862-31-7 220862-31-7D, prodrug derivs. 220862-32-8 220862-32-8D,  
 prodrug derivs. 220862-33-9 220862-33-9D, prodrug derivs.  
 220862-34-0 220862-34-0D, prodrug derivs. 220862-35-1 220862-35-1D,  
 prodrug derivs. 220862-37-3 220862-37-3D, prodrug derivs.  
 220862-38-4 220862-38-4D, prodrug derivs. 220862-39-5 220862-39-5D,  
 prodrug derivs. 220862-40-8 220862-40-8D, prodrug derivs.  
 220862-41-9 220862-41-9D, prodrug derivs. 220862-42-0 220862-42-0D,  
 prodrug derivs. 220862-43-1 220862-43-1D, prodrug derivs.  
 220862-44-2 220862-44-2D, prodrug derivs. 220862-45-3 220862-45-3D,  
 prodrug derivs. 220862-46-4 220862-46-4D, prodrug derivs.  
 220862-47-5 220862-47-5D, prodrug derivs. 220862-48-6 220862-48-6D,  
 prodrug derivs. 220862-49-7 220862-49-7D, prodrug derivs.  
 220862-50-0 220862-50-0D, prodrug derivs. 220862-51-1 220862-51-1D,  
 prodrug derivs. 220862-53-3 220862-53-3D, prodrug derivs.  
 220862-54-4 220862-54-4D, prodrug derivs. 220862-55-5 220862-55-5D,  
 prodrug derivs. 220862-56-6 220862-56-6D, prodrug derivs.  
 220862-57-7 220862-57-7D, prodrug derivs. 220862-58-8 220862-58-8D,  
 prodrug derivs. 220862-59-9 220862-59-9D, prodrug derivs.  
 220862-60-2 220862-60-2D, prodrug derivs. 220862-61-3 220862-61-3D,  
 prodrug derivs. 220862-62-4 220862-62-4D, prodrug derivs.  
 220862-63-5 220862-63-5D, prodrug derivs. 220862-64-6 220862-64-6D,  
 prodrug derivs. 220862-65-7 220862-65-7D, prodrug derivs.  
 220862-66-8 220862-66-8D, prodrug derivs. 220862-68-0 220862-68-0D,  
 prodrug derivs. 220862-70-4 220862-70-4D, prodrug derivs.  
 220862-72-6 220862-72-6D, prodrug derivs. 220862-74-8 220862-74-8D,  
 prodrug derivs. 220862-76-0 220862-76-0D, prodrug derivs.  
 220862-79-3 220862-79-3D, prodrug derivs. 220862-82-8 220862-82-8D,  
 prodrug derivs. 220862-83-9 220862-83-9D, prodrug derivs.  
 220862-84-0 220862-84-0D, prodrug derivs. 220863-33-2 220863-33-2D,  
 prodrug derivs. 222417-27-8 222417-27-8D, prodrug derivs.  
 225653-24-7 225653-24-7D, prodrug derivs. 225653-40-7 225653-40-7D,  
 prodrug derivs. 249730-08-3 249730-08-3D, prodrug derivs.  
 278171-82-7 278171-82-7D, prodrug derivs.

RL: BAC (Biological activity or effector, except adverse); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(activated protein C-secretory phospholipase A2 inhibitor combination  
for sepsis treatment)

IT 207340-86-1  
 RL: BAC (Biological activity or effector, except adverse); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phospholipase A2 inhibitor combination for sepsis treatment)

IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P  
 172733-06-1P 172733-07-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction; activated protein C-secretory phospholipase A2  
 inhibitor combination for sepsis treatment)

IT 96-32-2, Methyl bromoacetate 100-39-0, Benzyl bromide 104863-65-2,  
 N-Methoxy-N-methylpropanamide 164082-77-3  
 RL: RCT (Reactant)  
 (reaction; activated protein C-secretory phospholipase A2 inhibitor  
 combination for sepsis treatment)

IT 9001-84-7, Phospholipase A2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (secretory; activated protein C-secretory phospholipase A2 inhibitor  
 combination for sepsis treatment)

L108 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:260237 CAPLUS

DOCUMENT NUMBER: 132:279109

TITLE: Process for preparing 4-substituted-1H-indole-3-  
 glyoxamides

INVENTOR(S): Anderson, Benjamin Alan; Harn, Nancy Kay; Miller,  
 Richard Duane; Plocharczyk, Edward Francis

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021929	A1	20000420	WO 1999-US8325	19990415
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9935644	A1	20000501	AU 1999-35644	19990415
EP 1119549	A1	20010801	EP 1999-917552	19990415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1998-103604 P 19981009  
 WO 1999-US8325 W 19990415

OTHER SOURCE(S): CASREACT 132:279109; MARPAT 132:279109

GI





AB The title compds. [I; R1 = alkyl, (un)substituted CH2Ph, (CH2)2Ph, etc.; R2 = H, halo, alkyl, etc.; R4 = CO2H, SO3H, PO(OH)2, etc.; R5 = H, alkyl, alkoxy, etc.], useful for inhibiting sPLA2 (no data), were prepd. E.g.,

a multi-step synthesis of I [R1 = CH2Ph; R2 = Et; R4 = COOMe; R5 = H], was given.

IT 672-78-6P 172733-06-1P 172733-07-2P 218934-50-0P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)  
 IT 172732-68-2P 172733-08-3P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)  
 IT 96-32-2, Methyl bromoacetate 100-46-9, Benzylamine, reactions  
 824-79-3, p-Toluenesulfonic acid, sodium salt 24836-98-4,  
 2-(2-Oxobutyl)cyclohexane-1,3-dione 263714-81-4  
 RL: RCT (Reactant)

(process for prepg. 4-substituted-1H-indole-3-glyoxamides)

REFERENCE COUNT: 3

REFERENCE(S): (1) Draheim; Journal of Medicinal Chemistry 1996, V39(26) CAPLUS  
 (2) Eli Lilly And Company; EP 0675110 A1 1995, P37 CAPLUS  
 (3) Shionogi & Co Ltd; WO 9837069 A1 1998, P6 CAPLUS

L108 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:260062 CAPLUS

DOCUMENT NUMBER: 132:284251

TITLE: Remedies or preventives containing sPLA2 inhibitors for ischemic reflow failure

INVENTOR(S): Todo, Satoru

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021563	A1	20000420	WO 1999-JP5528	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9960047 A1 20000501 AU 1999-60047 19991007  
JP 1998-292423 A 19981014  
WO 1999-JP5528 W 19991007

PRIORITY APPLN. INFO.:  
OTHER SOURCE(S): MARPAT 132:284251

AB The invention relates to remedies or preventives for ischemic reflow failure which contain an sPLA2 inhibitor, e.g. [[3-[2-Amino-1,2-dioxoethyl]-2-methyl-1-[phenylmethyl]-1H-indol-4-yl]oxy]acetic acid, as active ingredient. Capsules were formulated contg. sPLA2 inhibitor 250, starch 200 and magnesium stearate 10 mg/capsule.

IT Drug delivery systems  
(aerosols; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(capsules; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(injections, i.v.; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Liver, disease  
(ischemia, ischemic reflow failure; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Reperfusion  
(ischemic, disorder of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(prodrugs; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Organ preservation  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(suppositories; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems  
(tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 172732-60-4 172732-61-5 172732-62-6  
172732-63-7 172732-64-8 172732-65-9  
172732-66-0 172732-67-1 172732-68-2  
172732-69-3 172732-70-6 172732-71-7  
172732-72-8 172732-73-9 182115-96-4 182115-97-5  
182116-01-4 211925-45-0 220862-64-6 245756-89-2 245756-93-8  
245757-15-7 263910-31-2 263910-32-3 263910-33-4 263910-34-5  
263910-35-6


RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT 9001-84-7, Phospholipase A2  
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(secretory, inhibitor of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

REFERENCE COUNT: 98  
 REFERENCE(S): (1) Anon; JP 07285933 A CAPLUS  
 (2) Anon; CN 1098714 A CAPLUS  
 (3) Anon; CN 1114310 A CAPLUS  
 (4) Anon; CA 2121321 A CAPLUS  
 (5) Anon; CA 2146097 A CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2001 ACS  
 ACCESSION NUMBER: 2000:116896 CAPLUS  
 DOCUMENT NUMBER: 132:151679  
 TITLE: Preparation of indole sPLA2 inhibitors  
 INVENTOR(S): Mihelich, Edward David; Phillips, Michael Leroy;  
 Warshawsky, Alan M.  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007591	A1	20000217	WO 1999-US17460	19990802
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9953314	A1	20000228	AU 1999-53314	19990802
EP 1100493	A1	20010523	EP 1999-938937	19990802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1998-95109	P 19980803
			WO 1999-US17460	W 19990802
OTHER SOURCE(S):			MARPAT 132:151679	
GI				



AB The title compds. [I; R1 = alkyl, haloalkyl, alkenyl, etc.; R2 = H, a group contg. 1-4 non-hydrogen atoms; R3 = L3-Z (wherein L3 = CH2, O, S, NH, CO; Z = acetamide, thioacetamide, glyoxylamide, etc.); R4, R5 = H, non-interfering substituent, La-acylsulfonamide (La = a divalent linker having a linker length of 1-8; provided that at least one of R4 and R5 must be La-acylsulfonamide); R6, R7 = H, cycloalkyl, heterocyclyl, etc.], useful for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock, were prepd. and formulated.

Thus, reacting 1-benzyl-2-ethyl-4-carboxymethyloxy-indole-3-glyoxylamide (prepn. given) with methanesulfonamide in the presence of 4-dimethylaminopyridine and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH2Cl2 afforded 19% II which showed IC50 of 12 nM against human secreted PLA2.

IT Anti-inflammatory agents  
(prepn. of indole sPLA2 inhibitors)

IT Shock (circulatory collapse)  
(septic, treatment of; prepn. of indole sPLA2 inhibitors)

IT 258262-49-6P 258262-50-9P 258262-51-0P 258262-52-1P 258262-53-2P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of indole sPLA2 inhibitors)

IT 9001-84-7, Phospholipase A2  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(prepn. of indole sPLA2 inhibitors)

IT 88-19-7, 2-Methylbenzenesulfonamide 96-32-2, Methyl bromoacetate  
98-10-2, Benzenesulfonamide 35303-76-5, 4-(2-Aminoethyl)benzenesulfonamide 104863-65-2,

N-Methoxy-N-methylpropanamide  
164082-77-3, N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline  
RL: RCT (Reactant)  
(prepn. of indole sPLA2 inhibitors)

IT 164082-78-4P 164082-79-5P 164082-80-8P 172732-68-2P  
172733-06-1P 172733-07-2P 172733-08-3P 258262-54-3P 258262-55-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of indole sPLA2 inhibitors)

REFERENCE COUNT: 2

REFERENCE(S): (1) Bach; US 5641800 A 1997 CAPLUS  
(2) Bach; US 5654326 A 1997 CAPLUS

L108 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:766432 CAPLUS

DOCUMENT NUMBER: 132:102409

TITLE: Simple Purification of Highly Active Biotinylated P-Glycoprotein: Enantiomer-Specific Modulation of Drug-Stimulated ATPase Activity

AUTHOR(S): Julien, Michel; Kajiji, Shama; Kaback, Ronald H.; Gros, Philippe

CORPORATE SOURCE: Department of Biochemistry, McGill University, Montreal, PQ, H3G 1Y6, Can.

SOURCE: Biochemistry (2000), 39(1), 75-85  
CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A simplified method for the expression and purifn. of P-glycoprotein (Pgp)

is presented. This method is based on the in-frame fusion of both a polyhistidine tail and a 100-amino acid residue biotin acceptor domain of oxaloacetate decarboxylase from *Klebsiella pneumoniae* at the carboxyl terminus end of Pgp (Pgp-H6BD). The expression/purifn. protocol for Pgp-H6BD involves high-level expression of the fusion protein in the yeast

*Pichia pastoris*, biotinylation in vitro with biotin ligase, solubilization

of crude membrane fractions in detergent, and affinity purifn. by a combination of nickel and avidin chromatog. Biotinylated Pgp binds to immobilized monomeric avidin and can be eluted with free biotin in a high state of purity. This protocol is rapid and efficient and yields purified

Pgp which shows robust ATPase activity, as detd. by vanadate-induced trapping of photoactive nucleotides and by direct measurement of ATP hydrolysis by Pgp-H6BD. This method should be useful for structural studies of the protein by spectroscopic or crystallog. approaches. This purified Pgp-H6BD prepn. has been used to study the enantiomer-specific effects of inhibitors of Pgp-mediated drug transport on the drug-stimulated ATPase activity of the protein. A series of 1,4-disubstituted piperazine derivs. with a central chiral carbon and modified at the head and tail groups are shown to stimulate Pgp ATPase activity in a dose-dependent fashion. Some of these compds. are also capable of inhibiting either vinblastine or verapamil stimulation of ATPase activity of Pgp in an enantiomer-specific fashion. The enantiomeric specific inhibitory activity of these compds. suggests complex interactions at a single substrate binding site(s) on Pgp.

IT Multidrug resistance proteins

RL: BAC (Biological activity or effector, except adverse); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation) (MDR1; simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

IT Biological transport

(drug, P-glycoprotein-mediated; simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

IT Affinity chromatography

Biotinylation

*Komagataella pastoris*

(simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

IT Fusion proteins (chimeric proteins)

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

IT 52-53-9, Verapamil 865-21-4, Vinblastine 153653-31-7, CP 147674 153653-33-9, CP 147673 154531-77-8, CP 162398 154531-78-9, CP 162399 163296-29-5, CP 172732 163297-58-3, CP 219994

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

IT 9000-83-3, ATPase

RL: BAC (Biological activity or effector, except adverse); BPR

(Biological

process); BIOL (Biological study); PROC (Process)

(simple purifn. of highly active biotinylated P-glycoprotein and enantiomer-specific modulation of drug-stimulated ATPase activity)

REFERENCE COUNT: 51

REFERENCE(S): (2) Al-Shawi, M; J Biol Chem 1993, V268, P4197 CAPLUS

- (3) Ambudkar, S; J Bioenerg Biomembr 1995, V27, P23  
CAPLUS  
(4) Ambudkar, S; Proc Natl Acad Sci USA 1992, V89,  
P8472 CAPLUS  
(5) Bear, C; Cell 1992, V68, P809 CAPLUS  
(6) Beaudet, L; Methods Enzymol 1998, V292, P397  
CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:723018 CAPLUS

DOCUMENT NUMBER: 131:332096

TITLE: Secretory phospholipase A2 (sPLA2) inhibitors for  
treatment of inflammatory bowel disease

INVENTOR(S): Macias, William Louis

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957100	A1	19991111	WO 1999-US8654	19990420
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
AU 9936562	A1	19991123	AU 1999-36562	19990420
BR 9910095	A	20001226	BR 1999-10095	19990420
EP 1084108	A1	20010321	EP 1999-918711	19990420
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO		
NO 2000005479	A	20001220	NO 2000-5479	20001031
PRIORITY APPLN. INFO.:			US 1998-83874	P 19980501
			WO 1999-US8654	W 19990420

OTHER SOURCE(S): MARPAT 131:332096

AB A method is disclosed for the treatment of inflammatory bowel disease by administering to a human in need thereof a therapeutically effective amt. of an sPLA2 inhibitor, such as a 1H-indole-3-glyoxylamide sPLA2 inhibitor.

IT Drugs  
(gastrointestinal; secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

IT Intestine, disease  
(inflammatory; secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

IT Drug delivery systems  
(injections, i.v.; secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

IT Drug delivery systems  
(oral; secretory phospholipase A2 inhibitors for treatment of inflammatory bowel disease)

IT Drug delivery systems  
     (prodrugs; secretory phospholipase A2 inhibitors for treatment of  
     inflammatory bowel disease)

IT Anti-inflammatory agents  
     Drug delivery systems  
     (secretory phospholipase A2 inhibitors for treatment of inflammatory  
     bowel disease)

IT Antibiotics  
     Antidiarrheals  
     Immunosuppressants  
     (secretory phospholipase A2 inhibitors for treatment of inflammatory  
     bowel disease, and formulations with other agents)

IT Steroids, biological studies  
     RL: BAC (Biological activity or effector, except adverse); THU  
     (Therapeutic use); BIOL (Biological study); USES (Uses)  
     (secretory phospholipase A2 inhibitors for treatment of inflammatory  
     bowel disease, and formulations with other agents)

IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P  
     172733-06-1P 172733-07-2P  
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
     (prepn. and reaction; secretory phospholipase A2 inhibitors for  
     treatment of inflammatory bowel disease, and formulations with other  
     agents)

IT 96-32-2, Methyl bromoacetate 100-39-0, Benzyl bromide 598-30-1,  
     sec-Butyl lithium 104863-65-2, N-Methoxy-N-methylpropanamide  
     164082-77-3, N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline  
     RL: RCT (Reactant)  
     (reaction; secretory phospholipase A2 inhibitors for treatment of  
     inflammatory bowel disease, and formulations with other agents)

IT 5548-10-7D, derivs. 172732-60-4 172732-60-4D, derivs.  
     172732-61-5 172732-61-5D, derivs. 172732-62-6  
     172732-62-6D, derivs. 172732-63-7 172732-63-7D  
     , derivs. 172732-64-8 172732-64-8D, derivs.  
     172732-65-9 172732-65-9D, derivs. 172732-66-0  
     172732-66-0D, derivs. 172732-67-1 172732-67-1D  
     , derivs. 172732-68-2 172732-68-2D, derivs.  
     172732-69-3 172732-69-3D, derivs. 172732-70-6  
     172732-70-6D, derivs. 172732-71-7 172732-71-7D  
     , derivs. 172732-72-8 172732-72-8D, derivs.  
     172732-73-9 172732-73-9D, derivs. 172732-74-0 172732-74-0D, derivs.  
     172733-08-3 172733-42-5  
     RL: BAC (Biological activity or effector, except adverse); THU  
     (Therapeutic use); BIOL (Biological study); USES (Uses)  
     (secretory phospholipase A2 inhibitors for treatment of inflammatory  
     bowel disease)

IT 9001-84-7, Phospholipase A2  
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
     (Biological study); PROC (Process)  
     (secretory phospholipase A2 inhibitors for treatment of inflammatory  
     bowel disease)

REFERENCE COUNT: 6

REFERENCE(S):

- (1) Dillard, R; J Med Chem V39(26), P5137 CAPLUS
- (2) Dillard, R; J Med Chem 1996, V39(26), P5119

CAPLUS

- (3) Draheim, S; Indole Inhibitors of Human  
     Nonpancreatic Secretory Phospholipase A2.3 inhole  
     3-glyoxamies 1996, V39(26), P5159 CAPLUS
- (4) Eli Lilly And Company; EP 675110 A1 1995 CAPLUS
- (5) Murthy, S; Increased Phospholipase A2 Activity in  
     Peritoneal Leukocytes in Rat Experimental Colitis

Inflammation 1992, V16(3), P259 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:722903 CAPLUS

DOCUMENT NUMBER: 131:336938

TITLE: Preparation of  
[(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-

(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid  
N-morpholino Et ester as sPLA2 inhibitor ester

INVENTOR(S): Denney, Michael Lyle; Morin, John Michael, Jr.; Sall,  
Daniel Jon; Sawyer, Jason Scott

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9956752	A1	19991111	WO 1999-US8538	19990420
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9936525	A1	19991123	AU 1999-36525	19990420
EP 1073440	A1	20010207	EP 1999-918666	19990420
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
US 6274578	B1	20010814	US 2000-673677	20001017
NO 2000005477	A	20001031	NO 2000-5477	20001031
PRIORITY APPLN. INFO.:			US 1998-83873	P 19980501
			WO 1999-US8538	W 19990420

AB Prepn. of

[(3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid N-morpholino Et ester is disclosed, together with its

use as a highly bioavailable indole sPLA2 inhibitor compd.

IT 172732-80-8P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);

SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as sPLA2 inhibitor)

IT 249730-08-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of [(aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic acid N-morpholino Et ester as sPLA2 inhibitor)

IT 172733-08-3 249730-09-4 249730-10-7 249730-11-8 249730-12-9  
249730-13-0 249730-14-1 249730-15-2 249730-16-3



RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(prepn. of [((aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic  
acid N-morpholino Et ester as sPLA2 inhibitor)

IT 9001-84-7, Phospholipase A2  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
(Biological study)  
(prepn. of [((aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic  
acid N-morpholino Et ester as sPLA2 inhibitor)


IT 100-39-0, Benzyl bromide 3647-69-6, 4-(2-Chloroethyl)morpholine  
hydrochloride 19500-02-8, 3-Methoxy-2-methylaniline 172733-39-0  
RL: RCT (Reactant)  
(prepn. of [((aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic  
acid N-morpholino Et ester as sPLA2 inhibitor)

IT 17897-50-6P 164082-77-3P 164083-26-5P 172732-60-4P  
172732-77-3P 172732-78-4P 172732-79-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of [((aminodioxoethyl)methyl(phenylmethyl)indolyl)oxy]acetic  
acid N-morpholino Et ester as sPLA2 inhibitor)

REFERENCE COUNT: 1  
REFERENCE(S): (1) Denny; WO 99215545 1999

L108 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1999:691078 CAPLUS  
DOCUMENT NUMBER: 131:299367  
TITLE: Process for preparing 1H-indole-3-glyoxamides  
INVENTOR(S): Anderson, Benjamin Alan; Harn, Nancy Kay  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954300	A1	19991028	WO 1999-US8332	19990415
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9935648	A1	19991108	AU 1999-35648	19990415
BR 9909697	A	20001219	BR 1999-9697	19990415
EP 1071663	A1	20010131	EP 1999-917556	19990415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
US 6265591	B1	20010724	US 2000-647471	20000927
NO 2000005148	A	20001109	NO 2000-5148	20001013
PRIORITY APPLN. INFO.:			US 1998-82110	P 19980417
			WO 1999-US8332	W 19990415
OTHER SOURCE(S):			CASREACT 131:299367; MARPAT 131:299367	
GI				



AB A multistep synthetic scheme for prepg. title compds. [I; R = COCONH2; R1 = alkyl, (un)substituted CH2Ph, biphenylmethyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R4 = CO2H, SO3H, P(O)(OH)2, etc.; R5 = H, halo, (halo)alkyl, etc.] was disclosed. Thus, 2-(2-oxobutyl)-1,3-cyclohexanedione was cyclocondensed with PhCH2NH2 and the product aromatized to give, after etherification by BrCH2CO2Me, I (R = R5 = H, R1 = CH2Ph, R2 = Et, R4 = CO2Me).

IT 536-57-2P, 4-Methylbenzenesulfinic acid 172733-07-2P 218934-50-0P  
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 1H-indole-3-glyoxamides)

IT 172732-68-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(process for prepg. 1H-indole-3-glyoxamides)

IT 96-32-2, Methyl bromoacetate 100-46-9, Benzylamine, reactions  
 824-79-3, 4-Methylbenzenesulfinic acid sodium salt 24836-98-4,  
 2-(2-Oxobutyl)-1,3-cyclohexanedione

RL: RCT (Reactant)

(process for prepg. 1H-indole-3-glyoxamides)

REFERENCE COUNT: 2

REFERENCE(S):

(1) Draheim; Journal of Medicinal Chemistry 1996, V39(26), P5161

(2) Eli Lilly and Company; EP 0675110 A1 1995 CAPLUS

L108 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:350593 CAPLUS

DOCUMENT NUMBER: 131:5185

TITLE: Preparation of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA2 inhibitors

INVENTOR(S): Watanabe, August Masaru

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925339	A1	19990527	WO 1998-US24234	19981113
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,				

TM


RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9914058 A1 19990607 AU 1999-14058 19981113  
 EP 1039901 A1 20001004 EP 1998-957915 19981113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1997-66036 P 19971114  
 WO 1998-US24234 W 19981113

OTHER SOURCE(S): MARPAT 131:5185  
 GI



AB Title compds. (I; R = COCONH<sub>2</sub>) [II; R<sub>1</sub> = (un)substituted CH<sub>2</sub>Ph, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>Ph-4, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(CH<sub>2</sub>Ph)-4, etc.; R<sub>2</sub> = halo, Me, Et, Pr, cyclopropyl;  
 1 of R<sub>4</sub>, R<sub>5</sub> = ZR<sub>3</sub> and the other = H or ZR<sub>3</sub>; R<sub>3</sub> = CO<sub>2</sub>H, SO<sub>3</sub>H, P(O)(OH)<sub>2</sub>;  
 R<sub>6</sub>, R<sub>7</sub> = H, halo, alkyl, alkoxy, etc.; when R<sub>4</sub> .noteq. H Z = CH<sub>2</sub>CH<sub>2</sub>, OCH<sub>2</sub>,  
 OCHMe,  
 etc.; when R<sub>5</sub> .noteq. H Z = OZ<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, NHZ<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, C<sub>6</sub>H<sub>4</sub>C<sub>6</sub>H<sub>4</sub>Z<sub>1</sub>C<sub>6</sub>H<sub>4</sub>, etc.; Z<sub>1</sub> = (un)substituted CH<sub>2</sub>] were prepd. as sPLA<sub>2</sub> inhibitors (no data). Thus, II (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = Et, R<sub>4</sub> = OCH<sub>2</sub>CO<sub>2</sub>H, R<sub>5</sub>-R<sub>7</sub> = H) was prepd. starting from 2,3-Me(MeO)C<sub>6</sub>H<sub>3</sub>NHCO<sub>2</sub>CMe<sub>3</sub> and EtCON(OMe)Me.

IT Alzheimer's disease  
 (treatment; prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA<sub>2</sub> inhibitors)

IT 172732-60-4P 172732-61-5P 172732-62-6P  
 172732-63-7P 172732-64-8P 172732-65-9P  
 172732-66-0P 172732-67-1P 172732-68-2P  
 172732-69-3P 172732-70-6P 172732-71-7P  
 172732-72-8P 172732-73-9P 172733-08-3P 172733-42-5P  
 220862-20-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA<sub>2</sub> inhibitors)

IT 100-39-0, Benzyl bromide 5292-43-3, tert-Butyl bromoacetate  
 104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3,  
 N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline  
 RL: RCT (Reactant)  
 (prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA<sub>2</sub> inhibitors)

IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P  
 172733-06-1P 220862-18-0P 220862-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA<sub>2</sub> inhibitors)

IT 9001-84-7, Phospholipase A2  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
 (secretory; mediated disorders; treatment; prepn. of  
 3-aminooxalyl-4-indolyloxyacetic acids and analogs as sPLA2  
 inhibitors)

REFERENCE COUNT: 1  
 REFERENCE(S): (1) Bach; US 5733923 A 1998 CAPLUS

L108 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:325791 CAPLUS

DOCUMENT NUMBER: 130:338017

TITLE: Method for the treatment of disorders associated with  
 apoptosis using N-heterocyclic glyoxylamide compounds

INVENTOR(S): Yagami, Tatsuro; Takasu, Nobuo

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924033	A1	19990520	WO 1997-JP4104	19971112
W: JP, US				
WO 9924026	A2	19990520	WO 1998-JP5042	19981110
WO 9924026	A3	19990715		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9897630	A1	19990531	AU 1998-97630	19981110
EP 1037630	A2	20000927	EP 1998-951749	19981110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: WO 1997-JP4104 A 19971112  
 WO 1998-JP5042 W 19981110

OTHER SOURCE(S): MARPAT 130:338017  
 GI



AB A method is disclosed for the treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds. I [E, F = C, N; the dotted line indicates the presence or absence of a double bond; R11 = alkyl, etc.; R12 = H, halo, etc.; R14 = H, etc.; R15 = H, etc.; R16 = H, carboxyl or ester thereof; R17 = H, alkyl, etc.; X = O, S]. Indole deriv.

II (prepn. given) in vitro suppressed neuronal death depending on its concn.

IT Neuroprotectants  
(N-heterocyclic glyoxylamide compds.)

IT Apoptosis  
(method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

IT 172732-60-4P 172732-61-5P 172732-62-6P  
172732-63-7P 172732-64-8P 172732-65-9P  
172732-66-0P 172732-67-1P 172732-68-2P  
172732-69-3P 172732-70-6P 172732-71-7P  
172732-72-8P 172732-73-9P 172732-74-0P 172733-08-3P  
172733-42-5P 177558-06-4P 182115-86-2P 182115-87-3P 182115-88-4P  
182115-90-8P 182115-92-0P 182115-96-4P 182115-97-5P 182115-98-6P  
182115-99-7P 182116-00-3P 182116-01-4P 182116-02-5P 211925-44-9P  
211925-45-0P 211925-46-1P 215160-62-6P 215160-63-7P 215160-64-8P  
215160-65-9P 224581-09-3P 224581-10-6P 224581-11-7P  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

IT 9001-84-7, Phospholipase A2  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
(method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

IT 96-32-2, Methyl bromoacetate 100-39-0, Benzyl bromide 100-44-7, reactions 816-40-0, 1-Bromo-2-butanone 2584-12-5 14002-52-9, 2-Phenylbenzoyl chloride 104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3  
RL: RCT (Reactant)  
(method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

IT 164082-78-4P 164082-79-5P 164082-80-8P 172733-06-1P 172733-07-2P  
177556-96-6P 177558-64-4P 177558-67-7P 177558-73-5P 177558-79-1P  
177558-91-7P 177560-06-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(method for treatment of disorders assocd. with apoptosis using N-heterocyclic glyoxylamide compds.)

REFERENCE COUNT: 6

REFERENCE (S): (1) Dillard, R; WO 9603383 A 1996 CAPLUS  
(2) Draheim; J Med Chem 1996, V39(26), P5159 CAPLUS  
(3) Gonzalo, J; European Journal of Immunology 1993, V23(9), P2372 CAPLUS  
(4) Lilly Co Eli; EP 0675110 A 1995 CAPLUS  
(5) Lilly Co Eli; WO 9517183 A 1995 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2001 ACS  
ACCESSION NUMBER: 1999:297296 CAPLUS  
DOCUMENT NUMBER: 130:311697  
TITLE: N,N-Diethylglycol amido ester prodrugs of indole  
SPLA2

INVENTOR(S): inhibitors  
 Denney, Michael Lyle; Morin, John Michael, Jr.; Sall,  
 Daniel Jon; Sawyer, Jason Scott  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921546	A1	19990506	WO 1998-US22690	19981026
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9912798	A1	19990517	AU 1999-12798	19981026
EP 1030661	A1	20000830	EP 1998-956223	19981026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001520991	T2	20011106	JP 2000-517704	19981026
US 6274616	B1	20010814	US 2000-509754	20000329
PRIORITY APPLN. INFO.:			US 1997-63280	P 19971027
			WO 1998-US22690	W 19981026
AB	The compd. ((3-(2-amino-1,2-dioxoethyl)-1-((1,1'-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid N,N-diethylglycolamido ester was prepd. and its use as a highly bioavailable indole compd. for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock examd.			
IT	214421-74-6P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N,N-diethylglycol amido ester prodrugs of indole sPLA2 inhibitors)			
IT	9001-84-7, Phospholipase A2 RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study) (prepn. of N,N-diethylglycol amido ester prodrugs of indole sPLA2 inhibitors)			
IT	96-32-2, Methyl bromoacetate 2315-36-8, 2-Chloro-N,N-diethylacetamide 17897-50-6 38580-82-4 RL: RCT (Reactant) (prepn. of N,N-diethylglycol amido ester prodrugs of indole sPLA2 inhibitors)			
IT	172732-63-7P 172732-87-5P 172732-88-6P 172732-89-7P 172732-90-0P 172732-91-1P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of N,N-diethylglycol amido ester prodrugs of indole sPLA2 inhibitors)			
REFERENCE COUNT:		1		
REFERENCE(S):		(1) Bach; US 5654326 A 1997 CAPLUS		

L108 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:297295 CAPLUS

DOCUMENT NUMBER: 130:311696

TITLE: Preparation of isopropyl ester prodrugs of indole sPLA2 inhibitors

INVENTOR(S): Denney, Michael Lyle; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer, Jason Scott

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921545	A1	19990506	WO 1998-US22678	19981026
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,			
TM	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9912007	A1	19990517	AU 1999-12007	19981026
PRIORITY APPLN. INFO.:			US 1997-63284	19971027
			WO 1998-US22678	19981026
AB	The compd., ((3-(2-amino-1,2-dioxoethyl)-1-((1,1'-biphenyl)-3-ylmethyl)-2-methyl-1H-indol-4-yl)oxy)acetic acid iso-Pr ester, is disclosed together with its use as a highly bioavailable indole compd. for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.			
IT	214421-73-5	214421-74-6	223676-72-0	223676-73-1
	RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study) (prepn. of iso-Pr ester prodrugs of indole sPLA2 inhibitors)			
IT	214421-72-4P			
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of iso-Pr ester prodrugs of indole sPLA2 inhibitors)			
IT	9001-84-7, Phospholipase A2			
	RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study) (prepn. of iso-Pr ester prodrugs of indole sPLA2 inhibitors)			
IT	96-32-2, Methyl bromoacetate	17897-50-6	38580-82-4	
	RL: RCT (Reactant) (prepn. of iso-Pr ester prodrugs of indole sPLA2 inhibitors)			
IT	172732-63-7P	172732-87-5P	172732-89-7P	172732-90-0P
	172732-91-1P			
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of iso-Pr ester prodrugs of indole sPLA2 inhibitors)			
REFERENCE COUNT:	1			
REFERENCE(S):	(1) Bach; US 5654326 A 1997 CAPLUS			

L108 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:233807 CAPLUS  
DOCUMENT NUMBER: 130:267344  
TITLE: Compounds for treatment of cystic fibrosis  
INVENTOR(S): Macias, William Louis  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 260 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916453	A1	19990408	WO 1998-US19906	19980923
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,			
TM	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9896641	A1	19990423	AU 1998-96641	19980923
EP 1007056	A1	20000614	EP 1998-950654	19980923
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
JP 2001517707	T2	20011009	JP 2000-513587	19980923
PRIORITY APPLN. INFO.:			US 1997-60128	P 19970926
			WO 1998-US19906	W 19980923
OTHER SOURCE(S):	MARPAT 130:267344			
AB	Title compds., sPLA2 inhibitors (no data), were selected from indoleglyoxylamides, -acetamides, -acetic acid hydrazides, etc. Prepn. of			
IT	[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl-1H-indol-4-yl]oxy]acetic acid was described.			
IT	Protein receptors			
IT	RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)			
IT	(phospholipase A2 receptors; compds. for treatment of cystic fibrosis)			
IT	Cystic fibrosis			
IT	(treatment; compds. for treatment of cystic fibrosis)			
IT	172732-60-4P 172732-61-5P 172732-62-6P 172732-63-7P 172732-64-8P 172732-65-9P 172732-66-0P 172732-67-1P 172732-68-2P 172732-69-3P 172732-70-6P 172732-71-7P 172732-72-8P 172732-73-9P 172732-74-0P 172733-08-3P 172733-42-5P 207340-66-7P 207340-74-7P 207340-75-8P 207340-77-0P 207340-78-1P 207340-79-2P 207340-81-6P 207340-82-7P 207340-85-0P 207340-86-1P 220862-21-5P 220862-22-6P 220862-23-7P 220862-24-8P 220862-25-9P 220862-26-0P 220862-27-1P 220862-28-2P 220862-30-6P 220862-31-7P 220862-32-8P 220862-33-9P 220862-34-0P 220862-35-1P 220862-36-2P 220862-37-3P 220862-38-4P 220862-39-5P 220862-40-8P 220862-41-9P 220862-42-0P 220862-43-1P 220862-44-2P 220862-45-3P 220862-46-4P 220862-47-5P 220862-48-6P 220862-49-7P 220862-50-0P 220862-51-1P 220862-53-3P 220862-54-4P 220862-55-5P 220862-56-6P 220862-57-7P 220862-58-8P 220862-59-9P 220862-60-2P 220862-61-3P 220862-62-4P 220862-63-5P 220862-64-6P 220862-65-7P 220862-66-8P 220862-68-0P 220862-70-4P 220862-72-6P 220862-74-8P 220862-76-0P			



220862-79-3P 220862-82-8P 220862-83-9P 220862-84-0P 220863-33-2P  
 222417-25-6P 222417-27-8P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (compds. for treatment of cystic fibrosis)  
 IT 220862-19-1  
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)  
 (compds. for treatment of cystic fibrosis)  
 IT 100-39-0, Benzyl bromide 5292-43-3, tert-Butyl bromoacetate  
 104863-65-2, N-Methoxy-N-methylpropionamide 164082-77-3,  
 N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline  
 RL: RCT (Reactant)  
 (compds. for treatment of cystic fibrosis)  
 IT 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P 172733-06-1P  
 220862-18-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (compds. for treatment of cystic fibrosis)

REFERENCE COUNT:

8

REFERENCE(S):

- (1) Blake; US 5436258 A 1995 CAPLUS
  - (2) Edwards; US 5532366 A 1996 CAPLUS
  - (3) Finke; US 5719149 A 1998 CAPLUS
  - (4) Gyorkos; US 5807829 A 1998 CAPLUS
  - (5) Perrier; US 5453443 A 1995 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:172589 CAPLUS

DOCUMENT NUMBER: 130:196575

TITLE: Method for treatment of non-rheumatoid arthritis by administration of an sPLA2 inhibitor.

INVENTOR(S): Macias, William Louis

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 273 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909978	A1	19990304	WO 1998-US17778	19980827
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9891231	A1	19990316	AU 1998-91231	19980827
EP 1011670	A1	20000628	EP 1998-943430	19980827
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI			
JP 2001513555	T2	20010904	JP 2000-507368	19980827
PRIORITY APPLN. INFO.:			US 1997-57726	P 19970828
			WO 1998-US17778	W 19980827
OTHER SOURCE(S):		MARPAT 130:196575		
GI				



- AB A method for treatment of non-rheumatoid arthritis by administration of  
of an sPLA2 inhibitor is claimed (no data). Thus, preferred compd. (I) was  
prepd. in 6 steps via 2-ethyl-4-methoxy-1H-indole.
- IT Antiarthritics  
(indolyloxyacetates, carbazolyloxyacetates, etc.; method for treatment  
of non-rheumatoid arthritis by administration of an sPLA2 inhibitor)
- IT 9001-84-7, Phospholipase A2  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL  
(Biological study)  
(inhibitors; method for treatment of non-rheumatoid arthritis by  
administration of an sPLA2 inhibitor)
- IT **172732-68-2P**  
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(method for treatment of non-rheumatoid arthritis by administration of  
an sPLA2 inhibitor)
- IT **172732-60-4 172732-61-5 172732-62-6**  
**172732-63-7 172732-64-8 172732-65-9**  
**172732-66-0 172732-67-1 172732-69-3**  
**172732-70-6 172732-71-7 172732-72-8**  
172732-73-9 172733-08-3 172733-42-5 207340-66-7 207340-74-7  
207340-75-8 207340-77-0 207340-78-1 207340-79-2 207340-81-6  
207340-82-7 207340-85-0 207340-86-1 220862-20-4 220862-21-5  
220862-22-6 220862-23-7 220862-24-8 220862-25-9 220862-26-0  
220862-27-1 220862-28-2 220862-29-3 220862-30-6 220862-31-7  
220862-32-8 220862-33-9 220862-34-0 220862-35-1 220862-36-2  
220862-37-3 220862-38-4 220862-39-5 220862-40-8 220862-41-9  
220862-42-0 220862-43-1 220862-44-2 220862-45-3 220862-46-4  
220862-47-5 220862-48-6 220862-49-7 220862-50-0 220862-51-1  
220862-53-3 220862-54-4 220862-55-5 220862-56-6 220862-57-7  
220862-58-8 220862-59-9 220862-60-2 220862-61-3 220862-62-4  
220862-63-5 220862-64-6 220862-65-7 220862-66-8 220862-68-0  
220862-70-4 220862-72-6 220862-74-8 220862-76-0 220862-79-3  
220862-80-6 220862-82-8 220862-83-9 220862-84-0 220863-33-2  
RL: BAC (Biological activity or effector, except adverse); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(method for treatment of non-rheumatoid arthritis by administration of  
an sPLA2 inhibitor)
- IT 100-39-0, Benzyl bromide 5292-43-3, tert-Butyl bromoacetate  
104863-65-2, N-Methoxy-N-methylpropionamide 164082-77-3,

N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline

RL: RCT (Reactant)

(method for treatment of non-rheumatoid arthritis by administration of an sPLA2 inhibitor)

IT 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P,  
2-Ethyl-4-methoxy-1-benzyl-1H-indole 172733-06-1P, 2-Ethyl-4-hydroxy-1-benzyl-1H-indole 220862-18-0P 220862-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(method for treatment of non-rheumatoid arthritis by administration of an sPLA2 inhibitor)

REFERENCE COUNT:

4

REFERENCE(S):

- (1) Chorvat; US 4180666 A 1979 CAPLUS
- (2) Hinkley; US 3732292 A 1973 CAPLUS
- (3) Kelley; Preparation of indanylideneacetamide and naphthylideneacetamide derivatives as muscle relaxants 1996, 15, P972 CAPLUS
- (4) Shen; US 3954852 A 1976 CAPLUS

L108 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:166097 CAPLUS

DOCUMENT NUMBER: 130:332298

TITLE: Pharmacology of LY315920/S-5920,

[[3-(aminooxoacetyl)-

2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs,

SPI

AUTHOR(S):

Snyder, David W.; Bach, Nicholas J.; Dillard, Robert D.; Draheim, Susan E.; Carlson, Donald G.; Fox,

Niles;

Roehm, Neal W.; Armstrong, Christopher T.; Chang,

Chan

H.; Hartley, Lawrence W.; Johnson, Lea M.; Roman, Carlos R.; Smith, Amy C.; Song, Min; Fleisch, Jerome H.

CORPORATE SOURCE:

Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA

SOURCE:

J. Pharmacol. Exp. Ther. (1999), 288(3), 1117-1124  
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER:

American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB LY315920 is a potent, selective inhibitor of recombinant human, group IIA,

nonpancreatic secretory PLA2 (sPLA2). In a chromogenic isolated enzyme assay, LY315920 inhibited sPLA2 activity with an IC50 of 9 +/- 1 nM or 7.3 .times. 10-6 mole fraction, which approached the stoichiometric limit of this assay. The true potency of LY315920 was defined using a deoxycholate/phosphatidylcholine assay with a mole fraction of 1.5 .times.

10-6. LY315920 was 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase. Human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by LY315920 with an IC50 of 0.79 .mu.M. The release of TXA2 from these cells by N-formyl-methionyl-leucyl-phenylalanine or arachidonic acid was not inhibited. The i.v. administration of LY315920, 5 min before harvesting the bronchoalveolar lavage cells, resulted in the inhibition of sPLA2-induced prodn. of TXA2

with an ED50 of 16.1 mg/kg. Challenge of guinea pig lung pleural strips with sPLA2 produced contractile responses that were suppressed in a concn.-dependent manner by LY315920 with an apparent KB of 83  $\pm$  14 nM. Contractile responses induced by arachidonic acid were not altered. I.v. or oral administration of LY315920 to transgenic mice expressing the human sPLA2 protein inhibited serum sPLA2 activity in a dose-related manner over a 4-h time course. LY315920 is a potent and selective sPLA2 inhibitor and represents a new class of anti-inflammatory agent designated SPI. This agent is currently undergoing clin. evaluation and should help to define the role of sPLA2 in various inflammatory disease states.

IT Anti-inflammatory drugs

(pharmacol. of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor, in relation to SPI anti-inflammatory drugs)

IT 39391-18-9

RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BIOL (Biological study); PROC (Process)

(1 and 2; pharmacol. of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor, in relation to SPI anti-inflammatory drugs)

IT 9001-84-7, Phospholipase a2

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(inhibitors; pharmacol. of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor, in relation to SPI anti-inflammatory drugs)

IT 172732-68-2, Ly315920

RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacol. of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor, in relation to SPI anti-inflammatory

drugs)

IT 57576-52-0, Thromboxane a2

RL: BPR (Biological process); BIOL (Biological study); PROC (Process) (release of; pharmacol. of LY315920/S-5920, a potent and selective secretory phospholipase A2 inhibitor, in relation to SPI anti-inflammatory drugs)

REFERENCE COUNT: 38

REFERENCE(S): (1) Arbibe, L; J Clin Invest 1998, V102, P1152 CAPLUS  
(2) Beaton, H; J Med Chem 1994, V37, P557 CAPLUS  
(3) Becker, G; BioTechnology 1994, V12, P69 CAPLUS  
(4) Brideau, C; Inflamm Res 1996, V45, P68 CAPLUS  
(5) Dillard, R; J Med Chem 1996, V39, P5119 CAPLUS  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:31976 CAPLUS

DOCUMENT NUMBER: 130:81400

TITLE: Process for preparing 4-substituted-1H-indole-3-glyoxamides

INVENTOR(S): Khau, Vien Van; Martinelli, Michael John; Pawlak, Joseph Matthew

PATENT ASSIGNEE(S): Eli Lilly and Company, USA


SOURCE: Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 887342	A2	19981230	EP 1998-304994	19980625
EP 887342	A3	19990107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 9900360	A1	19990107	WO 1998-US12173	19980622
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9879613	A1	19990119	AU 1998-79613	19980622
AU 735516	B2	20010712		
BR 9810481	A	20000912	BR 1998-10481	19980622
US 5986106	A	19991116	US 1998-105381	19980626
NO 9906432	A	20000209	NO 1999-6432	19991223
PRIORITY APPLN. INFO.:			US 1997-50877	P 19970626
			US 1997-50891	P 19970626
			WO 1998-US12173	W 19980622
OTHER SOURCE(S):			MARPAT 130:81400	
GI				



AB An 8-step process for prepg. 1H-indole-3-glyoxamides I [R1 = alkyl, aralkyl; R2 = H, halogen, alkyl, cycloalkyl, cycloalkenyl, alkoxy, alkylthio, aryl, aryloxy, heterocyclic; R3 = CO2H, SO3H, P(O)(OH)2; R4-R6 = H, alkyl, alkoxy, haloalkoxy, haloalkyl, Br, Cl, F, I, aryl], useful for inhibiting sPLA2, from R2COCH2CO2R7 [R7 = alkyl, aryl, heterocyclic] is claimed. Thus, EtCOCH2CO2Me was treated with 1,3-cyclohexanedione to give 2-(2-oxobutyl)-1,3-cyclohexanedione which was cyclized to tetrahydroindole with PhCH2NH2. The tetrahydroindole was dehydrogenated over Pd-C, treated with BrCH2CO2Me, treated with oxalyl chloride and NH3, and subjected to ester hydrolysis to give I [R1 = CH2Ph, R2 = Et, R3 = CO2H, R4-R6 = H].

IT 9001-84-7, Phospholipase A2  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of 4-substituted-1H-indole-3-glyoxamides with sPLA2-inhibiting activity)

IT 96-32-2, Methyl bromoacetate 100-46-9, Benzylamine, reactions

141-97-9, Ethyl acetoacetate 504-02-9, 1,3-Cyclohexanedione  
 10544-63-5, Ethyl crotonate 30414-53-0, Methyl propionylacetate  
 RL: RCT (Reactant)  
 (prepn. of 4-substituted-1H-indole-3-glyoxamides with sPLA2-inhibiting activity)  
 IT 4341-24-6P, 5-Methyl-1,3-cyclohexanedione 24836-98-4P 38321-40-3P  
 172733-06-1P 172733-07-2P 172733-08-3P 218934-50-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of 4-substituted-1H-indole-3-glyoxamides with sPLA2-inhibiting activity)  
 IT 172732-68-2P 172733-42-5P 218934-51-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of 4-substituted-1H-indole-3-glyoxamides with sPLA2-inhibiting activity)

L108 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:708940 CAPLUS  
 DOCUMENT NUMBER: 129:326101  
 TITLE: Method for the treatment of stroke using  
 N-heterocyclic glyoxylamide compounds  
 INVENTOR(S): Genba, Takefumi; Hori, Yozo  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847507	A1	19981029	WO 1997-JP1421	19970424
W: JP				
WO 9847508	A1	19981029	WO 1998-JP1880	19980423
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870807	A1	19981113	AU 1998-70807	19980423
EP 977566	A1	20000209	EP 1998-917656	19980423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6214855	B1	20010410	US 1999-402084	19990929
PRIORITY APPLN. INFO.:			WO 1997-JP1421 A	19970424
			WO 1998-JP1880 W	19980423

OTHER SOURCE(S): MARPAT 129:326101

AB A method or compn. is disclosed for the treatment and/or prevention of stroke using N-heterocyclic glyoxylamide compds.

IT Anti-ischemic agents  
 Capsules (drug delivery systems)  
 Cerebral infarction  
 Drug delivery systems  
 Intravenous injections  
 Neuroprotectants  
 Oral drug delivery systems  
 Parenteral solutions (drug delivery systems)

Prodrugs  
 Sprays (drug delivery systems)  
 Stroke  
 Suppositories (drug delivery systems)  
 Suspensions (drug delivery systems)  
 Tablets (drug delivery systems)  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 172732-68-2P 182115-97-5P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 5548-10-7D, derivs. 172732-60-4 172732-61-5  
 172732-62-6 172732-63-7 172732-64-8  
 172732-65-9 172732-66-0 172732-67-1  
 172732-69-3 172732-70-6 172732-71-7  
 172732-72-8 172732-73-9 172732-74-0 172733-42-5  
 177557-97-0 182115-86-2 182115-87-3 182115-88-4 182115-90-8  
 182115-92-0 182115-96-4 182115-99-7 182116-00-3 182116-01-4  
 215160-61-5D, derivs. 215160-62-6 215160-63-7 215160-64-8  
 215160-65-9 215160-66-0  
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 164082-78-4P 164082-79-5P 164082-80-8P 172733-06-1P 172733-07-2P  
 172733-08-3P 177556-96-6P 177558-64-4P 177558-67-7P 177558-73-5P  
 177558-79-1P 177558-91-7P 177560-06-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and reaction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 79-37-8, Oxalyl chloride 100-39-0, Benzyl bromide 100-44-7, Benzyl chloride, reactions 598-30-1, sec-Butyl lithium 816-40-0, 1-Bromo-2-butanone 2584-12-5 14002-52-9, [1,1'-Biphenyl]-2-carbonyl chloride 104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3  
 RL: RCT (Reactant)  
 (reaction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

L108 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:672466 CAPLUS  
 DOCUMENT NUMBER: 129:298393  
 TITLE: Method for treatment of chronic bronchitis  
 INVENTOR(S): Macias, William L.  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842343	A1	19981001	WO 1998-US5791	19980324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG

US 5972988	A	19991026	US 1998-42686	19980312
AU 9867717	A1	19981020	AU 1998-67717	19980324
EP 1007046	A1	20000614	EP 1998-913085	19980324

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI  
 PRIORITY APPLN. INFO.: US 1997-42101 P 19970326  
 WO 1998-US5791 W 19980324

OTHER SOURCE(S): MARPAT 129:298393  
 GI



AB Chronic bronchitis is treated in mammals by administering a  
 therapeutically effective amt. of a 1H-indole-3-glyoxylamide [I; X = O,  
 S;  
 R11 = (substituted) C7-20 alkyl, alkenyl, or alkynyl, cycloalkyl, aryl,  
 etc., or any of these groups attached through a linking group; R12 = H,  
 halo, C1-3 alkyl, C3-4 cycloalkyl or cycloalkenyl, OMe, OEt, SMe, SET;  
 R14, R15 = H, non-interfering substituent, acidic group attached through  
 a  
 linker; R16, R17 = H, alkyl, alkoxy, alkylcarbonyl, alkylamino,  
 alkylthio,  
 PhO, NH2, Br, Cl, CO2H, NHNH2, SO3H, etc.] or a prodrug thereof. Thus,  
 Na  
 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-  
 yl]oxy]acetate (II), administered as a continuous i.v. infusion for 7  
 days  
 to achieve a blood II level of 400 ng/mL, alleviated smoker's cough in a  
 subject and increased the peak expiratory flow rate measured by  
 spirometry. II was prepd. by reaction of  
 N-tert-butoxycarbonyl-3-methoxy-  
 2-methylaniline with sec-BuLi and N-methoxy-N-methylpropanamide followed  
 by F3CCO2H to produce 2-ethyl-4-methoxy-1H-indole, benzylation with  
 PhCH2Br, O-demethylation with BBr3, carboxymethylation with BrCH2CO2Me,,  
 reaction with oxalyl chloride and NH3, and sapon.

IT Bronchitis  
 Chronic bronchitis  
 (treatment of chronic bronchitis with indoleglyoxylamides)

IT 172732-60-4P 172732-61-5P 172732-62-6P  
 172732-63-7P 172732-64-8P 172732-65-9P  
 172732-66-0P 172732-67-1P 172732-68-2P  
 172732-69-3P 172732-70-6P 172732-71-7P  
 172732-72-8P 172732-73-9P 172732-74-0P 172733-08-3P  
 172733-42-5P 214421-72-4P 214421-73-5P 214421-74-6P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP



(Preparation); USES (Uses)  
 (treatment of chronic bronchitis with indoleglyoxylamides)  
 IT 75-26-3, 2-Bromopropane 79-37-8, Oxalyl chloride 96-32-2, Methyl  
 bromoacetate 100-39-0, Benzyl bromide 2315-36-8, 2-Chloro-N,N-  
 diethylacetamide 3240-94-6, 4-(2-Chloroethyl)morpholine 38580-82-4.  
 104863-65-2, N-Methoxy-N-methylpropanamide  
 RL: RCT (Reactant)  
 (treatment of chronic bronchitis with indoleglyoxylamides)  
 IT 164082-78-4P 164082-79-5P 164082-80-8P 172732-87-5P 172732-88-6P  
 172732-89-7P 172732-90-0P 172732-91-1P 172733-06-1P 172733-07-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (treatment of chronic bronchitis with indoleglyoxylamides)

L108 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:604907 CAPLUS  
 DOCUMENT NUMBER: 129:189241  
 TITLE: Preparation and formulation of indoledicarboxylic  
 acid

INVENTOR(S): derivatives as sPLA2 inhibitors  
 Ohtani, Mitsuaki; Hagishita, Sanji  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 39 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9837069	A1	19980827	WO 1998-JP679	19980219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862292	A1	19980909	AU 1998-62292	19980219
EP 987250	A1	20000322	EP 1998-904379	19980219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			JP 1997-35984	19970220
			WO 1998-JP679	19980219
OTHER SOURCE(S):			MARPAT 129:189241	
GI				



CCESSION NUMBER: 2001:52079 USPATFULL  
 TITLE: Method for the treatment of stroke using N-heterocyclic glyoxlyamide compounds  
 INVENTOR(S): Gemba, Takefumi, Hyogo, Japan  
 Hori, Yozo, Osaka, Japan  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214855	B1	20010410
	WO 9847508		19981029
APPLICATION INFO.:	US 1999-402084		19990929 (9)
	WO 1998-JP1880		19980423
			19990929 PCT 371 date
			19990929 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-1421	19970424
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Henley, III, Raymond	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1404	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and composition for the treatment and/or prevention of stroke is disclosed using N-heterocyclic glyoxamide compounds having the following general formula: ##STR1##

wherein X, E, F, R.sub.11, R.sub.12, R.sub.14, R.sub.15, R.sub.16 and R.sub.17 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 172732-60-4 172732-61-5 172732-72-8  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Drug delivery systems  
 (capsules; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Anti-ischemic agents  
 IT Drug delivery systems  
 (heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Brain, disease  
 (infarction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Drug delivery systems  
 (injections, i.v.; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Cytoprotective agents  
 (neuroprotectants; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Drug delivery systems  
 (oral; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Drug delivery systems  
 (parenterals; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)  
 IT Drug delivery systems

(prodrugs; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT Drug delivery systems  
(sprays; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT Brain, disease  
(stroke; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT Drug delivery systems  
(suppositories; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT Drug delivery systems  
(suspensions; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT Drug delivery systems  
(tablets; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 172732-68-2P 182115-97-5P  
(heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 5548-10-7D, derivs. **172732-60-4 172732-61-5**  
172732-62-6 172732-63-7 172732-64-8 172732-65-9 172732-66-0  
172732-67-1 172732-69-3 172732-70-6 172732-71-7 **172732-72-8**  
172732-73-9 172732-74-0 172733-42-5 177557-97-0 182115-86-2  
182115-87-3 182115-88-4 182115-90-8 182115-92-0 182115-96-4  
182115-99-7 182116-00-3 182116-01-4 215160-61-5D, derivs.  
215160-62-6 215160-63-7 215160-64-8 215160-65-9 215160-66-0  
(heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 164082-78-4P 164082-79-5P 164082-80-8P 172733-06-1P 172733-07-2P  
172733-08-3P 177556-96-6P 177558-64-4P 177558-67-7P 177558-73-5P  
177558-79-1P 177558-91-7P 177560-06-4P  
(prepn. and reaction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

IT 79-37-8, Oxalyl chloride 100-39-0, Benzyl bromide 100-44-7, Benzyl chloride, reactions 598-30-1, sec-Butyl lithium 816-40-0, 1-Bromo-2-butanone 2584-12-5 14002-52-9, [1,1'-Biphenyl]-2-carbonyl chloride 104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3  
(reaction; heterocyclic glyoxylamide compds. for stroke treatment, prepn., and pharmaceutical compns.)

=>

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:260062 CAPLUS

DOCUMENT NUMBER: 132:284251

TITLE: Remedies or preventives containing sPLA2 inhibitors  
for ischemic reflow failure

INVENTOR(S): Todo, Satoru

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021563	A1	20000420	WO 1999-JP5528	19991007
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9960047	A1	20000501	AU 1999-60047	19991007
EP 1157704	A1	20011128	EP 1999-970328	19991007
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: JP 1998-292423 A 19981014

WO 1999-JP5528 W 19991007

OTHER SOURCE(S): MARPAT 132:284251

AB The invention relates to remedies or preventives for ischemic reflow failure which contain an sPLA2 inhibitor, e.g. [[3-[2-Amino-1,2-dioxoethyl]-2-methyl-1-[phenylmethyl]-1H-indol-4-yl]oxy]acetic acid, as active ingredient. Capsules were formulated contg. sPLA2 inhibitor 250, starch 200 and magnesium stearate 10 mg/capsule.

IT **172732-60-4 172732-61-5 172732-72-8**  
**211925-45-0 263910-31-2 263910-32-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(aerosols; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(capsules; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(injections, i.v.; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Liver, disease

(**ischemia**, ischemic reflow failure; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Reperfusion

(ischemic, disorder of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)

IT Drug delivery systems

(prodrugs; remedies or preventives contg. sPLA2 inhibitors for ischemic

reflow failure)  
 IT Organ preservation  
 (remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)  
 IT Drug delivery systems  
 (suppositories; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)  
 IT Drug delivery systems  
 (tablets; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)  
 IT **172732-60-4 172732-61-5** 172732-62-6 172732-63-7  
 172732-64-8 172732-65-9 172732-66-0 172732-67-1 172732-68-2  
 172732-69-3 172732-70-6 172732-71-7 **172732-72-8**  
 172732-73-9 182115-96-4 182115-97-5 182116-01-4 **211925-45-0**  
 220862-64-6 245756-89-2 245756-93-8 245757-15-7 **263910-31-2**  
**263910-32-3** 263910-33-4 263910-34-5 263910-35-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)  
 IT 9001-84-7, Phospholipase A2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (secretory, inhibitor of; remedies or preventives contg. sPLA2 inhibitors for ischemic reflow failure)  
 REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitrn it l11 2